

Exhibit B



IN THE CIRCUIT COURT OF MOBILE COUNTY, ALABAMA

**THE ESTATE OF BRUCE BROCKEL,
Deceased, by and through DONNA
BROCKEL, as Personal Representative**

Plaintiff,

v.

**JOHN PATRICK COUCH, RASSAN M.
TARABEIN, PHYSICIANS PAIN
SPECIALISTS OF ALABAMA, P.C.,
C&R PHARMACY, LLC,
EASTERN SHORE NEUROLOGY
CLINIC, INC., PURDUE PHARMA L.P.,
PFIZER INC., ENDO PHARMACEUTICALS
INC., KVK-TECH, INC., ZYDUS
PHARMACEUTICALS (USA) INC., NESHER
PHARMACEUTICALS (USA) LLC, WATSON
LABORATORIES, INC., MALLINCKRODT
BRAND PHARMACEUTICALS, INC.,
WEST-WARD PHARMACEUTICALS CORP.,
ACTAVIS PHARMA, INC., ROXANE
LABORATORIES, INC., PAR
PHARMACEUTICAL, INC., RHODES
PHARMACEUTICALS L.P., TEVA
PHARMACEUTICALS USA, INC.,
CEPHALON, INC., K, L, M, N, O, P, Q, R,
S,T,U,V,W, X,Y, and Z,**

Defendants.

Civil Action No. 2017-CV-902787

**PLAINTIFF DEMANDS
TRIAL BY JURY**

SECOND AMENDED COMPLAINT

Plaintiff, the Estate of Bruce Brockel, deceased, by and through Donna Brockel, as Personal Representative, amends the Complaint to (a) add a cause of action for recklessness/gross negligence; and (b) clarify and/or supplement factual allegations. Plaintiff's Complaint shall hereinafter state as follows:

PARTIES

1. **DONNA BROCKEL** is an individual resident of Mobile, Mobile County, Alabama over the age of 19. **DONNA BROCKEL** is the duly appointed Personal Representative of the Estate of Bruce Brockel, Deceased, appointed as such on or about October 19, 2017, by the Probate Court of Mobile County, Alabama. A copy of the Letters of Administration is attached hereto as Exhibit "1".

2. **DONNA BROCKEL** brings this wrongful death action as the duly appointed Personal Representative of the Estate of Bruce Brockel, Deceased (**DONNA BROCKEL** and the Estate shall hereinafter be collectively referred to as "**PLAINTIFF**").

3. On information and belief, Defendant, doctor **JOHN PATRICK COUCH** (hereinafter referred to as "**COUCH**"), is an individual currently serving time in a federal prison in Forrest City, Arkansas. **COUCH** may be served with process at 1400 Dale Bumpers Road, Forrest City, Arkansas 72335. **COUCH** conducted substantial business activities in Mobile County at all times referred to in this Complaint.

4. Defendant, doctor **RASSAN M. TARABEIN** (hereinafter referred to as "**TARABEIN**"), is an individual resident of Fairhope, Baldwin County, Alabama. **TARABEIN** may be served with process at 22341 Main Street, Fairhope, Alabama 36532.

5. Defendant, **PHYSICIANS PAIN SPECIALISTS OF ALABAMA, P.C.** (hereinafter referred to as "**PPSA**"), is an Alabama professional corporation with its principal place of business located in Mobile County, Alabama. **COUCH** is one of the Members and Shareholders of **PPSA**. **PPSA** conducted substantial business activities in Mobile County at all times referred to in this Complaint.

6. Defendant, **C&R PHARMACY, LLC** (hereinafter referred to as “**C&R**”), is an Alabama limited liability company with its principal place of business located in Mobile, Mobile County, Alabama. **COUCH** is one of the Members and Shareholders of **C&R**. **C&R** is/was located adjacent to **PPSA**’s location on Airport Boulevard in Mobile, Alabama. **C&R** conducted substantial business activities in Mobile County at all times referred to in this Complaint.

7. Defendant, **EASTERN SHORE NEUROLOGY CLINIC, INC.** (hereinafter referred to as “**ESNC**”), is a corporation with its principal place of business located in Daphne, Baldwin County, Alabama. **TARABEIN** is/was the owner of **ESNC**. On information and belief, **TARABEIN** and/or **ESNC** were doing business as Eastern Shore Neurology and Pain Center (a private clinic located at 27535 U.S. HWY 98, Daphne, Alabama 36526) where they provided services relating to neurology and pain management.

8. Defendants **COUCH, TARABEIN, PPSA, C&R** and **ESNC** are collectively referred to as “Provider Defendants” herein.

9. **PLAINTIFF** was prescribed numerous opioids during the 2010 through 2017 time period. These opioids were manufactured by numerous pharmaceutical companies many of which are named Defendants herein. Copies of **PLAINTIFF**’s records from CVS Pharmacy and Walgreens Pharmacy are attached hereto as cumulative Exhibit “2”. These records show the types of opioids, the manufacturers of the opioids (either by name and/or NDC Number), the prescriber’s names, the dates when the prescriptions were filled, and the quantity of opioids. These are not the complete pharmacy records for the 2010 through 2017 time period. For example, **PLAINTIFF** does not have the records from **C&R** and is still trying to obtain same.

10. Defendant, **PURDUE PHARMA L.P.** (hereinafter referred to as “**PURDUE PHARMA**”), is a Delaware limited partnership headquartered in Stamford, Connecticut.

PURDUE PHARMA manufactures, promotes, markets and sells Schedule II controlled substances such as Oxycodone, OxyContin, Oxy IR, MS Contin, and MS IR. On information and belief, these drugs were prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. **PURDUE PHARMA** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

11. Defendant, **PFIZER INC.** (hereinafter referred to as “**PFIZER**”), is a corporation located in New York, New York. **PFIZER** manufactures, markets and sells Schedule II controlled substances such as Avinza. On information and belief, Avinza was prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “3”. **PFIZER** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

12. Defendant, **ENDO PHARMACEUTICALS INC.** (hereinafter referred to as “**ENDO**”), is a Delaware corporation headquartered in Malvern, Pennsylvania. **ENDO** manufactures, promotes, markets and sells Schedule II controlled substances such as Morphine

Sulfate ER, Acetaminophen/Oxycodone (Percocet) and Oxymorphone (Opana). On information and belief, these drugs were prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. In 2010, Qualitest Pharmaceuticals became a wholly owned subsidiary of **ENDO** (Qualitest effectively dissolved in 2016). **ENDO** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

13. Defendant, **KVK-TECH, INC.** (hereinafter referred to as “**KVK-TECH**”), is a corporation located in Newtown, Pennsylvania. **KVK-TECH** manufactures, promotes, markets and sells Schedule II controlled substances such as Oxycodone Hydrochloride and Oxycodone IR. On information and belief, these drugs were prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. **KVK-TECH** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

14. Defendant, **ZYDUS PHARMACEUTICALS (USA) INC.** (hereinafter referred to as “**ZYDUS**”), is a Delaware corporation headquartered in Pennington, New Jersey. **ZYDUS**

manufactures, promotes, markets, sells and/or distributes Schedule II controlled substances such as Morphine Sulfate ER. On information and belief, Morphine Sulfate ER was prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. According to **ZYDUS**, it does not manufacture Morphine Sulfate ER but only distributes same. According to **ZYDUS**, Nesher Pharmaceuticals (USA) LLC is the manufacturer of Morphine Sulfate ER. However, the records from CVS Pharmacy and Walgreens Pharmacy show otherwise. *See* Exhibit “2”. In addition, **ZYDUS**’s own website indicates/implies that it manufactures Morphine Sulfate. *See* cumulative Exhibit “4”. Moreover, the actual prescription bottles state that **ZYDUS** is the manufacturer of some of the Morphine Sulfate ER prescribed to **PLAINTIFF**. *See* Exhibit “5”. **ZYDUS** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

15. Defendant, **NESHER PHARMACEUTICALS (USA) LLC** (hereinafter referred to as “**NESHER**”), is a corporation headquartered in Bridgeton, Missouri. **NESHER** is being substituted for former fictitious/unknown party “A”. **NESHER** is a subsidiary of **ZYDUS**. **NESHER** manufactures, promotes, markets, sells and/or distributes Schedule II controlled substances such as Morphine Sulfate ER. On information and belief, Morphine Sulfate ER was prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. **NESHER** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting

in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama's Long Arm Statute.

16. Defendant, **WATSON LABORATORIES, INC.** (hereinafter referred to as "**WATSON**"), is a Nevada corporation with its principal place of business in Corona, California. **WATSON** is being substituted for former fictitious/unknown party "**B**". **WATSON** manufactures, promotes, markets and sells Schedule II controlled substances such as Oxycodone/APAP, Oxycodone/Acetaminophen and Morphine Sulfate ER. On information and belief, these drugs were prescribed to **PLAINTIFF** during the 2010 through 2017 time period. See Exhibit "2". **WATSON** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama's Long Arm Statute.

17. Defendant, **MALLINCKRODT BRAND PHARMACEUTICALS, INC.** (hereinafter referred to as "**MALLINCKRODT**"), is a Delaware corporation with its principal place of business in Hazelwood, Missouri. **MALLINCKRODT** is being substituted for former fictitious/unknown party "**C**". **MALLINCKRODT** is a subsidiary of Mallinckrodt plc which is based in Dublin, Ireland. **MALLINCKRODT** manufactures, promotes, markets, sells and/or distributes Schedule II controlled substances such as Oxycodone/Acetaminophen, Morphine Sulfate ER, Oxycodone Hydrochloride and Roxicodone. On information and belief, these drugs

were prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibits “2” and “6”. Xanodyne Pharmaceuticals, Inc. formerly manufactured Roxicodone. In 2012, **MALLINCKRODT** purchased Roxicodone from Xanodyne Pharmaceuticals, Inc. **MALLINCKRODT** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

18. Defendant, **WEST-WARD PHARMACEUTICALS CORP.** (hereinafter referred to as “**WEST-WARD**”), is a Delaware corporation with its principal place of business in Eatontown, New Jersey. **WEST-WARD** is being substituted for former fictitious/unknown party “**D**”. **WEST-WARD** manufactures, promotes, markets and sells Schedule II controlled substances such as Morphine Sulfate IR. On information and belief, Morphine Sulfate IR was prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. **WEST-WARD** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

19. Defendant, **ACTAVIS PHARMA, INC.** (hereinafter referred to as “**ACTAVIS**”), is a Delaware corporation with its principal place of business in Parsippany, New

Jersey. **ACTAVIS** is being substituted for former fictitious/unknown party “E”. **ACTAVIS** manufactures, promotes, markets and sells Schedule II controlled substances such as Oxycodone/APAP, Oxycodone/Acetaminophen, Oxycodone IR and Hydrocodone/Acetaminophen. On information and belief, these drugs were prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. **ACTAVIS** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

20. Defendant, **ROXANE LABORATORIES, INC.** (hereinafter referred to as “**ROXANE**”), is a Nevada corporation with its principal place of business in Columbus, Ohio. **ROXANE** is being substituted for former fictitious/unknown party “F”. **ROXANE** manufactures, promotes, markets and sells Schedule II controlled substances such as Morphine Sulfate IR. On information and belief, Morphine Sulfate IR was prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. **ROXANE** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

21. Defendant, **PAR PHARMACEUTICAL, INC.** (hereinafter referred to as “**PAR**”), is a Delaware corporation with its principal place of business in Spring Valley, New York. **PAR** is being substituted for former fictitious/unknown party “**G**”. **PAR** manufactures, promotes, markets and sells Schedule II controlled substances such as Hydrocodone/APAP, Hydrocodone/Acetaminophen and Oxycodone HCL. On information and belief, these drugs were prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. **PAR** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama’s Long Arm Statute.

22. Defendant, **RHODES PHARMACEUTICALS L.P** (hereinafter referred to as “**RHODES**”), is a Delaware corporation with its principal place of business in Coventry, Rhode Island. **RHODES** is being substituted for former fictitious/unknown party “**H**”. **RHODES** manufactures, promotes, markets and sells Schedule II controlled substances such as Morphine Sulfate ER. On information and belief, Morphine Sulfate ER was prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* Exhibit “2”. **RHODES** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled

substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama's Long Arm Statute.

23. Defendant, **TEVA PHARMACEUTICALS USA, INC.** (hereinafter referred to as "**TEVA**"), is a Delaware corporation with its principal place of business in North Wales, Pennsylvania. **TEVA** is being substituted for former fictitious/unknown party "**I**". **TEVA** manufactures, promotes, markets, sells and/or distributes Schedule II controlled substances such as Fentora/Fentanyl. On information and belief, Fentora/Fentanyl was prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* cumulative Exhibit "7". **TEVA** is a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd., an Israeli corporation. **TEVA** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County, Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama's Long Arm Statute.

24. Defendant, **CEPHALON, INC.** (hereinafter referred to as "**CEPHALON**"), is a Delaware corporation with its principal place of business in Frazer, Pennsylvania. **CEPHALON** is being substituted for former fictitious/unknown party "**J**". **CEPHALON** manufactures, promotes, markets, sells and/or distributes Schedule II controlled substances such as Fentora/Fentanyl. On information and belief, Fentora/Fentanyl was prescribed to **PLAINTIFF** during the 2010 through 2017 time period. *See* cumulative Exhibit "7". In 2011, Teva Pharmaceutical Industries, Ltd. acquired **CEPHALON**. **CEPHALON** has transacted substantial business activities in Mobile County, Alabama; contracted to render services in Mobile County,

Alabama; caused tortious and/or contractual injury resulting in the **PLAINTIFF** sustaining substantial damages by acts or omissions conducted in Mobile County, Alabama; and has derived substantial revenue from the sale of goods, including Schedule II controlled substances in the State of Alabama. Therefore, this Court has personal jurisdiction over the Defendant pursuant to Alabama's Long Arm Statute.

25. **TEVA** and **CEPHALON** work together to manufacture, promote, distribute and sell Fentora/Fentanyl.

26. Defendants **PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA** and **CEPHALON** are collectively referred to as "Manufacturing Defendants" herein.

27. Defendants **K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y** and **Z** are individuals, partnerships, corporations or other legal entities (including but not limited to doctors, manufacturers, distributors, and drug/pharmaceutical representatives) whose identities are currently unknown to the **PLAINTIFF**, and whose wrongful conduct described herein resulted in damage to the **PLAINTIFF** and the death of Bruce Brockel.

BACKGROUND/FACTS – MANUFACTURING DEFENDANTS

28. Opioids include brand-name drugs like OxyContin and Percocet and generics like oxycodone and hydrocodone. They are derived from or possess properties similar to opium and heroin, and, as such, they are highly addictive and dangerous and therefore are regulated by the United States Food and Drug Administration ("FDA") as controlled substances.

29. Opioids provide effective treatment for short-term post-surgical and trauma-related pain, and for palliative end-of-life care. They are approved by the FDA for use in the

management of moderate to severe pain where use of an opioid analgesic is appropriate for more than a few days.

30. However, the Manufacturing Defendants have manufactured, promoted, marketed and sold opioids for the management of pain by misleading consumers (including **PLAINTIFF**) and medical providers (including **COUCH** and **TARABEIN**) through misrepresentations or omissions regarding the appropriate uses, risks, and safety of opioids, and by flooding Alabama with highly addictive prescription medications without regard for the adverse consequences to the State and its residents like **PLAINTIFF**.

31. The Manufacturing Defendants knew that, barring exceptional circumstances, opioids are too addictive and debilitating for long-term use for chronic non-cancer pain lasting three months or longer.

32. The Manufacturing Defendants knew that, with prolonged use, the effectiveness of opioids wanes, requiring increases in doses to achieve pain relief and markedly increasing the risk of significant side effects and addiction.¹

33. The Manufacturing Defendants knew that controlled studies of the safety and efficacy of opioids were limited to short-term use (*i.e.*, not longer than 90 days) in managed settings (*e.g.*, hospitals) where the risk of addiction and other adverse outcomes was significantly minimized.

34. To date, there have been no long-term studies demonstrating the safety and efficacy of opioids for long-term use.

35. Despite the foregoing knowledge, in order to expand the market for opioids and realize blockbuster profits, the Manufacturing Defendants sought to create a false perception of

¹ See, *e.g.*, Russell K. Portenoy, *Opioid Therapy for Chronic Nonmalignant Pain: Current Status*, 1 Progress in Pain Res. & Mgmt., 247-287 (H.L. Fields and J.C. Liebeskind eds. 1994).

the safety and efficacy of opioids in the minds of medical professionals and members of the public that would encourage the use of opioids for longer periods of time and to treat a wider range of problems, including such common aches and pains as lower back pain, arthritis, and headaches.

36. The Manufacturing Defendants accomplished that false perception through a coordinated, sophisticated, and highly deceptive marketing campaign that began in the late 1990s, became more aggressive in or about 2006, and continues to the present.

37. The Manufacturing Defendants accomplished their marketing campaign goal by convincing doctors (including **COUCH** and **TARABEIN**), patients (including **PLAINTIFF**), and others that the benefits of using opioids to treat chronic pain outweighed the risks, and that opioids could be safely used by most patients.

38. The Manufacturing Defendants, individually and collectively, knowing that long-term opioid use causes addiction, misrepresented the dangers of long-term opioid use to physicians (including **COUCH** and **TARABEIN**), pharmacists, and patients (including **PLAINTIFF**) by engaging in a campaign to minimize the risks of, and to encourage, long-term opioid use.

39. The Manufacturing Defendants' marketing campaign has been extremely successful in expanding opioid use. Since 1999, the amount of prescription opioids sold in the U.S. has nearly quadrupled.² In 2010, 254 million prescriptions for opioids were filed in the U.S. – enough to medicate every adult in America around the clock for a month. In that year, 20% of all doctors' visits resulted in the prescription of an opioid (nearly double the rate in 2000).³

² CDC, Injury Prevention & Control: Opioid Overdose, Understanding the Epidemic, Available at: <http://www.cdc.gov/drugoverdose/epidemic/index.html> (accessed March 31, 2016)(internal footnotes omitted).

³ M. Daubresse, et al., Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000-2010, 51(10) Med. Care 870-78 (2013).

While Americans represent only 4.6% of the world's population, they consume 80% of the opioids supplied around the world and 99% of the global hydrocodone supply.⁴ By 2014, nearly two million Americans either abused or were dependent on opioids.⁵

40. The Manufacturing Defendants' campaign has been extremely profitable for them. In 2012 alone, opioids generated \$8 billion in revenue for drug companies.⁶ Of that amount, \$3.1 billion went to **PURDUE PHARMA** for its OxyContin sales.⁷

41. In 2007, **PURDUE PHARMA**, pleaded guilty and agreed to pay more than \$600 million in fines for misleading the public about the risks of OxyContin. But the drug continued to rack up blockbuster sales, generating more than \$22 billion over the last decade.⁸

42. The Manufacturing Defendants' marketing campaign has been extremely harmful to Americans. Overdoses from prescription pain relievers are a driving factor in a 15-year increase in opioid overdose deaths. Deaths from prescription opioids have also quadrupled since 1999. From 2000 to 2016, nearly half a million-people died from such overdoses. One hundred and fifteen Americans die every day from an opioid overdose.⁹

43. In 2012, an estimated 2.1 million people in the United States suffered from substance use disorders related to prescription opioid pain relievers.¹⁰ Between 30% and 40% of long-term users of opioids experience problems with opioid use disorders.¹¹

⁴ I. Manchikanti, et al., Therapeutic Use, Abuse, and Nonmedical Use of Opioids: A Ten-Year Perspective, 13 Pain Physician 401-435 (2010).

⁵ CDC, Injury Prevention & Control: Opioid Overdose, Prescription Opioids. Available at: <http://www.cdc.gov/drugoverdose/opioids/prescribed.html> (accessed March 31, 2016).

⁶ B. Meier & B. Marsh, *The Soaring Cost of the Opioid Economy*, N.Y. Times (June 22, 2013).

⁷ K. Eban, *Purdue Pharma's Painful Medicine*, Fortune Magazine (Nov. 9, 2011).

⁸ <https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic>.

⁹ CDC, Injury Prevention & Control: Opioid Overdose, Understanding the Epidemic, *supra*.

¹⁰ Substance Abuse and Mental Health Services Administration, Results from the 2012 *National Survey on Drug Use and Health: Summary of National Findings*, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.

¹¹ J. Boscarino et al., Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system, 105(10) *Addiction* 1776 (2010); J. Boscarino et al., Prevalence of Prescription Opioid-Use Disorder

44. The National Institutes of Health (“NIH”) not only recognizes the opioid abuse problem, but also identifies the Manufacturing Defendants’ “aggressive marketing” as a major cause: “Several factors are likely to have contributed to the severity of the current prescription drug abuse problem. They include drastic increases in the number of prescriptions written and dispensed, greater social acceptability for using medications for different purposes, and *aggressive marketing by pharmaceutical companies*.¹²

45. The Manufacturing Defendants’ misrepresentations regarding the safety and efficacy of long-term opioid use proximately caused injury to **PLAINTIFF**.

46. Due to concerns about their addictive properties, opioids have been regulated at the federal level as controlled substances by the U.S. Drug Enforcement Administration (“DEA”) since 1970. The labels for scheduled opioid drugs carry black box warnings of potential addiction and “[s]erious, life-threatening, or fatal respiratory depression,” as the result of an excessive dose.

47. Studies and articles from the 1970s and 1980s also made clear the reasons to avoid opioids. Scientists observed negative outcomes from long-term opioid therapy in pain management programs; opioids’ mixed record in reducing pain long-term and failure to improve patients’ function; greater pain complaints as most patients developed tolerance to opioids; opioid patients’ diminished ability to perform basic tasks; their inability to make use of complementary treatments like physical therapy due to the side effects of opioids; and addiction. Leading authorities discouraged, or even prohibited, the use of opioid therapy for chronic pain.

Among Chronic Pain Patients: Comparison of the DSM-4 Diagnostic Criteria, 30(3) Journal of Addictive Diseases 185 (2011).

¹² America’s Addiction to Opioids: Heroin and Prescription Drug Abuse. Available at http://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2015/americas-addiction-to-opioids-heroin-prescription-drug-abuse#_ftn2 (accessed March 31, 2016)(emphasis added).

48. Discontinuing opioids after more than just a few weeks of therapy will cause most patients to experience withdrawal symptoms. These withdrawal symptoms include: severe anxiety, nausea, vomiting, headaches, agitation, insomnia, tremors, hallucinations, delirium, pain, and other serious symptoms, which may persist for months after a complete withdrawal from opioids, depending on how long the opioids were used.

49. When under the continuous influence of opioids over time, patients grow tolerant to their analgesic effects. As tolerance increases, a patient typically requires progressively higher doses in order to obtain the same levels of pain reduction to which he has become accustomed – up to and including doses that are “frighteningly high.”¹³ At higher doses, the effects of withdrawal are more substantial, thus leaving a patient at a much higher risk of addiction. A patient can take the opioids at the continuously escalating dosages to match pain tolerance and still overdose at recommended levels.

50. The Manufacturing Defendants promoted the idea that pain should be treated by taking long-acting opioids continuously and supplementing them by also taking short-acting, rapid-onset opioids for episodic pain.

51. In 2013, in response to a petition to require manufacturers to strengthen warnings on the labels of long-acting opioid products, the FDA warned of the “grave risks” of opioids, including “addiction, overdose, and even death.” The FDA further warned, “[e]ven proper use of opioids under medical supervision can result in life-threatening respiratory depression, coma, and death.” Because of those grave risks, the FDA said that long-acting or extended release opioids “should be used only when alternative treatments are inadequate.”¹⁴ The FDA required

¹³ M. Katz, Long-term Opioid Treatment of Nonmalignant Pain: A Believer Loses His Faith, 170(16) Archives of Internal Med. 1422 (2010).

¹⁴ Letter from Janet Woodcock, M.D., Dir., Ctr. For Drug Eval. & Res., to Andrew Kolodny, M.D., Pres. *Physicians for Responsible Opioid Prescribing*, Re Docket No. FDA-2012-P-0818 (Sept. 10, 2013)(emphasis in original).

that – going forward – opioid makers of long-acting formulations clearly communicate these risks in their labels.

52. In 2016, the FDA expanded its warnings for immediate-release opioid pain medications, requiring similar changes to the labeling of immediate-release opioid pain medications as it had for extended release opioids in 2013. The FDA also required several additional safety-labeling changes across all prescription opioid products to include additional information on the risk of these medications.¹⁵

53. The facts on which the FDA relied in 2013 and 2016 were well known to the Manufacturing Defendants in the 1990s when their deceptive marketing began.

54. There is no scientific evidence supporting the safety or efficacy of opioids for long-term use. The Manufacturing Defendants are well aware of the lack of such scientific evidence. While promoting opioids to treat chronic pain, the Manufacturing Defendants failed to disclose the lack of evidence to support their use long-term and have failed to disclose the substantial scientific evidence that chronic opioid therapy actually makes patients sicker.

55. There are no controlled studies of the use of opioids beyond 16 weeks, and no evidence that opioids improve patients' pain and function long-term. For example, a 2007 systematic review of opioids for back pain concluded that opioids have limited, if any, efficacy for back pain and that evidence did not allow judgments regarding long-term use.

56. Substantial evidence exists that opioid drugs are ineffective to treat chronic pain, and actually worsen patients' health. For example, a 2006 study-of-studies found that opioids as

¹⁵ FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death. Available at <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm491739.htm> (accessed March 31, 2016).

a class did not demonstrate improvement in functional outcomes over other non-addicting treatments.¹⁶

57. Increasing duration of opioid use is strongly associated with an increasing prevalence of mental health conditions (including depression, anxiety, post-traumatic stress disorder, or substance abuse), increased psychological distress, and greater health care utilization.

58. While opioids may work acceptably well for a while, when they are used on a long-term basis, function generally declines, as does general health, mental health, and social function. Over time, even high doses of potent opioids often fail to control pain, and patients exposed to such doses are unable to function normally.¹⁷

59. The foregoing is true both generally and for specific pain-related conditions. Studies of the use of opioids long-term for chronic lower back pain have been unable to demonstrate an improvement in patients' function. Instead, research consistently shows that long-term opioid therapy for patients who have lower back injuries does not cause patients to return to work or physical activity. This is due partly to addiction and other side effects.

60. Before the Manufacturing Defendants began the marketing campaign complained of herein, generally accepted standards of medical practice dictated that opioids should only be used short-term, for instance, for acute pain, pain relating to recovery from surgery, or for cancer or palliative care. In those instances, the risks of addiction are low or of little significance.

¹⁶ A. Furlan et al., *Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects*, 174(11) Can. Med. Ass'n J. 1589 (2006). This same study revealed that efficacy studies do not typically include data on opioid addiction. In many cases, patients who may be more prone to addiction are pre-screened out of the study pool. This does not reflect how doctors actually prescribe the drugs, because even patients who have past or active substance use disorders tend to receive higher doses of opioids. K. Seal, *Association of Mental Health Disorders With Prescription Opioids and High-Risk Opioids in US Veterans of Iraq and Afghanistan*, 307(9) J. Am. Med. Ass'n 940 (2012).

¹⁷ See A. Rubenstein, *Are we making pain patients worse?* Sonoma Medicine (Fall 2009).

61. The market for short-term pain relief is significantly more limited than the market for long-term chronic pain relief. The Manufacturing Defendants recognized that if they could sell opioids not just for short term pain relief but also for long-term chronic pain relief, they could achieve blockbuster levels of sales and profits. Further, they recognized that if they could cause their customers to become physically addicted to their drugs, they would increase the likelihood that their blockbuster profits would continue indefinitely.

62. The Manufacturing Defendants knew that in order to increase their profits from the sale of opioids they would need to convince doctors (including **COUCH** and **TARABEIN**) and patients (including **PLAINTIFF**) that long-term opioid therapy was safe and effective. The Manufacturing Defendants needed, in other words, to persuade physicians to abandon their long-held apprehensions about prescribing opioids, and instead to prescribe opioids for durations previously understood to be unsafe.

63. Rather than add to the collective body of medical knowledge concerning the best ways to treat pain and improve patient quality of life, however, The Manufacturing Defendants instead sought to distort medical and public perception of existing scientific data.

64. The Manufacturing Defendants, collectively and individually, poured vast sums of money into generating articles, continuing medical education courses (“CMEs”), and other “educational” materials, conducting sales visits to individual doctors, and supporting a network of professional societies and advocacy groups, which was intended to, and which did, create a new but phony “consensus” supporting the long-term use of opioids.

65. Drug companies’ promotional activity can be branded or unbranded. Unbranded marketing refers not to a specific drug, but more generally to a disease state or treatment. By

using unbranded communications, drug companies can evade the extensive regulatory framework governing branded communications.

66. A drug company's branded marketing, which identifies and promotes a specific drug, must: (a) be consistent with its label and supported by substantial scientific evidence; (b) not include false or misleading statements or material omissions; and (c) fairly balance the drug's benefits and risks.

67. Further, the Federal Food, Drug, and Cosmetic Act ("FDCA") places further restrictions on branded marketing. It prohibits the sale in interstate commerce of drugs that are "misbranded." A drug is "misbranded" if it lacks "adequate directions for use" or if the label is false or misleading "in any particular." "Labeling" includes more than the drug's physical label; it also includes "all ... other written, printed, or graphic matter ... accompanying "the drug, including promotional material. The term "accompanying" is interpreted broadly to include promotional materials – posters, websites, brochures, books, and the like – disseminated by or on behalf of the manufacturer of the drug. Thus, The Manufacturing Defendants' promotional materials are part of their drugs' labels and required to be accurate, balanced, and not misleading.

68. The Manufacturing Defendants generally avoided using branded advertisements to spread their deceptive messages and claims regarding opioids. The Manufacturing Defendants did so in order to evade regulatory review.

69. Instead, the Manufacturing Defendants disseminated much of their false, misleading, imbalanced, and unsupported statements through unregulated unbranded marketing materials – materials that generally promoted opioid use but did not name a specific opioid while doing so. Through these unbranded materials, the Manufacturing Defendants presented information and instructions concerning opioids generally that were false and misleading.

70. By acting through third parties, the Manufacturing Defendants were able to give the false appearance that their messages reflected the views of independent third parties. Later, the Manufacturing Defendants would cite to these sources as “independent” corroboration of their own statements. Further, as one physician adviser to the Manufacturing Defendants noted, third-party documents had not only greater credibility, but also broader distribution, as doctors did not “push back” at having materials, for example, from the non-profit American Pain Foundation (“APF”) on display in their offices, as they would with drug company pieces.

71. As part of their marketing scheme, the Manufacturing Defendants spread and validated their deceptive messages through the following unbranded vehicles (“the Vehicles”): (i) so-called “key opinion leaders” (*i.e.*, physicians who influence their peers’ medical practice, including but not limited to prescribing behavior) (“KOLs”), who wrote favorable journal articles and delivered supportive CMEs, (ii) a body of biased and unsupported scientific literature; (iii) treatment guidelines; (iv) CMEs; and (v) unbranded patient education materials disseminated through groups purporting to be patient-advocacy and professional organizations (“Front Groups”), which exercised their influence both directly and indirectly through Defendant-controlled KOLs who served in leadership roles in these organizations.

72. The Manufacturing Defendants disseminated many of their false, misleading, imbalanced and unsupported messages through the Vehicles because they appeared to uninformed observers to be independent. Through unbranded materials, the Manufacturing Defendants presented information and instructions concerning opioids generally that were false and misleading.

73. Even where such unbranded messages were disseminated through third-party vehicles, the Manufacturing Defendants adopted these messages as their own when they cited to,

edited, approved, and distributed such materials knowing they were false, misleading, unsubstantiated, unbalanced, and incomplete. As described herein, the Manufacturing Defendants' sales representatives distributed third-party marketing material to Defendants' target audience that was deceptive.

74. The Manufacturing Defendants took an active role in guiding, reviewing, and approving many of the misleading statements issued by third parties, ensuring that Defendants were consistently in control of their content. By funding, directing, editing, and distributing these materials, Defendants exercised control over their deceptive messages and acted in concert with these third parties fraudulently to promote the use of opioids for the treatment of chronic pain.

75. The unbranded marketing materials that the Manufacturing Defendants assisted in creating and distributing either did not disclose the risks of addiction, abuse, misuse, and overdose, or affirmatively denied or minimized those risks.

76. Rather than actually test the safety and efficacy of opioids for long-term use, the Manufacturing Defendants led physicians (including **COUCH** and **TARABEIN**), patients (including **PLAINTIFF**), and health care payors to believe that such tests had already been done. Upon information and belief, the Manufacturing Defendants created a body of false, misleading, and unsupported medical and popular literature about opioids that (a) understated the risks and overstated the benefits of long-term use; (b) appeared to be the result of independent, objective research; and (c) was likely to shape the perceptions of prescribers, patients, and payors. This literature was, in fact, marketing material intended to persuade doctors and consumers that the benefits of long-term opioid use outweighed the risks.

77. The Manufacturing Defendants also made sure that favorable articles were disseminated and cited widely in the medical literature, even when they knew that the articles distorted the significance or meaning of the underlying study. Most notably, **PURDUE PHARMA** frequently cited a 1980 item in the well-respected New England Journal of Medicine, J. Porter & H. Jick, *Addiction Rare in Patients Treated with Narcotics*, 302(2) New Eng.J.Med. 123(1980) ("Porter & Jick Letter"), in a manner that makes it appear that the item reported the results of a peer reviewed study. It is also cited in two CME programs sponsored by **ENDO**. The Manufacturing Defendants and those acting on their behalf failed to reveal that this "article" is actually a letter-to-the-editor, not a study, much less a peer-reviewed study. The letter, reproduced in full below, states that the authors examined their files of hospitalized patients who had received opioids.

ADDICTION RARE IN PATIENTS TREATED WITH NARCOTICS

To the Editor: Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized medical patients¹ who were monitored consecutively. Although there were 11,882 patients who received at least one narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no history of addiction. The addiction was considered major in only one instance. The drugs implicated were meperidine in two patients², Percodan in one, and hydromorphone in one. We conclude that despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.

JANE PORTER
HERSCHEL JICK, M.D.
Boston Collaborative Drug
Surveillance Program
Boston University Medical Center

Waltham, MA 02154

¹ Jick H, Mietinen OS, Shapiro S, Lewis GP, Siskind Y, Slone D.
Comprehensive drug surveillance. JAMA. 1970; 213:1455-60

² Miller RR, Jick H. Clinical effects of meperidine in hospitalized medical patients.
J Clin Pharmacol. 1978; 18:180-8

78. The patients referred to in the letter were all treated prior to the letter, which was published in 1980. Because of standards of care prior to 1980, the treatment of those patients

with opioids would have been limited to acute or end-of-life situations, not chronic pain. The letter notes that, when these patients' records were reviewed, the authors found almost no references to signs of addiction, though there is no indication that caregivers were instructed to look for, assess, or document signs of addiction. Nor, indeed, is there any indication whether the patients were followed after they were discharged from the hospital or, if they were, for how long. None of these serious limitations was disclosed when the Manufacturing Defendants and those acting on their behalf cited the letter, typically as the sole scientific support for the proposition that opioids are rarely addictive.

79. Dr. Jick has complained that his letter has been distorted and misused – as indeed it has.

80. The Manufacturing Defendants' strategy – to plant and promote supportive literature and then to cite the pro-opioid evidence in their promotional materials, while failing to disclose evidence that contradicted those claims – was flatly inconsistent with their legal obligations. The strategy was intended to, and did, distort prescribing patterns by distorting the truth regarding the risks and benefits of opioids for chronic pain relief.

81. Like cigarette makers, which engaged in an industry-wide effort to misrepresent the safety and risks of smoking, the Manufacturing Defendants worked with each other and with the Front Groups and KOLs they funded and directed to carry out a common scheme to deceptively market opioids by misrepresenting the risks, benefits, and superiority of opioids to treat chronic pain.

82. The Manufacturing Defendants, through their own marketing efforts and publications and through their sponsorship and control of patient advocacy and medical societies and projects, caused deceptive materials and information to be placed into the marketplace,

including to prescribers (including **COUCH** and **TARABEIN**) and patients (including **PLAINTIFF**) in Alabama. These promotional messages were intended to and did encourage patients to ask for, doctors to prescribe, and payors to pay for chronic opioid therapy.

83. Doctors are the gatekeepers for all prescription drugs so, not surprisingly, the Manufacturing Defendants focused the bulk of their marketing efforts, and their multimillion-dollar budgets, on the professional medical community. Particularly because of barriers to prescribing opioids, which are regulated as controlled substances, the Manufacturing Defendants knew doctors would not treat patients with common chronic pain complaints with opioids unless doctors were persuaded that opioids had real benefits and minimal risks. Accordingly, the Manufacturing Defendants did not disclose to prescribers (including **COUCH** and **TARABEIN**), patients (including **PLAINTIFF**) or the public that evidence in support of their promotional claims was inconclusive, non-existent or unavailable. Rather, each Manufacturing Defendant disseminated misleading and unsupported messages that caused the target audience to believe those messages were corroborated by scientific evidence. As a result, doctors in Alabama (including **COUCH** and **TARABEIN**) began prescribing opioids long-term to treat chronic pain – something that most never would have considered prior to the Manufacturing Defendants' campaign.

84. As described in detail below, the Manufacturing Defendants:

- misrepresented the truth about how opioids lead to addiction;
- misrepresented that opioids improve function;
- misrepresented that addiction risk can be managed;

- misled doctors (including **COUCH** and **TARABEIN**), patients (including **PLAINTIFF**), and payors through the use of misleading terms like “pseudoaddiction;”
- falsely claimed that withdrawal is simply managed;
- misrepresented that increased doses pose no significant additional risks;
- falsely omitted or minimized the adverse effects of opioids and overstated the risks of alternative forms of pain treatment.

85. The Manufacturing Defendants’ misrepresentations were aimed at doctors (including **COUCH** and **TARABEIN**), patients (including **PLAINTIFF**), and payors.

86. Underlying each of the Manufacturing Defendants’ misrepresentations and deceptions in promoting the long-term continuous use of opioids to treat chronic pain was Defendants’ collective effort to hide from the medical community the fact that there exist no adequate and well-controlled studies of opioid use longer than 12 weeks.¹⁸

87. The Manufacturing Defendants’ fraudulent representation that opioids are rarely addictive is central to Defendants’ scheme. Through their well-funded, comprehensive, aggressive marketing efforts, the Manufacturing Defendants succeeded in changing the perceptions of many physicians (including **COUCH** and **TARABEIN**), patients (including **PLAINTIFF**), and health care payors and in getting them to accept that addiction rates are low and that addiction is unlikely to develop when opioids are prescribed for pain. That, in turn, directly led to the expected, intended, and foreseeable result that doctors (including **COUCH** and **TARABEIN**) prescribed more opioids to more patients (including **PLAINTIFF**) – thereby enriching Defendants.

¹⁸ Letter from Janet Woodcock, M.D., Dir., Ctr. For Drug Eval. & Res., to Andrew Kolodnay, M.D., Pres. *Physicians for Responsible Opioid Prescribing*, Re Docket No. FDA-2012-P-0818 (Sept. 10, 2013).

88. Each of the Manufacturing Defendants claimed that the potential for addiction from its drugs was relatively small or non-existent, even though there was no scientific evidence to support those claims.

89. To help downplay and misrepresent the addictiveness of their opioids, the Manufacturing Defendants used the term “pseudo addiction”. When patients seek more frequent prescriptions or higher doses of opioids, it is often a sign of addictive behavior. But the “pseudo addiction” approach – essentially taking the patients at their word – argues that they are not addicts, they just need more pain relief. Dr. J. David Haddox coined the term “pseudo addiction” in a 1989 paper in a medical journal. Dr. Haddox is a physician and paid speaker for **PURDUE PHARMA**.

90. In 1996, the American Academy of Pain Medicine and the American Pain Society (organizations that receive substantial funding from drug companies) issued a statement endorsing the use of opioids to treat chronic pain and claiming the risk of addiction was low. The chairman of the group issuing the statement was Dr. Haddox. Dr. Haddox became a **PURDUE PHARMA** executive just three years later.

91. From 2001 through 2015, **PURDUE PHARMA** hosted the website www.inthefaceofpain.com, which promoted “the notion that if a patient’s doctor does not prescribe what, in the patient’s view, is a sufficient dosage of opioids, he or she should find another doctor who will.”

92. Dr. Russell Portenoy is a **PURDUE PHARMA** affiliated pain doctor who received funding from **PURDUE PHARMA**. He spoke out about the problem of untreated chronic pain and the wisdom of using opioids to treat it. In 1993, he reportedly told the *Times* that “[t]here is growing literature showing that these drugs can be used for a long time, with few

side effects”. In addition, Dr. Portenoy said that opioids needed to be destigmatized and described them as a “gift from nature”. Moreover, Dr. Portenoy decried the reticence among clinicians to administer such narcotics for chronic pain, claiming that is was indicative of “opiophobia”, and suggesting that concerns about addiction and abuse amounted to a “medical myth”. Incredibly, in 2011, Dr. Portenoy conceded that research he relied on to push his and **PURDUE PHARMA**’s pro-opioid campaign did not prove anything about the treatment of chronic pain.

93. **ENDO** was also heavily involved in downplaying and misrepresenting the addictiveness of its opioids. For example, **ENDO** advertised that an abuse-deterrent reformation of Opana ER made it crush-resistant, despite its own studies disproving that claim. On July 6, 2017, in response to pressure from the FDA to stop sales of Opana ER due to abuse risks, **ENDO** pulled Opana ER from the market,

94. As aforementioned, **TEVA** and **CEPHALON** work together to manufacture, promote, distribute and sell Fentora/Fentanyl. In 2006, the FDA approved Fentora/Fentanyl for the management of pain in cancer patients who were already receiving, and who were tolerant to, opioid therapy for their underlying persistent cancer related pain. **PLAINTIFF** did not have cancer. Notwithstanding the fact that Fentora/Fentanyl was supposed to be used to treat cancer patients, it was marketed and promoted by **TEVA** and **CEPHALON** for other uses such as to treat chronic pain like **PLAINTIFF** experienced. This was improper and was done to maximize the profits of **TEVA** and **CEPHALON**.

95. Transmucosal instant-release fentanyl (“TIRF”) drugs are a subset of other fentanyl-based drugs. TIRF drugs are sold under several brand names, including Fentora and Abstral. Fentora is a buccal tablet placed in the cheek. The only FDA approved indication for

TIRF drugs is “for the management of breakthrough pain in patients with cancer who are already receiving, and who are tolerant to, around-the-clock opioid therapy for their persistent pain.” Since fentanyl is approximately 100 times more potent than morphine, and 40-60 times more potent than pure heroin, fentanyl in TIRF drugs is measured in micrograms.

96. TIRF drugs are extremely expensive. Due to both the exceptional danger and expense of TIRF drugs, many insurance providers required prior approval before they reimbursed for a TIRF prescription. For example, Viva Medicare refused to approve **PLAINTIFF**’s prescription for Abstral because he did not have cancer. *See* Exhibit “8”.

97. The brand-name Manufacturing Defendants have a duty to warn of the risks which it knew or reasonably should have known, regardless of whether the consumer (including Plaintiff) is prescribed the brand-name drug or its competitors’ generic bioequivalent. The brand-name Manufacturing Defendants are liable for the generic versions of their opioids because they intentionally failed to update warning labels for their drugs despite knowing the risks.

98. The generic Manufacturing Defendants colluded/conspired with the brand-name Manufacturing Defendants to cause the brand-name Manufacturing Defendants not to update their warning labels despite knowing the risks. Therefore, the generic Manufacturing Defendants are liable along with the brand-name Manufacturing Defendants.

99. Due to many years of taking drugs that were manufactured, marketed, promoted and sold by the Manufacturing Defendants, Mr. Brockel developed severe health problems including chronic obstructive pulmonary disease, shortness of breath, asthma, anxiety, and depression. He also had a history of suicidal ideations. These health problems proximately caused and/or contributed to his death.

100. Due to the wrongful conduct of the Manufacturing Defendants as outlined herein, Mr. Brockel committed suicide on or about August 7, 2017 in the parking lot of **COUCH's/PPS's** office in Mobile, Alabama. He was just 48 years old.

101. **PLAINTIFF** avers that the death of Bruce Brockel was proximately caused by the wrongful conduct of the Manufacturing Defendants.

102. **PLAINTIFF** brings this action for damages under the Alabama wrongful death statute, i.e., Alabama Code §6-5-410 (1975).

BACKGROUND/FACTS – PROVIDER DEFENDANTS

103. In approximately 2004, Bruce Brockel was involved in a motor vehicle accident in Atlanta, Georgia resulting in a broken back, neck and arm.

104. From 2004 to approximately 2010, Mr. Brockel was treated by doctors in the Dothan, Alabama area for pain caused by the motor vehicle accident. They primarily prescribed him Lortab and muscle relaxers.

105. Bruce and Donna Brockel moved to Mobile, Alabama in 2010.

106. According to the government, between January 1, 2011 and May 20, 2015, **COUCH** and his partner Dr. Xiulu Ruan wrote approximately 285,000 prescriptions for controlled substances.

107. According to the government, between January 1, 2011 and May 20, 2015, **COUCH** and Dr. Xiulu Ruan wrote over 6,000 prescriptions for TIRF drugs to approximately 1,000 different **PPSA** patients. Virtually all of these patients filled their expensive TIRF prescriptions at **C&R**, which was owned by **COUCH** and Dr. Xiulu Ruan.

108. From approximately February 2011 until **COUCH's** arrest in approximately May 2015, **COUCH** treated Mr. Brockel for pain with prescription drugs including Oxycodone,

Oxycodone HCL, Oxycodone/Acetaminophen, Oxymorphone, OxyContin, Oxy IR, MS Contin, MS IR, Morphine Sulfate ER, Morphine Sulfate IR, Hydrocodone/Acetaminophen, Avinza, Percocet, Opana, Roxicodone, Neurontin/Gabapentin and Fentora/Fentanyl. Said treatment took place at **PPSA** in Mobile, Alabama. These opioids were manufactured, marketed, promoted and sold by the Manufacturing Defendants.

109. **COUCH** prescribed drugs (including Oxycodone, Oxycodone HCL, Oxycodone/Acetaminophen, Oxymorphone, OxyContin, Oxy IR, MS Contin, MS IR, Morphine Sulfate ER, Morphine Sulfate IR, Hydrocodone/Acetaminophen, Avinza, Percocet, Opana, Roxicodone, Neurontin/Gabapentin and Fentora/Fentanyl) to Mr. Brockel without medical necessity or justification for profit.

110. During the treatment of Mr. Brockel, **COUCH** kept increasing the amounts, potency, and types of drugs without necessity or justification in order to make a profit.

111. On information and belief, in order to maximize profits and conceal his illegal activity, **COUCH** instructed and persuaded Mr. Brockel to fill his prescriptions at **C&R** which is a pharmacy that he co-owned in Mobile, Alabama. Mr. Brockel followed his doctor's instructions.

112. In 2006, the FDA approved Fentora/Fentanyl for the management of pain in cancer patients who were already receiving, and who were tolerant to, opioid therapy for their underlying persistent cancer related pain. Notwithstanding the fact that Fentora/Fentanyl was supposed to be used to treat cancer patients, **COUCH** treated **PLAINTIFF** for his non-cancer chronic pain. This was improper and was done to maximize the profits of **COUCH**.

113. In 2017, **COUCH** was found guilty on a slate of federal charges including health care fraud and unlawful distribution of controlled substances.

114. From approximately June 2015 until approximately April 2017, **TARABEIN** treated Mr. Brockel for pain with prescription drugs including Oxycodone, Oxycodone HCL, OxyContin, Oxy IR, MS Contin, MS IR, Avinza, Morphine Sulfate, Morphine Sulfate ER, Morphine Sulfate IR, Hydrocodone/Acetaminophen and Neurontin/Gabapentin. Said treatment took place at **ESNC** in Daphne, Alabama. These opioids were manufactured, marketed, promoted and sold by the Manufacturing Defendants.

115. **TARABEIN** prescribed drugs (Oxycodone, Oxycodone HCL, OxyContin, Oxy IR, MS Contin, MS IR, Avinza, Morphine Sulfate, Morphine Sulfate ER, Morphine Sulfate IR, Hydrocodone/Acetaminophen and Neurontin/Gabapentin) to Mr. Brockel without medical necessity or justification for profit.

116. During the treatment of Mr. Brockel, **TARABEIN** kept increasing the amounts, potency, and types of drugs without medical necessity or justification in order to make an unjust profit.

117. During **TARABEIN's** treatment of Mr. Brockel, it appears that **TARABEIN** routinely charged him for receiving services and procedures (e.g. epidural blocks even though he was only providing trigger point injections, etc.) that were not actually provided. On information and belief, **TARABEIN** did the same to maximize and unjustly profit which defrauded Mr. Brockel, BCBS of AL, and Medicare.

118. Due to many years of taking drugs that were overprescribed by **COUCH** and **TARABEIN**, Mr. Brockel developed severe health problems including chronic obstructive pulmonary disease, shortness of breadth, asthma, anxiety, and depression. He also had a history of suicidal ideations. These health problems proximately caused and/or contributed to his death.

119. In approximately April 2017, **TARABEIN** told Mr. Brockel to smoke marijuana for nausea because the government had legalized Cannabidiol (“CBD”) oil. Therefore, no one would know that he was smoking marijuana because marijuana and CBD oil would both test positive for THC during a drug test. Mr. Brockel followed **TARABEIN**’s instruction and smoked marijuana.

120. In approximately March 2017, Mr. Brockel asked **TARABEIN** to reduce the dosage of Morphine Sulfate. Accordingly, **TARABEIN** reluctantly reduced the dosage of Morphine Sulfate from 60 mg to 30 mg.

121. Subsequently, **TARABEIN** ordered a DNA swab test and lied about the results (Patients receiving prescription narcotics are required to submit a one-time DNA swab for analysis to determine the patient’s ability to process and metabolize the narcotic drugs). In addition, **TARABEIN** told Mr. Brockel that he was in control of his future and to pay his account balance or he would not be able to get any further pain medication from anyone in the medical field.

122. **TARABEIN** claimed that Mr. Brockel owed him approximately \$2,413 and sent him a bill for same. Mr. Brockel went to **TARABEIN**’s office at **ESNC** and tried to pay the balance allegedly owed on the account. However, **TARABEIN**’s office refused to accept payment. Instead, **TARABEIN**’s office said they would no longer treat him.

123. Mr. Brockel pleaded for **TARABEIN**’s office to help him with detoxification/withdrawal but they refused. Instead, **TARABEIN**’s office told Mr. Brockel he was on his own.

124. Thereafter, Mr. Brockel was unable to get the amounts and types of pain medications that he was accustomed to and as a result suffered severe pain, withdrawal, anxiety and depression.

125. Due to the fact that Mr. Brockel had been taking pain medication for approximately 14 years, **TARABEIN** knew (or should have known) that Mr. Brockel would suffer from severe pain, withdrawal, anxiety and depression when he abruptly stopped taking the addictive medications but did nothing to attempt to detoxify Mr. Brockel.

126. Due to **COUCH's** and **TARABEIN's** overprescribing of drugs to Mr. Brockel as well as **TARABEIN's** extortion and abrupt stoppage of treatment without proper detoxification, Mr. Brockel committed suicide on or about August 7, 2017 in the parking lot of **COUCH's/PPS's** office in Mobile, Alabama. He was just 48 years old.

127. August 7, 2017 was the same day **TARABEIN** filed his intent to plead guilty to health care fraud and unlawful distribution of controlled substances.

128. **PLAINTIFF** avers that the death of Bruce Brockel was proximately caused by the wrongful conduct of the Defendants.

129. **PLAINTIFF** brings this action for damages under the Alabama wrongful death statute, i.e., Alabama Code §6-5-410 (1975).

FIRST CAUSE OF ACTION (AGAINST COUCH & TARABEIN)
(Medical Malpractice)

130. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 129 as if fully set out herein including the "Background/Facts" section. **PLAINTIFF** is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

131. **PLAINTIFF** avers that **COUCH** and **TARABEIN** did not meet the applicable standard of care while treating Bruce Brockel, and that such failure was the proximate cause of Mr. Brockel's injuries and death. Examples of their failure to meet the applicable standard of care include, but are not limited to: overprescribing of prescription drugs; prescribing drugs to Mr. Brockel without medical necessity/justification; prescribing cancer related drugs to Mr. Brockel even though he did not have cancer; conducting unnecessary procedures; improperly charging for goods/services/procedures not actually performed; improperly charging for goods/services/procedures not medically necessary; billing for physician office visits when Mr. Brockel was only seen by staff; re-using epidural needles and/or needles in radio frequency machines; receiving illegal kickbacks and referral payments from pharmaceutical companies, distributors and/or other third parties; and failing to properly detox Mr. Brockel.

132. Accordingly, **COUCH** and **TARABEIN** are liable under the Alabama Medical Liability Act (Alabama Code §6-5-480, et seq. (1975)).

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

SECOND CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Negligence)

133. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 132 as if fully set out herein including the "Background/Facts" sections. **PLAINTIFF** is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

134. **PLAINTIFF** avers that Defendants negligently failed to properly inform and/or warn Bruce Brockel of the harmful effects, addictiveness, and limited application (i.e. effective treatment for short-term post-surgical and trauma-related pain, and for palliative end-of-life care) of the opioids that were manufactured, marketed, promoted, sold, distributed, and/or prescribed by Defendants and consumed by Mr. Brockel.

135. **PLAINTIFF** avers that the Manufacturing Defendants negligently failed to properly inform and/or warn the Provider Defendants (e.g. **COUCH** and **TARABEIN**) of the harmful effects, addictiveness, and limited application (i.e. effective treatment for short-term post-surgical and trauma-related pain, and for palliative end-of-life care) of the opioids that they manufactured, marketed, promoted and sold and that were ultimately consumed by Mr. Brockel. But for the Manufacturing Defendants' lack of information/warnings given to the Provider Defendants (e.g. **COUCH** and **TARABEIN**), the Provider Defendants would not have prescribed the subject opioids to **PLAINTIFF**. In other words, the Provider Defendants (e.g. **COUCH** and **TARABEIN**) would have changed their prescribing decisions had different or additional information/warnings accompanied the opioids.

136. **PLAINTIFF** avers that the Manufacturing Defendants negligently marketed and promoted the opioids as specifically set out in the "Background/Facts" section.

137. **PLAINTIFF** avers that the Manufacturing Defendants were negligent by failing to properly study/test the opioids for long term treatment of chronic pain. For example, as outlined in the "Background/Facts" section, the Manufacturing Defendants knew that controlled studies of the safety and efficacy of opioids were limited to short-term use (*i.e.*, not longer than 90 days) in managed settings (*e.g.*, hospitals) where the risk of addiction and other adverse

outcomes was significantly minimized. To date, there have been no long-term studies demonstrating the safety and efficacy of opioids for long-term use.

138. **PLAINTIFF** avers that the Manufacturing Defendants negligently failed to provide the FDA with sufficient and vital information when the opioids and their respective warning labels were approved by the FDA. For example, the Manufacturing Defendants failed to inform the FDA that controlled studies of the safety and efficacy of opioids were limited to short-term use (*i.e.*, not longer than 90 days) in managed settings (*e.g.*, hospitals) where the risk of addiction and other adverse outcomes was significantly minimized. Had the FDA been aware of this information, it likely would have limited the scope of opioid use and/or required changes to the warning labels.

139. **PLAINTIFF** avers that the Manufacturing Defendants negligently failed to inform the FDA of “newly acquired information” that would have allowed them to change their warning labels unilaterally after FDA approval through the FDA’s Changes Being Effectuated (“CBE”) process. This newly acquired information includes, but is not limited to: (1) opioids being only effective for treatment of short-term post-surgical and trauma-related pain, and for palliative end-of-life care; and (2) the full magnitude of the dangers associated with opioids as evidenced by the incredible number of overdoses and deaths across the Country.

140. **PLAINTIFF** avers that Defendants negligently misrepresented the harmful effects and addictiveness of the opioids and drugs that were manufactured, marketed, promoted, sold, distributed, and/or prescribed by Defendants and consumed by Mr. Brockel. **PLAINTIFF** also avers that Defendants negligently misrepresented that the opioids were effective for long term treatment of chronic pain, and that they should be prescribed for long term use.

141. **PLAINTIFF** avers that Defendants were negligent by manufacturing, marketing, promoting, selling, distributing, and/or prescribing opioids to Mr. Brockel which were dangerously unsafe.

142. **PLAINTIFF** avers that the Manufacturing Defendants negligently supplied opioids to suspicious physicians (including **COUCH** and **TARABEIN**) and pharmacies (including **C&R**). Indeed, on information and belief, a disproportional amount of opioids were being prescribed by **COUCH** and **TARABEIN** and filled at **C&R**. Yet, the Manufacturing Defendants did not do anything to help stop same because it would have adversely affected their profits. Had the Manufacturing Defendants adequately monitored and reported these suspicious purchases, **COUCH** and **TARABEIN** would not have been able to prescribe the opioids to **PLAINTIFF** which ultimately caused his death.

143. **PLAINTIFF** avers that Defendants negligently failed to alert the U.S. Drug Enforcement Administration of suspicious purchases of opioids, such as orders of unusual size, frequency or pattern. Defendants negligently failed to monitor and/or report the suspicious purchases and orders of controlled substances.

144. **PLAINTIFF** avers that **TEVA** and **CEPHALON** negligently marketed and promoted Fentora/Fentanyl for off label uses. In 2006, the FDA approved Fentora/Fentanyl for the management of pain in cancer patients who were already receiving, and who were tolerant to, opioid therapy for their underlying persistent cancer related pain. **PLAINTIFF** did not have cancer. Notwithstanding the fact that Fentora/Fentanyl was supposed to be used to treat cancer patients, it was marketed and promoted by **TEVA** and **CEPHALON** for other uses such as to treat chronic pain like **PLAINTIFF** experienced. This was improper and was done to maximize the profits of **TEVA** and **CEPHALON**.

145. Among other things, **PLAINTIFF** avers that **COUCH** and **TARABEIN** were negligent by: overprescribing prescription drugs to Bruce Brockel; prescribing drugs to Mr. Brockel without medical necessity/justification; conducting unnecessary procedures; prescribing cancer related drugs to Mr. Brockel even though he did not have cancer; improperly charging for goods/services/procedures not actually performed; improperly charging for goods/services/procedures not medically necessary; billing for physician office visits when Mr. Brockel was only seen by staff; re-using epidural needles and/or needles in radio frequency machines; receiving illegal kickbacks and referral payments from pharmaceutical companies, distributors and/or other third parties; and failing to properly detox Mr. Brockel.

146. **PLAINTIFF** avers that Bruce Brockel's injuries and death were the direct and proximate result of the aforementioned negligent conduct of Defendants.

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

THIRD CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Wantonness)

147. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 146 as if fully set out herein including the "Background/Facts" sections. **PLAINTIFF** is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

148. **PLAINTIFF** avers that Bruce Brockel's injuries and death were the direct and proximate result of the wanton and/or reckless conduct of the Defendants as outlined herein including in the "Background/Facts" sections. In addition, **PLAINTIFF** avers that Defendants knowingly and/or recklessly supplied opioids to suspicious physicians (including **COUCH** and **TARABEIN**) and pharmacies (including **C&R**) to maximize profits.

149. The brand-name Manufacturing Defendants have a duty to warn of the risks which it knew or reasonably should have known, regardless of whether the consumer (including Plaintiff) is prescribed the brand-name drug or its competitors' generic bioequivalent. The brand-name Manufacturing Defendants are liable for the generic versions of their opioids because they intentionally failed to update warning labels for their drugs despite knowing the risks. Therefore, said Defendants are liable for wantonness and/or recklessness.

150. The generic Manufacturing Defendants colluded with the brand-name Manufacturing Defendants to cause the brand-name Manufacturing Defendants not to update their warning labels despite knowing the risks. Therefore, the generic Manufacturing Defendants are liable for wantonness and/or recklessness along with the brand-name Manufacturing Defendants.

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory and punitive damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

FOURTH CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Alabama Extended Manufacturer's Liability Doctrine)

151. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 150 as if fully set out herein including the "Background/Facts" sections. **PLAINTIFF** is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

152. **PLAINTIFF** avers that opioids are products that are unreasonably dangerous to the ultimate user or consumer including Bruce Brockel.

153. **PLAINTIFF** avers that Bruce Brockel's injuries and ultimate death were proximately caused by Defendants who sold and/or distributed opioids in a defective condition that made them unreasonably dangerous to Mr. Brockel as the ultimate user and consumer; that Defendants were engaged in the business of selling and/or distributing opioids; and that the opioids were expected to, and did, reach Mr. Brockel without substantial change in the condition in which they were sold.

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

FIFTH CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Fraud & Misrepresentation)

154. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 153 as if fully set out herein including the "Background/Facts" section. **PLAINTIFF** is

exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

155. **PLAINTIFF** avers that Defendants committed fraud by misrepresenting and/or concealing the harmful effects and addictiveness of the opioids that were manufactured, marketed, promoted, sold, distributed, and/or prescribed by Defendants and consumed by Mr. Brockel. **PLAINTIFF** also avers that Defendants fraudulently misrepresented that the opioids were effective for long term treatment of chronic pain, and that they should be prescribed for long term use.

156. **PLAINTIFF** avers that Defendants **PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** exaggerated the benefits of the medication and knew the drugs were being overprescribed, yet failed to warn doctors (including **COUCH** and **TARABEIN**) and others (including **PLAINTIFF**) of the extremely addictive nature of the narcotics and the need to strictly limit the dose. In addition, **PLAINTIFF** avers that Defendants knowingly and/or recklessly supplied opioids to suspicious physicians (including **COUCH** and **TARABEIN**) and pharmacies (including **C&R**) to maximize profits.

157. **PLAINTIFF** avers that Defendants **PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** lobbied politicians and doctors in an effort to artificially increase the use of opioids.

158. The brand-name Manufacturing Defendants have a duty to warn of the risks which it knew or reasonably should have known, regardless of whether the consumer (including Plaintiff) is prescribed the brand-name drug or its competitors' generic bioequivalent. The brand-name Manufacturing Defendants are liable for the generic versions of their opioids because they intentionally failed to update warning labels for their drugs despite knowing the risks. Therefore, said Defendants are liable for fraud.

159. The generic Manufacturing Defendants committed fraud by colluding/conspiring with the brand-name Manufacturing Defendants to cause the brand-name Manufacturing Defendants not to update their warning labels despite knowing the risks. Therefore, the generic Manufacturing Defendants are liable for fraud along with the brand-name Manufacturing Defendants.

160. **PLAINTIFF** avers that **TEVA** and **CEPHALON** committed fraud and misrepresentation by marketing and promoting Fentora/Fentanyl for off label uses. In 2006, the FDA approved Fentora/Fentanyl for the management of pain in cancer patients who were already receiving, and who were tolerant to, opioid therapy for their underlying persistent cancer related pain. Notwithstanding the fact that Fentora/Fentanyl was supposed to be used to treat cancer patients, it was marketed and promoted by **TEVA** and **CEPHALON** for other uses such as to treat chronic pain like **PLAINTIFF** experienced. This was improper and was done to maximize the profits of **TEVA** and **CEPHALON**.

161. **PLAINTIFF** avers that Defendants **COUCH** and **TARABEIN** routinely charged for procedures that were not done in order to maximize profits. For example, during **TARABEIN's** treatment of Mr. Brockel, it appears that **TARABEIN** routinely charged him for epidural blocks even though he was only providing trigger point injections. On information and

belief, **TARABEIN** did same to maximize profits which defrauded Mr. Brockel, BCBS of AL, and Medicare.

162. Moreover, **COUCH** and **TARABEIN** committed fraud/misrepresentation by doing the following: prescribing drugs to Mr. Brockel without medical necessity or justification to make a profit; conducting unnecessary procedures; submitting improper charges for goods, services and procedures not actually performed; submitting improper charges for goods, services and procedures not medically necessary; billing for physician office visits when Mr. Brockel was only seen by staff; re-using epidural needles and/or needles in radio frequency machines; and receiving illegal kickbacks and referral payments from pharmaceutical companies, distributors and/or other third parties.

163. **PLAINTIFF** avers that these actions were misrepresentations of material facts made willfully to deceive, or recklessly without knowledge, and were acted on by Mr. Brockel. Accordingly, Defendants are liable for fraud and misrepresentation pursuant to Alabama Code §6-5-100 and §6-5-101 (1975).

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory and punitive damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

SIXTH CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Suppression & Concealment)

164. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 163 as if fully set out herein including the “Background/Facts” sections. **PLAINTIFF**

is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

165. **PLAINTIFF** avers that Defendants committed fraud by suppressing and/or concealing the harmful effects and addictiveness of the opioids that were manufactured, marketed, promoted, sold, distributed, and/or prescribed by Defendants and consumed by Mr. Brockel. **PLAINTIFF** also avers that Defendants misrepresented that the opioids were effective for long term treatment of chronic pain, and that they should be prescribed for long term use.

166. The generic Manufacturing Defendants are guilty of suppression/concealment by colluding/conspiring with the brand-name Manufacturing Defendants to cause the brand-name Manufacturing Defendants not to update their warning labels despite knowing the risks. Therefore, the generic Manufacturing Defendants are liable for suppression/concealment along with the brand-name Manufacturing Defendants.

167. **PLAINTIFF** avers that said suppression/concealment of material facts was in violation of Alabama Code §6-5-102 (1975), and tolled the applicable statutes of limitations regarding the Causes of Action alleged herein.

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory and punitive damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

SEVENTH CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Deceit)

168. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 167 as if fully set out herein including the “Background/Facts” section. **PLAINTIFF** is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

169. **PLAINTIFF** avers that Defendants deceived Mr. Brockel regarding the harmful effects and addictiveness of the opioids that were manufactured, marketed, promoted, sold, distributed, and/or prescribed by Defendants and consumed by Mr. Brockel. **PLAINTIFF** also avers that Defendants misrepresented that the opioids were effective for long term treatment of chronic pain, and that they should be prescribed for long term use.

170. The brand-name Manufacturing Defendants have a duty to warn of the risks which it knew or reasonably should have known, regardless of whether the consumer (including Plaintiff) is prescribed the brand-name drug or its competitors’ generic bioequivalent. The brand-name Manufacturing Defendants are liable for the generic versions of their opioids because they intentionally failed to update warning labels for their drugs despite knowing the risks. Therefore, said Defendants are liable for deceit.

171. The generic Manufacturing Defendants deceptively colluded/conspired with the brand-name Manufacturing Defendants to cause the brand-name Manufacturing Defendants not to update their warning labels despite knowing the risks. Therefore, the generic Manufacturing Defendants are liable for deceit along with the brand-name Manufacturing Defendants.

172. **PLAINTIFF** avers that these actions were willful misrepresentations of material facts made to induce Mr. Brockel to act, and which he did causing his injuries and death. Accordingly, Defendants are liable for deceit pursuant to Alabama Code §6-5-103 (1975).

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory and punitive damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

EIGHTH CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Unjust Enrichment)

173. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 172 as if fully set out herein including the “Background/Facts” section. **PLAINTIFF** is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

174. **PLAINTIFF** avers that Defendants have been unjustly enriched as a result of their wrongful actions as outlined herein. Defendants should not be able to retain the profits made by their wrongful actions.

175. **PLAINTIFF** avers that Defendants have retained and continue to retain the benefits conferred upon them as a result of their unlawful conduct and to the detriment of **PLAINTIFF**. Defendants’ retention of the benefits is unjust.

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory and punitive damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

NINTH CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Civil Conspiracy)

176. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 175 as if fully set out herein including the “Background/Facts” sections. **PLAINTIFF** is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

177. **PLAINTIFF** avers that Defendants conspired to suppress and/or conceal the harmful effects and addictiveness of the opioids that were manufactured, marketed, promoted, sold, distributed, and/or prescribed by Defendants and consumed by Mr. Brockel.

178. The generic Manufacturing Defendants colluded/conspired with the brand-name Manufacturing Defendants to cause the brand-name Manufacturing Defendants not to update their warning labels despite knowing the risks. Therefore, the generic Manufacturing Defendants are liable along with the brand-name Manufacturing Defendants.

179. **PLAINTIFF** avers that said suppression and concealment constitutes conspiracy.

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory and punitive damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

TENTH CAUSE OF ACTION (AGAINST ALL DEFENDANTS)
(Recklessness and Gross Negligence)

180. **PLAINTIFF** adopts by reference all allegations contained in paragraphs 1 through 179 as if fully set out herein including the “Background/Facts” sections. **PLAINTIFF**

is exclusively pleading causes of action under Alabama Law, and pleads no Federal Law causes of action.

181. Defendants' aforesaid acts and omissions were done and omitted knowing that injury to **PLAINTIFF** would likely or probably result; were done or omitted with a reckless or conscious disregard of the rights of **PLAINTIFF**; were done or omitted without the exercise of even a slight degree of care; were done or omitted with conscious indifference to the consequences; and/or constituted a substantial deviation from the standard of care applicable.

182. **PLAINTIFF** avers that the damages sustained by **PLAINTIFF** were the direct and proximate result of the recklessness and/or gross negligence of the Defendants as outlined herein. In addition, **PLAINTIFF** avers that the Manufacturing Defendants knowingly and/or recklessly supplied opioids to suspicious physicians and pharmacies to maximize profits.

183. The brand-name Manufacturing Defendants have a duty to warn of the risks which it knew or reasonably should have known, regardless of whether the consumer (including Plaintiff) is prescribed the brand-name drug or its competitors' generic bioequivalent. The brand-name Manufacturing Defendants are liable for the generic versions of their opioids because they intentionally failed to update warning labels for their drugs despite knowing the risks. Therefore, said Defendants are liable for recklessness and/or gross negligence.

184. The generic Manufacturing Defendants colluded/conspired with the brand-name Manufacturing Defendants to cause the brand-name Manufacturing Defendants not to update their warning labels despite knowing the risks. Therefore, the generic Manufacturing Defendants are liable for recklessness and/or gross negligence along with the brand-name Manufacturing Defendants.

185. By reason of the foregoing, and as a direct and proximate result of Defendants' recklessness and/or gross negligence, **PLAINTIFF** has suffered damages.

WHEREFORE, **PLAINTIFF** demands judgment against Defendants **COUCH, TARABEIN, PPSA, C&R, ESNC, PURDUE PHARMA, PFIZER, ENDO, KVK-TECH, ZYDUS, NESHER, WATSON, MALLINCKRODT, WEST-WARD, ACTAVIS, ROXANE, PAR, RHODES, TEVA, CEPHALON, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z** for compensatory and punitive damages in an amount in excess of the minimum jurisdictional limit of this Court, as well as such other and further relief as the Court may deem just and proper.

PLAINTIFF RESPECTFULLY DEMANDS TRIAL BY JURY

Respectfully submitted,



DAVID A. BUSBY (BUS021)

JONATHAN R. LAW (LAW039)

DANIELL, UPTON & PERRY, P.C.

30421 HIGHWAY 181

DAPHNE, AL 36527

jrl@dupm.com (E-mail)

dab@dupm.com (E-mail)

(251) 625-0046 (Voice)

(251) 625-0464 (Fax)

Attorneys for the ESTATE OF BRUCE BROCKEL,
deceased, by and through DONNA BROCKEL, as
Personal Representative

C. BENNETT, LONG

LONG & LONG

301 ST. LOUIS STREET

MOBILE, AL 36602

bennett@longandlong.com

(251) 432-2277 (Voice)

CERTIFICATE OF SERVICE

I hereby certify that I have on April 5, 2018, electronically filed the foregoing with the Clerk of the Court using the CM/ECF System which will automatically serve the same via electronic mail and/or by placing same in the United States mail, first class postage prepaid, and properly addressed to the following:

Counsel for Defendant Purdue Pharma L.P.

Michael E. Upchurch, Esquire
Blair Graffeo Mattei, Esquire
Frazer, Green, Upchurch & Baker, LLC
P.O. Box 1686
Mobile, AL 36633
334-431-6020
meu@frazergreene.com
bgm@frazergreene.com

Hayden A. Coleman, Esquire
Mark S. Cheffo, Esquire
Quinn, Emanuel, Urquhart & Sullivan, LLP
51 Madison Avenue
New York, NY 10010
212-849-7000
haydencoleman@quinnemanuel.com
markcheffo@quinnemanuel.com

Patrick J. Fitzgerald, Esquire
R. Ryan Stoll, Esquire.
Skadden, Arps, Slate, Meagher & Flom LLP
155 North Wacker Drive, Suite 2700
Chicago, IL 60606
312 407-0700
patrick.fitzgerald@skadden.com
ryan.stoll@skadden.com

Counsel for Defendants Endo Pharmaceuticals Inc. & Par Pharmaceutical, Inc.

Lee E. Bains, Jr., Esquire
Maynard, Cooper and Gale, PC
1901 6th Avenue N., Ste. 2400
Birmingham, AL 35203
205-254-1000
lbains@mcglaw.com

Ingo W. Sprie, Jr., Esquire
Arnold & Porter, Kaye Scholer LLP
250 West 55th Street
New York, NY 10019-9710
212-836-8000
Ingo.sprie@apks.com

Sean Morris, Esquire
Arnold & Porter Kaye Scholer LLP
777 S. Figueroa Street
44th Floor
Los Angeles, CA 90017
213-243-4000
Sean.morris@apks.com

F. Grey Redditt, Jr., Esquire
Maynard, Cooper and Gale, P.C.
RSA Battle House Tower
11 N. Water Street, Suite 24290
Mobile, AL 36602
251-405-8647
gredditt@maynardcooper.com

Counsel for Defendant Pfizer, Inc.

Fred M. Haston, III, Esquire
 Angelique A. Ciliberti, Esquire
 Bradley, Arant, Boult, Cummings, LLP
 One Federal Place
 1819 Fifth Ave. N.
 Birmingham, AL 35203
 205-521-8000
thaston@babco.com
aciliberti@bradley.com

Loren H. Brown, Esquire
 DLA Piper
 1251 Avenue of the Americas
 New York, NY 10020-1104
 212-335-4846
Loren.brown@dlapiper.com

**Counsel for Defendants Zydus
 Pharmaceuticals (USA) Inc. & Neshor
 Pharmaceuticals (USA) LLC**

Arthur J. Liederman, Esquire
 Morris, Mahoney LLP
 120 Broadway
 New York, NY 10271
 212-428-2480
aliederman@morrismahoney.com

Clifford C. Brady, Esquire
 Brady, Radcliff & Brown, LLP
 P.O. Box 1668
 Mobile, AL 36633
 251-405-0077
 251-405-0076 Fax
cbrady@brblawyers.com

Counsel for Defendant KVK-Tech, Inc.

Thomas E. Rice, Esquire
 Baker, Sterchi, Cowden & Rice, LLC
 2400 Pershing Road, Suite 500
 Kansas City, MO 64108-2533
 816-471-2121
rice@bscr-law.com

Frederick G. Helmsing, Jr., Esquire
 T. Hart Benton, III, Esquire
 Archibald T. Reeves, IV, Esquire
 McDowell, Knight, Roedder & Sledge, LLC
 P.O. Box 350
 Mobile, AL 36601
 251-432-5300
fhelmsing@mcdowellknight.com
tbenton@mcdowellknight.com
areeves@mcdowellknight.com

**Counsel Defendants for Teva
 Pharmaceuticals USA, Inc., Cephalon,
 Inc., Actavis Pharma, Inc. & Watson
 Laboratories, Inc.**

Terry M. Henry, Esquire.
 BlankRome LLP
 One Logan Square
 130 North 18th Street
 Philadelphia, PA 19103-6998
 215-569-5644
THenry@BlankRome.com

**Counsel for Defendant Rhodes
 Pharmaceuticals L.P.**

Steven F. Napolitano, Esquire
 Skarzynski Black LLC
 One Battery Park Plaza, 32nd Floor
 New York, NY 10004
 212-820-7746
snapolitano@skarzynski.com

Counsel for Defendant West-Ward Pharmaceuticals Corp.

Thomas E. Walker, Esquire
 H. Eli Lightner, II, Esquire
 White Arnold & Dowd P.C.
 2025 Third Avenue North, Suite 500
 Birmingham, AL 35203
 205-323-1888
twalker@whitearnolddowd.com
elightner@whitearnolddowd.com

Defendant Mallinckrodt Pharmaceuticals, Inc.

Mallinckrodt Pharmaceuticals, Inc.
 675 McDonnell Blvd.
 Hazelwood, MO 63042

Defendant John Patrick Couch

John Patrick Couch
 Register No. #14290-003
 c/o FCI Forrest City Low
 1400 Dale Bumpers Road
 Forrest City, AR 72335

Defendant C & R Pharmacy, LLC

C & R Pharmacy, LLC
 c/o John Patrick Couch
 Register No. #14290-003
 c/o FCI Forrest City Low
 1400 Dale Bumpers Road
 Forrest City, AR 72335

Defendant Roxane Laboratories, Inc.

Roxane Laboratories, Inc.
 1809 Wilson Rd.
 Columbus, OH 43216-6532

Defendant Eastern Shore Neurology Clinic, Inc.


Eastern Shore Neurology Clinic, Inc.
 c/o Rassan M. Tarabein
 22341 Main Street
 Fairhope, AL 36532

Defendant Physicians Pain Specialists of Alabama, P.C.

c/o John Patrick Couch
 Register No. #14290-003
 c/o FCI Forrest City Low
 1400 Dale Bumpers Road
 Forrest City, AR 72335

Defendant Rassan M. Tarabein

Rassan M. Tarabein
 22341 Main Street
 Fairhope, AL 36532



DAVID A. BUSBY

EXHIBIT 1

THE STATE OF ALABAMA

COURT OF PROBATE

COUNTY OF MOBILE

CASE NO. 2017-1954

RE: BRUCE RUSSELL BROCKEL, DECEASED

LETTERS OF ADMINISTRATION

Letters of Administration of the Estate of BRUCE RUSSELL BROCKEL, are hereby granted to DONNA J BROCKEL, who has duly qualified and given bond as such Personal Representative and is authorized to administer such estate with authority to take actions as set forth in §43-2-830, et seq. (1975). The powers and duties of said Personal Representative specifically include, but are not limited to, gathering and retaining estate assets, preparing an inventory of estate assets, paying taxes, uncontested claims, fees, and expenses, including court costs, incident to the administration of the estate. The authority of the Personal Representative is restricted as follows:

Restrictions:

- (1) With the exception of wrongful death matters, the Personal Representative shall not distribute any monies or estate assets to heirs, legatees, and/or beneficiaries resulting from litigation or settlement of litigation without prior Court approval.
- (2) Personal Representative must immediately report to the Court the receipt of any monies or assets which were not reported in the initial inventory and/or are received while these Letters are in effect.


Ordered this 19th day of October, 2017.



DON DAVIS, Judge of Probate

CERTIFIED COPY
DON DAVIS, JUDGE OF PROBATE
MOBILE COUNTY, ALABAMA

By: _____



C. MARK ERWIN, Chief Clerk

EXHIBIT 2

CVS PHARMACY
PATIENT PRESCRIPTION RECORD
BETWEEN 07/01/2007 AND 10/05/2017
PHARMACY# 4903

PAGE: 1 of 10
RUN DATE: 11/03/2017 TIME: 09:01:46
Request NBR: 3639613

PHARMACY NAME:
ADDRESS:
CITY, ST, ZIP:

3100 DAUPHIN ISLAND PKWY
MOBILE AL 36605

PATIENT KEY
PATIENT NAME:
ADDRESS:
CITY, ST, ZIP:

4903513741
BROCKEL BRUCE DECEAS
4013 MARYDALE DR
MOBILE AL 36605

TELEPHONE 251-727-8511

RX NUMBER	REL NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILED	QUANT DISP.	PATIENT PD AMT	PAYER TP AUTHORIZATION #
783933	0	GABAPENTIN 600 MG TABLET TEV	JANUSH, RACHE B	03/23/2010	75	6.00	23635 100825002827003998
783933	1	GABAPENTIN 600 MG TABLET TEV	JANUSH, RACHE B	04/22/2010	75	6.00	23635 101124424220009999
783933	2	GABAPENTIN 600 MG TABLET TEV	JANUSH, RACHE B	06/21/2010	75	155.99	1 ** NO AUTH NO
783934	0	BUSPIRONE HCL 10 MG TABLET MYL	JANUSH, RACHE B	03/23/2010	120	6.00	23635 100825010043009988
783934	1	BUSPIRONE HCL 10 MG TABLET MYL	JANUSH, RACHE B	04/22/2010	120	6.00	23635 101124424019001999
783935	0	METHADONE HCL 10 MG TABLET ROX	JANUSH, RACHE B	03/23/2010	240	12.00	23635 100825028054010999
783936	0	OXYCODONE APAP 10-325 MG TAVAT	JANUSH, RACHE B	03/23/2010	45	6.00	23635 100825320809007998
783946	1	SERTRALINE HCL 100 MG TABLET GRE	JANUSH, RACHE B	03/23/2010	60	3.00	23635 101124423603007999
783946	2	SERTRALINE HCL 100 MG TABLET GRE	JANUSH, RACHE B	06/05/2010	60	3.00	23635 101124423603007999
783946	0	ZOLPIDEM TARTRATE 10 MG TABLET	JANUSH, RACHE B	04/19/2010	30	4.84	23635 101094832783001999
788405	0	METHADONE HCL 10 MG TABLET ROX	JANUSH, RACHE B	04/22/2010	45	6.00	23635 101566378273001999
788980	0	BUSPIRONE HCL 10 MG TABLET MYL	JANUSH, RACHE B	05/11/2010	180	6.00	23635 101315105012006999
792081	1	BUSPIRONE HCL 10 MG TABLET MYL	JANUSH, RACHE B	06/25/2010	180	6.00	23635 101763250362003999
792081	2	BUSPIRONE HCL 10 MG TABLET MYL	JANUSH, RACHE B	08/02/2010	180	6.00	23635 102146620258005999
792081	3	BUSPIRONE HCL 10 MG TABLET MYL	JANUSH, RACHE B	08/29/2010	180	6.00	23635 102410099588004999
792081	4	BUSPIRONE HCL 10 MG TABLET MYL	JANUSH, RACHE B	09/28/2010	180	6.00	23635 102710097160002599
792081	5	BUSPIRONE HCL 10 MG TABLET MYL	JANUSH, RACHE B	11/27/2010	180	6.00	23635 103310154777002999
792082	0	METHADONE HCL 10 MG TABLET SAN	JANUSH, RACHE B	05/11/2010	30	60.00	23635 101315118895001999
792083	0	GABAPENTIN 600 MG TABLET TEV	JANUSH, RACHE B	05/11/2010	90	6.00	23635 101315137303003999
792499	0	METHADONE HCL 10 MG TABLET ROX	JANUSH, RACHE B	06/03/2010	30	4.84	1 ** NO AUTH NO
795876	0	ZOLPIDEM TARTRATE 10 MG TABLET	JANUSH, RACHE B	07/01/2010	30	4.84	23635 101545262005002999
800621	0	ZOLPIDEM TARTRATE 10 MG TABLET	JANUSH, RACHE B	08/02/2010	30	4.84	23635 101826005695010999
800621	1	ZOLPIDEM TARTRATE 10 MG TABLET	JANUSH, RACHE B	09/01/2010	30	4.84	23635 102146620505008999
800621	2	ZOLPIDEM TARTRATE 10 MG TABLET	JANUSH, RACHE B	07/01/2010	30	3.00	23635 102445427933008999
800623	1	SERTRALINE HCL 100 MG TABLET	JANUSH, RACHE B	07/01/2010	60	3.00	23635 101826058945008999
800623	2	SERTRALINE HCL 100 MG TABLET	JANUSH, RACHE B	08/29/2010	60	3.00	23635 102127394966009999
800623	3	SERTRALINE HCL 100 MG TABLET	JANUSH, RACHE B	10/01/2010	60	3.00	23635 102413963988009999
800623	4	SERTRALINE HCL 100 MG TABLET	JANUSH, RACHE B	11/02/2010	60	3.00	23635 102744457832001999
800623	5	SERTRALINE HCL 100 MG TABLET	JANUSH, RACHE B	12/02/2010	60	3.00	23635 103063767154007999
801446	0	AMOXICILLIN 500 MG CAPSULE	JANUSH, RACHE B	07/07/2010	21	5.36	23635 103365427268002999
801447	0	HYDROCODONE APAP 10-325 TABLET	DEVANEY, JAMES O	07/07/2010	60	6.00	23635 101886715570003999
803302	0	AMOXICILLIN 500 MG CAPSULE	DICKERSON, MARY	07/19/2010	21	5.36	23635 101886725282004999
808804	0	GABAPENTIN 600 MG TABLET	JANUSH, RACHE B	08/20/2010	90	6.00	23635 102004829563008999
808804	1	GABAPENTIN 600 MG TABLET	JANUSH, RACHE B	09/16/2010	90	6.00	23635 102326747813009999
808804	2	GABAPENTIN 600 MG TABLET	JANUSH, RACHE B	10/13/2010	90	6.00	23635 102593977578008999
808804	3	GABAPENTIN 600 MG TABLET	JANUSH, RACHE B	11/18/2010	90	6.00	23635 102864580208001999
810024	0	PROAIR HFA 90 MCG INHALER	INFIRMARY, WEST	08/28/2010	9	35.00	23635 103224649274005999



211000002

3639613

CVS PHARMACY
PATIENT PRESCRIPTION RECORD
BETWEEN 07/01/2007 AND 10/05/2017
PHARMACY# 4903

PAGE: 2 of 10
RUN DATE: 11/03/2017 TIME: 09:01:48
Request NBR: 3639613

PHARMACY NAME: 3100 DAUPHIN ISLAND PKWY
ADDRESS: MOBILE AL 36605
CITY, ST, ZIP: MOBILE AL 36605

PATIENT KEY: 4903513741
PATIENT NAME: BROCKEL BRUCE DECEAS
ADDRESS: 4013 MARYDALE DR
CITY, ST, ZIP: MOBILE AL 36605

TEL: 251-722-8511

DOCUMENT 124

RX NUMBER	REL NDC NUMBER	DRUG DESCRIPTION	PREScriBER NAME	DATE FILED	QUAN- TY DISP	PATIENT PD AMT	PAYER ID AUTHORIZATION #
810026	0	59746000103 METHYLPREDNISOLONE 4 MG	INFIRMARY, WEST	08/28/2010	21	5.11	23635 102405678136009999
810027	0	00143211205 DOXYCYCLINE HYCLATE 100 MG TAB	TYON, WARRE G	08/28/2010	20	3.76	23635 102405752557003996
813234	0	00378401001 TEMAZEPAM 15 MG CAPSULE	JANUSH, RACHE B	09/16/2010	30	11.99	1
813234	1	00378401001 TEMAZEPAM 15 MG CAPSULE	JANUSH, RACHE B	10/21/2010	30	11.99	1
814356	0	00591093201 OXYCODONE APAP 10-325 MG TAB	JANUSH, RACHE B	09/23/2010	30	6.00	23635 102664537368001999
814362	0	00054457125 METHADONE HCL 10 MG TABLET	JANUSH, RACHE B	09/23/2010	300	6.00	23635 102664536323002999
815787	0	00173068220 VENTOLIN HFA 90 MCG INHALER	MITCHELL, BARBA	10/01/2010	18	33.61	23635 102744620501005999
815787	1	00173068220 VENTOLIN HFA 90 MCG INHALER	MITCHELL, BARBA	05/10/2011	18	36.31	23635 111026706139010999
815787	2	00173068220 VENTOLIN HFA 90 MCG INHALER	MITCHELL, BARBA	10/01/2010	16	6.00	23635 102744636564029999
815789	0	00054327099 FLUTICASONE PROP 50 MCG SPRAY	MITCHELL, BARBA	10/01/2010	16	6.00	23635 103625595123010999
815789	1	00054327099 FLUTICASONE PROP 50 MCG SPRAY	MITCHELL, BARBA	12/28/2010	16	6.00	23635 10274464996009999
815789	2	00054327099 FLUTICASONE PROP 50 MCG SPRAY	MITCHELL, BARBA	04/12/2011	16	7.00	23635 111026708134006999
815789	3	00054327099 FLUTICASONE PROP 50 MCG SPRAY	MITCHELL, BARBA	07/20/2011	16	7.00	23635 112014373180030999
815790	0	66993010902 FEXOFENADINE HCL 180 MG TABLET	MITCHELL, BARBA	10/01/2010	30	6.00	23635 102744653473010999
815790	1	66993010902 FEXOFENADINE HCL 180 MG TABLET	MITCHELL, BARBA	11/23/2010	30	6.00	23635 103063756234010999
815790	2	66993010902 FEXOFENADINE HCL 180 MG TABLET	MITCHELL, BARBA	12/28/2010	30	6.00	23635 103625591345010998
815790	3	55111019401 CEFUROXIME AXETIL 500 MG TAB	MITCHELL, BARBA	10/01/2010	14	6.00	23635 102744656705010999
816114	0	00093007401 ZOLPIDEM TARTRATE 10 MG TABLET	JANUSH, RACHE B	10/04/2010	30	4.84	23635 102774140901010999
816114	1	00093007401 ZOLPIDEM TARTRATE 10 MG TABLET	JANUSH, RACHE B	11/02/2010	30	4.84	23635 103063769134009999
816114	2	00093007401 ZOLPIDEM TARTRATE 10 MG TABLET	JANUSH, RACHE B	12/02/2010	30	4.84	23635 10336542099806999
821839	0	00378699052 ALBUTEROL 0.083% INHAL SOLN	MITCHELL, BARBA	11/07/2010	75	16.09	1
822630	0	00591093201 OXYCODONE ACETAMINOPHEN	JANUSH, RACHE B	11/11/2010	100	6.00	23635 103155181366009999
827405	0	00406052301 OXYCODONE ACETAMINOPHEN	MITCHELL, BARBA	12/10/2010	28	6.00	23635 103446580627008999
827406	0	00378699052 ALBUTEROL 0.083% INHAL SOLN	MITCHELL, BARBA	12/13/2010	75	16.09	22415 00007544528301
827407	0	00378400505 ALPRAZOLAM 1 MG TABLET	MITCHELL, BARBA	12/10/2010	60	10.68	27165 3302948566
827407	1	00378400505 ALPRAZOLAM 1 MG TABLET	MITCHELL, BARBA	01/14/2011	60	10.68	27165 3327235193
827407	2	00378400505 ALPRAZOLAM 1 MG TABLET	MITCHELL, BARBA	02/16/2011	60	10.68	27165 3347454281
828060	0	00603388728 HYDROCODONE ACETAMINOPHN	JANUSH, RACHE B	12/15/2010	28	6.00	23635 103496270028003999
829158	0	00591374001 MORPHINE SULF ER 15 MG TABLET	JANUSH, RACHE B	12/21/2010	90	6.00	23635 103556885428600999
829159	0	00054457125 METHADONE HCL 10 MG TABLET	JANUSH, RACHE B	12/21/2010	240	12.00	23635 103556885109001996
829160	0	00093444401 GABAPENTIN 800 MG TABLET	JANUSH, RACHE B	12/21/2010	90	12.00	23635 103556906207007999
833982	0	00591374001 MORPHINE SULF ER 15 MG TABLET	COUCH, JOHN P	03/28/2011	30	4.86	23635 110214733041017999
845083	1	00093007401 ZOLPIDEM TARTRATE 10 MG TABLET	COUCH, JOHN P	04/28/2011	30	4.86	23635 110874335557010998
845084	0	00591374101 MORPHINE SULF ER 30 MG TABLET	COUCH, JOHN P	03/28/2011	90	7.00	23635 111837625480079999
845085	0	00054023625 CARISOPRODOL 350 MG TABLET	COUCH, JOHN P	04/21/2011	30	13.59	23635 1108743363536020998
849056	0	00603258228 HYDROCODONE ACETAMINOPHN	COUCH, JOHN P	04/21/2011	15	4.08	22415 000068718376401
849057	0	00603388821 MORPHINE SULFATE ER 30 MG TAB	COUCH, JOHN P	04/27/2011	90	7.00	23635 111114804792010999
849881	0	00054023625 MORPHINE SULFATE ER 30 MG TAB	COUCH, JOHN P	04/27/2011	90	7.00	23635 111173943766017999



311000002

3639613

PHARMACY NAME: 3100 DAUPHIN ISLAND PKWY
ADDRESS: MOBILE AL 36605
CITY, ST, ZIP: MOBILE AL 36605

PATIENT KEY: 4903513741
PATIENT NAME: BROCKEL BRUCE DECEAS
ADDRESS: 4013 MARYDALE DR
CITY, ST, ZIP: MOBILE AL 36605

CVS PHARMACY
PATIENT PRESCRIPTION RECORD
BETWEEN 07/01/2007 AND 10/05/2017
PHARMACY# 4903

TELEPHONE 251-727-8511

PAGE: 3 of 10
RUN DATE: 11/03/2017 TIME: 09:01:48
Request NBR: 3639613

RX NUMBER	REL	NDU NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILED	QUANT DISP	PATIENT PD AMT	PAYER #	TP AUTHORIZATION #
849882	0	60951065370	MORPHINE SULF ER 30 MG TABLET	COUCH, JOHN P	04/27/2011	120	14.00	23635	111173951410007996
851976	0	00378699052	ALBUTEROL 0.083% INHAL SOLN	MITCHELL, BARBA	05/10/2011	75	16.09	27165	3396282619
851976	1	00378699052	ALBUTEROL 0.083% INHAL SOLN	MITCHELL, BARBA	11/03/2011	75	16.09	27165	3507052947
852670	0	59762306001	AZITHROMYCIN 250 MG TABLET	RAO, SUDEE N	05/13/2011	6	7.00	23635	111335753179013997
852671	0	55111015810	OMEPRAZOLE DR 20 MG CAPSULE	RAO, SUDEE N	05/13/2011	30	7.00	23635	111335753360023996
854381	0	59011042010	OXYCONTIN 20 MG TABLET	COUCH, JOHN P	05/25/2011	45	72.38	23635	111454350565020999
854403	0	00093444401	GABAPENTIN 800 MG TABLET	JANUSH, RACHE B	05/25/2011	90	7.00	23635	111454756686020999
861090	0	13668001005	CITALOPRAM HBR 20 MG TABLET	SAITZ, MARIA	07/08/2011	30	6.27	23635	11189527900604999
861091	0	50111043401	TRAZODONE 100 MG TABLET	SAITZ, MARIA	07/08/2011	30	3.60	23635	111895281481008999
862705	0	13668000905	TRAZODONE 100 MG TABLET	SAITZ, MARIA	08/05/2011	30	3.60	23635	112173358064001999
865702	0	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	COUCH, JOHN P	07/20/2011	30	4.86	23635	112014444774004999
865702	1	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	COUCH, JOHN P	08/18/2011	30	4.86	23635	112306772454011999
865703	0	00406833001	MORPHINE SULF ER 30 MG TABLET	COUCH, JOHN P	09/18/2011	30	4.86	23635	112614664027007999
865704	0	00054023625	MORPHINE SULF ER 30 MG TAB	COUCH, JOHN P	08/08/2011	90	7.00	23635	112206963139023999
866540	0	00093444401	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	08/08/2011	120	7.00	23635	112206963139023999
866540	1	68462012705	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	08/26/2011	90	7.00	23635	112385196303028998
866540	2	68462012705	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	10/27/2011	90	7.00	23635	113003340559016998
866540	3	68462012705	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	12/21/2011	90	7.00	23635	113555819332008999
866540	4	68462012705	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	01/20/2012	90	2.60	23065	120317131648132999
866540	5	68462012705	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	04/17/2012	90	2.60	23065	121085024391062999
874572	1	00591033960	DICLOFENAC SOD EC 75 MG TAB	COUCH, JOHN P	05/22/2012	90	2.60	23065	121434989484128999
874572	1	00591033960	DICLOFENAC SOD EC 75 MG TAB	COUCH, JOHN P	10/04/2011	60	7.00	23635	112773581139006999
887459	0	00406838001	MORPHINE SULF ER 60 MG TABLET	COUCH, JOHN P	10/27/2011	60	7.00	23635	113003311488006998
887460	0	00054023625	MORPHINE SULF ER 30 MG TAB	COUCH, JOHN P	12/21/2011	60	7.00	23635	113554753718019998
887461	0	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	COUCH, JOHN P	12/21/2011	120	7.00	23635	113554771560030997
894354	0	00173068220	VENTOLIN HFA 90 MCG INHALER	RUSSELL, JOY	01/31/2012	18	6.50	23635	113554786601027999
894355	0	00054327099	FLUTICASON PROP 50 MCG SPRAY	RUSSELL, JOY	01/31/2012	16	2.60	23065	12031708460803999
894356	0	00378699052	ALBUTEROL 0.083% INHAL SOLN	RUSSELL, JOY	01/31/2012	75	16.09	27165	3607521273
903512	0	59310057920	PROAIR HFA 90 MCG INHALER	PERCY, ROBERE	03/20/2012	9	6.50	23065	120806489426122999
903512	1	59310057920	PROAIR HFA 90 MCG INHALER	PERCY, ROBERE	05/09/2012	9	6.50	23065	121305566968023999
903512	2	59310057920	PROAIR HFA 90 MCG INHALER	PERCY, ROBERE	07/08/2012	9	6.50	23065	12190485142008999
903512	3	59310057920	PROAIR HFA 90 MCG INHALER	PERCY, ROBERE	10/08/2012	9	6.50	23065	122827134704126999
903512	4	59310057920	PROAIR HFA 90 MCG INHALER	PERCY, ROBERE	12/15/2012	9	6.50	23065	123503127447072999
903512	5	59310057920	PROAIR HFA 90 MCG INHALER	PERCY, ROBERE	01/07/2013	9	6.50	23065	136074551537070999
912420	0	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	COUCH, JOHN P	06/09/2012	30	0.88	23065	121305955165070999
916280	0	42858090301	MORPHINE SULF ER 60 MG TABLET	COUCH, JOHN P	05/30/2012	60	2.60	23065	121515434901032999
929128	0	00054023625	MORPHINE SULF ER 30 MG TAB	COUCH, JOHN P	08/20/2012	90	2.60	23065	122333890865106999
933195	0	42858090301	MORPHINE SULF ER 60 MG TABLET	COUCH, JOHN P	09/17/2012	90	2.60	23065	122613250911135999
933196	0	65862052405	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	09/17/2012	90	2.60	23065	122613264926084999



411000002

3639613

CVS PHARMACY
PATIENT PRESCRIPTION RECORD
BETWEEN 07/01/2007 AND 10/05/2017
PHARMACY # 4903

PAGE: 4 of 10
RUN DATE: 11/03/2017 TIME: 09:01:48
Request NBR: 3639613

PHARMACY NAME:
ADDRESS:
CITY, ST, ZIP:

3100 DAUPHIN ISLAND PKWY
MOBILE AL 36605

PATIENT KEY:
PATIENT NAME:
ADDRESS:
CITY, ST, ZIP:

4903513741
BROCKEL BRUCE DECEAS
4013 MARYDALE DR
MOBILE AL 36605

TELEPHONE 251-727-8511

RX NUMBER	REL NUMBER	MDX NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILED	QUANT DISP.	PATIENT PD AMT	PAYER #	TP AUTHORIZATION #
933196	1	65862052405	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	10/19/2012	90	2.60	23065	12293341517113999
933196	2	65862052405	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	12/10/2012	90	2.60	23065	123454399568038999
933196	3	65862052405	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	02/01/2013	90	2.65	23065	130325745432073999
933196	4	65862052405	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	03/02/2013	90	2.65	23065	130614979117036999
933053	0	00591093201	TESTOSTERONE CYP 200 MG/ML	COUCH, JOHN P	09/17/2012	10	2.60	23065	122613284591052999
938470	0	00781261305	OXYCODONE-ACETAMINOPHEN	COUCH, JOHN P	10/08/2012	20	2.60	23065	122826280657139999
941879	0	00591093201	AMOXICILLIN 500 MG CAPSULE	COUCH, JOHN P	10/16/2012	30	2.60	23065	122906910652141999
941881	0	00781261305	OXYCODONE-ACETAMINOPHEN	COUCH, JOHN P	11/06/2012	40	2.60	23065	123113739580125999
942738	0	42858080301	MORPHINE SULF ER 60 MG TABLET	COUCH, JOHN P	11/06/2012	30	2.60	23065	123113782070084999
942739	0	00054023625	MORPHINE SULF ER 60 MG TAB	COUCH, JOHN P	11/12/2012	90	2.60	23065	123173661324092997
943082	0	00054327099	FLUTICASON PROPR 50 MCG SPRAY	PERCY, ROBERE	11/13/2012	16	2.60	23065	123173679944034999
943082	1	00054327099	FLUTICASON PROPR 50 MCG SPRAY	PERCY, ROBERE	12/10/2012	16	2.60	23065	123185699028039999
943082	2	00054327099	FLUTICASON PROPR 50 MCG SPRAY	PERCY, ROBERE	02/17/2013	16	2.65	23065	123454936786008999
951870	0	00603258228	CARISOPRODOL 350 MG TABLET	COUCH, JOHN P	02/17/2013	16	2.65	23065	130074530728114999
951870	1	00603258228	CARISOPRODOL 350 MG TABLET	COUCH, JOHN P	02/06/2013	60	2.65	23065	130486027093142999
951871	0	00955170310	ZOLPIDEM TART ER 12.5 MG TAB	COUCH, JOHN P	01/07/2013	30	2.65	23065	130075695391096999
951871	1	00955170310	ZOLPIDEM TART ER 12.5 MG TAB	COUCH, JOHN P	02/23/2013	30	2.65	23065	130074547464036999
951883	0	42858080301	MORPHINE SULF ER 60 MG TABLET	COUCH, JOHN P	01/07/2013	90	2.65	23065	130545784554145999
951884	0	00054023625	MORPHINE SULF ER 60 MG TAB	COUCH, JOHN P	01/07/2013	90	2.65	23065	130074683278123999
964243	0	00603258228	CARISOPRODOL 350 MG TABLET	COUCH, PATRI	03/04/2013	60	1.41	23065	130674687125083999
964939	0	63402019310	LUNESTA 3 MG TABLET	COUCH, PATRI	04/04/2013	60	1.41	23065	130636619921109999
964939	1	63402019310	LUNESTA 3 MG TABLET	COUCH, PATRI	03/07/2013	30	6.60	23065	130944436244121999
964939	0	00093511298	DILTIAZEM 24HR ER 120 MG CAP	PERCY, ROBERE	04/06/2013	30	6.60	23065	130965449362073999
964999	1	00093511298	DILTIAZEM 24HR ER 120 MG CAP	PERCY, ROBERE	03/07/2013	30	2.65	23065	130665663665085999
970963	0	65862052405	GABAPENTIN 800 MG TABLET	COUCH, JOHN P	04/04/2013	120	2.65	23065	131022793875034999
972667	0	00054327099	FLUTICASON PROPR 50 MCG SPRAY	PERCY, ROBERE	04/12/2013	32	2.65	23065	130694461833712999
972667	1	00054327099	FLUTICASON PROPR 50 MCG SPRAY	PERCY, ROBERE	07/16/2013	32	2.65	23065	131025830413140999
972667	2	00054327099	FLUTICASON PROPR 50 MCG SPRAY	PERCY, ROBERE	07/16/2013	32	2.65	23065	131974970998094999
972667	3	00054327099	FLUTICASON PROPR 50 MCG SPRAY	PERCY, ROBERE	11/12/2013	32	2.65	23065	132603481763098998
979205	0	00093511298	DILTIAZEM 24HR ER 120 MG CAP	PERCY, ROBERE	05/16/2013	30	0.00	23065	133164324380061998
979205	1	00093511298	DILTIAZEM 24HR ER 120 MG CAP	PERCY, ROBERE	06/16/2013	30	2.65	23065	131365139774107999
979205	2	00093511298	DILTIAZEM 24HR ER 120 MG CAP	PERCY, ROBERE	07/16/2013	30	2.65	23065	131675481778133999
979205	3	00093511298	DILTIAZEM 24HR ER 120 MG CAP	PERCY, ROBERE	08/15/2013	30	2.65	23065	131974970000499999
979205	4	00093511298	DILTIAZEM 24HR ER 120 MG CAP	PERCY, ROBERE	09/17/2013	30	2.65	23065	132275835627098999
979205	5	00093511298	DILTIAZEM 24HR ER 120 MG CAP	PERCY, ROBERE	10/17/2013	30	2.65	23065	132633479460133999
979324	0	63402019310	LUNESTA 3 MG TABLET	COUCH, JOHN P	05/16/2013	30	6.60	23065	132904145715073999
979324	1	63402019310	LUNESTA 3 MG TABLET	COUCH, JOHN P	06/16/2013	30	6.60	23065	131367396257101998



511000002

3639613

CVS PHARMACY
PATIENT PRESCRIPTION RECORD
BETWEEN 07/01/2007 AND 10/05/2017
PHARMACY# 4903

PAGE: 5 of 10
RUN DATE: 11/03/2017 TIME: 09:01:48
Request NBR: 3639613

PHARMACY NAME: 3100 DAUPHIN ISLAND PKWY
ADDRESS: MOBILE AL 36605
CITY, ST, ZIP: MOBILE AL 36605

PATIENT KEY: 4903513741
PATIENT NAME: BROCKEL BRUCE DECEAS
ADDRESS: 4013 MARYDALE DR
CITY, ST, ZIP: MOBILE AL 36605

TELEPHONE: 251-727-8511

RX NUMBER	REL NDC NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILED	QUANT DISP	PATIENT PD AMT	PAYER #	TP AUTHORIZATION #
980361	0	59310057922	PERCY, ROBER E	05/22/2013	9	6.60	23065	131424973359037999
980361	1	59310057922	PERCY, ROBER E	07/08/2013	9	6.60	23065	131890077081104999
980361	2	59310057922	PERCY, ROBER E	08/02/2013	9	6.60	23065	132140068102131999
980361	3	59310057922	PERCY, ROBER E	11/16/2013	9	0.00	23065	133204458447074998
980361	4	59310057922	PERCY, ROBER E	12/12/2013	9	0.00	23065	133467257999128998
990236	0	10370011610	COUCH, JOHN P	07/16/2013	30	2.65	23065	131974963926088997
990236	1	10370011610	COUCH, JOHN P	08/15/2013	30	2.65	23065	132276840175104998
990236	2	10370011610	COUCH, JOHN P	10/10/2013	30	2.65	23065	132276840175104998
991184	0	00054023625	COUCH, JOHN P	07/22/2013	120	2.65	23065	132835520926031999
1001283	0	00378014701	BORCICKY, DAVID J	09/24/2013	20	11.39	23065	132033101137147997
1001283	1	00378014701	BORCICKY, DAVID J	10/05/2013	20	11.39	22415	132675859224037999
1009073	0	00093511298	PERCY, ROBER E	11/12/2013	30	0.00	23065	133163770961003999
1009073	1	00093511298	PERCY, ROBER E	12/12/2013	30	0.00	23065	133163770961003999
1009073	2	00093511298	PERCY, ROBER E	01/08/2014	30	2.55	23065	133467255688139999
1009073	3	00093511298	PERCY, ROBER E	02/01/2014	30	2.55	23065	14008689833122999
1009073	4	00093511298	PERCY, ROBER E	03/01/2014	30	2.55	23065	140324794172159999
1011932	0	68180030360	ANDREWS, STEPH J	11/29/2013	14	0.00	23065	140884401842022999
1011934	0	60432045516	ANDREWS, STEPH J	11/29/2013	60	11.99	23065	133334967073105999
1013260	0	00603258228	COUCH, JOHN P	12/09/2013	60	0.00	23065	133434327199067999
1013260	1	00603258228	COUCH, JOHN P	01/30/2014	60	1.34	23065	140028526217109999
1016891	0	00054023625	COUCH, JOHN P	01/02/2014	120	2.55	23065	140093210603001999
1017865	0	00054023625	PERCY, ROBER E	02/02/2014	16	2.55	23065	140333670002125998
1017865	1	00054023625	PERCY, ROBER E	03/01/2014	16	2.55	23065	140604924712091999
1017865	2	00054023625	PERCY, ROBER E	03/24/2014	16	2.55	23065	140836753878120998
1017865	3	00054023625	COUCH, JOHN P	01/09/2014	10	2.55	23065	140094173779095997
1017865	4	00054023625	COUCH, JOHN P	02/14/2014	30	1.27	23065	140824220190014999
1017865	5	00054023625	MITCHELL, BARBA	02/18/2014	7	2.55	23065	140454537976039999
1017865	6	00054023625	MITCHELL, BARBA	02/24/2014	21	2.55	23065	140554587745007999
1017865	7	00054023625	RAO, SUDEE N	03/01/2014	60	1.34	23065	140603301181092999
1017865	8	00054023625	COUCH, JOHN P	03/01/2014	90	2.55	23065	140603417843018999
1017865	9	00054023625	COUCH, JOHN P	03/01/2014	120	2.55	23065	140603422876108999
1017865	10	00054023625	COUCH, JOHN P	03/04/2014	60	6.35	23065	140636999812169999
1017865	11	00054023625	COUCH, JOHN P	05/04/2014	36	2.55	23065	141244409754089996
1017865	12	00054023625	MITCHELL, BARBA	03/07/2014	10	2.55	23065	140665399564003999
1017865	13	00054023625	MITCHELL, BARBA	03/24/2014	90	2.55	23065	140836509622173999
1017865	14	00054023625	MITCHELL, BARBA	04/27/2014	90	2.55	23065	141175941101123999



611000002

3639613

CVS PHARMACY
PATIENT PRESCRIPTION RECORD
BETWEEN 07/01/2007 AND 10/05/2017
PHARMACY# 4903

PAGE: 7 of 10
RUN DATE: 11/03/2017 TIME: 09:01:48
Request NBR 3639613

PHARMACY NAME:
ADDRESS:
CITY, ST, ZIP:
3109 DAUPHIN ISLAND PKWY
MOBILE AL 36605

PATIENT KEY:
PATIENT NAME:
ADDRESS:
CITY, ST, ZIP:
4903613741
BROCKEL BRUCE DECEAS
4013 MARYDALE DR
MOBILE AL 36605

TELEPHONE 251-727-8511

RX NUMBER	REL NDC NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILED	QUANT DISP.	PATIENT PO AMT	PAYER #	TP AUTHORIZATION #
1126500	2	66993066330	DULOXETINE HCL DR 30 MG CAP	LINTON, JANET L	02/24/2016	60	2.95	23065
1126518	0	66993066430	DULOXETINE HCL DR 60 MG CAP	LINTON, JANET L	10/26/2015	30	0.00	23065
1126518	1	66993066430	DULOXETINE HCL DR 60 MG CAP	LINTON, JANET L	11/25/2015	30	0.00	23065
1126518	2	66993066430	DULOXETINE HCL DR 60 MG CAP	LINTON, JANET L	12/19/2015	30	0.00	23065
1126518	3	66993066430	DULOXETINE HCL DR 60 MG CAP	LINTON, JANET L	01/31/2016	30	2.95	23065
1131039	0	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	TARABEIN, RASSA	11/02/2015	30	0.00	23065
1135932	0	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	TARABEIN, RASSA	12/02/2015	30	0.00	23065
1139744	0	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	12/28/2015	90	0.00	23065
1139744	1	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	01/25/2016	90	2.95	23065
1139753	0	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	02/24/2016	90	2.95	23065
1139753	1	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	12/28/2015	120	0.00	23065
1139753	2	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	02/03/2016	120	2.95	23065
1142616	0	65862007601	CIPROFLOXACIN HCL 250 MG TAB	SIMPSON, STEPH T	02/24/2016	20	2.95	23065
1143593	0	00378081005	HYDROCHLOROTHIAZIDE 12.5 MG CP	SIMPSON, STEPH T	01/14/2016	20	2.95	23065
1143600	0	68382075810	METFORMIN HCL 500 MG TABLET	SIMPSON, STEPH T	01/20/2016	90	2.95	23065
1144732	0	50458014030	INVOKANA 100 MG TABLET	SIMPSON, STEPH T	01/20/2016	180	2.95	23065
1144860	0	50458014030	INVOKANA 100 MG TABLET	SIMPSON, STEPH T	01/27/2016	30	7.40	23065
1145448	0	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	TARABEIN, RASSA	03/03/2016	30	7.40	23065
1150443	0	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	TARABEIN, RASSA	01/31/2016	30	0.48	23065
1154153	0	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	03/01/2016	30	0.48	23065
1154153	1	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	03/23/2016	120	2.95	23065
1154153	2	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	04/22/2016	120	2.95	23065
1154154	0	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	120	2.95	23065
1154154	1	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	03/23/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/22/2016	90	2.95	23065
1154154	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/19/2016			



811000002

3639613

CVS PHARMACY
PATIENT PRESCRIPTION RECORD
BETWEEN 07/01/2007 AND 10/05/2017
PHARMACY# 4903

PAGE: 8 of 10
RUN DATE: 11/03/2017 TIME: 09:01:48
Request NBR: 3639613

PHARMACY NAME:
ADDRESS:
CITY, ST, ZIP:
3100 DAUPHIN ISLAND PKWY
MOBILE AL 36605

PATIENT KEY:
PATIENT NAME:
ADDRESS:
CITY, ST, ZIP:
4903513741
BROCKEL BRUCE DECEAS
4013 MARYDALE DR
MOBILE AL 36605

TELEPHONE: 251-727-8511

RX NUMBER	REL NUMBER	NDC NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILED	QUANT DISP.	PATIENT PD AMT	PAYER #	IP AUTHORIZATION #
1157799	1	00378245710	LORAZEPAM 1 MG TABLET	LINTON, JANET L	05/12/2016	60	2.95	23065	161335175246107999
1159638	0	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	04/27/2016	30	0.57	23065	161184409405177999
1159639	0	65162052110	PROMETHAZINE 25 MG TABLET	TARABEIN, RASSA	04/27/2016	12	0.53	23065	161184423129196999
1159991	0	13668000805	ZOLPIDEM TARTRATE 10 MG TABLET	TARABEIN, RASSA	04/29/2016	30	1.93	23065	161204403639212999
1163281	0	10702001801	OXYCODONE HCL 5 MG TABLET	MCINTYRE, MATTH	05/20/2016	45	0.78	23065	161414165881129998
1163282	0	45802048678	DOCUSATE SODIUM 100 MG SOFTGEL	MCINTYRE, MATTH	05/20/2016	30	2.40	27735	61126171
1166847	0	00378245710	LORAZEPAM 1 MG TABLET	LINTON, JANET L	06/15/2016	26	1.27	23065	161675097191062999
1167606	0	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	06/22/2016	30	2.43	23065	161745220209177999
1167607	0	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	06/22/2016	120	2.95	23065	161743360590211999
1167607	1	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	07/20/2016	120	2.95	23065	162024833579057999
1167607	2	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	08/21/2016	120	2.95	23065	162343642157055998
1167608	0	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	06/22/2016	90	2.95	23065	161743367567111999
1167608	1	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	07/18/2016	90	2.95	23065	162002968229314999
1167609	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	08/14/2016	90	2.95	23065	162273404199205999
1167609	0	65162052110	PROMETHAZINE 25 MG TABLET	TARABEIN, RASSA	06/29/2016	12	2.15	23065	161813638305105999
1170290	0	68462010530	ONANSETRON HCL 4 MG TABLET	SIMPSON, STEPH T	07/13/2016	30	0.98	23065	161955552790198999
1171214	0	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	07/21/2016	30	1.36	23065	162033548935169999
1171215	0	65162052110	PROMETHAZINE 25 MG TABLET	TARABEIN, RASSA	07/21/2016	12	1.17	23065	162033652716132999
1172648	0	68180051403	LISINAPRIL 10 MG TABLET	SIMPSON, STEPH T	08/02/2016	90	2.43	23065	162154962782164999
1172648	1	68180051403	LISINAPRIL 10 MG TABLET	SIMPSON, STEPH T	11/13/2016	90	0.00	23065	163186268870157999
1175221	0	65162052110	PROMETHAZINE 25 MG TABLET	TARABEIN, RASSA	08/18/2016	12	2.16	23065	162313765239100999
1175222	0	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	08/25/2016	15	2.95	23065	162386511328164999
1176470	0	00574200815	FLUCONAZOLE 200 MG TABLET	SIMPSON, STEPH T	08/25/2016	7	0.68	23065	162386520223092999
1176471	0	00172541346	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	10/18/2016	120	2.95	23065	162656752131224999
1180527	0	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	11/14/2016	120	2.95	23065	163004631490165999
1180527	1	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	09/21/2016	30	0.00	23065	163192965734074999
1180527	2	65862052405	GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	09/21/2016	30	0.00	23065	162655755330122999
1180528	0	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	10/26/2016	30	1.36	23065	163004631490165999
1180528	1	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	11/23/2016	30	0.00	23065	162923358488094999
1180528	2	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	09/21/2016	90	2.95	23065	16265575644109999
1180529	0	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	10/18/2016	90	2.95	23065	163192965734074999
1180529	1	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	09/21/2016	90	2.95	23065	162923338339131999
1180529	2	00378072419	TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	10/18/2016	90	2.95	23065	16265575644109999
1180532	0	65162052110	PROMETHAZINE 25 MG TABLET	TARABEIN, RASSA	09/21/2016	12	2.16	23065	16265575644109999
1184795	0	68180036109	FENOFIBRATE 145 MG TABLET	SIMPSON, STEPH T	10/21/2016	90	2.95	23065	162956312804172999
1185341	0	55111029336	SUMATRIPTAN SUCC 100 MG TABLET	TARABEIN, RASSA	10/26/2016	15	0.00	23065	163004133555104999
1185365	0	50574200815	NYSTOP 100,000 UNITS/GM POWDER	SIMPSON, STEPH T	10/26/2016	30	0.00	23065	163004744629118999
1185366	0	50458014130	INVOKANA 300 MG TABLET	SIMPSON, STEPH T	10/26/2016	30	0.00	23065	163004744629118999
1189561	0	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	02/11/2017	30	0.34	23065	170424024713071999
1189561	1	00378015210	CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA					



911000002

3639613

PHARMACY NAME
ADDRESS
CITY, ST, ZIP

3100 DAUPHIN ISLAND PKWY
MOBILE AL 36605

PATIENT KEY:
PATIENT NAME:
ADDRESS:
CITY, ST, ZIP

4903613741
BROCKEL BRUCE DECEAS
4013 MARYDALE DR
MOBILE AL 36605

TELEPHONE 251.727.8511

HX NUMBER	REL NDC NUMBER	DRUG DESCRIPTION	PRESCRIBER NAME	DATE FILED	QUANT DISP.	PATIENT PD AMT	PAYER IP AUTHORIZATION #
1189561	2	00378015210 CLONIDINE HCL 0.1 MG TABLET	TARABEIN, RASSA	03/22/2017	30	0.34	23065 170813558698145999
1189562	0	65862052405 GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	12/13/2016	120	0.00	23065 163482742285157999
1189562	1	69367013506 GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	01/12/2017	120	3.30	23065 170124155360129998
1189562	2	69367013506 GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	02/12/2017	120	3.30	23065 170433155394195998
1189563	0	00378072419 TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	12/13/2016	90	0.00	23065 163482744663113999
1189563	1	00378072419 TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	01/10/2017	90	3.30	23065 170102873551074999
1189563	2	00378072419 TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	02/12/2017	90	3.30	23065 170433149243102999
1189582	0	50458014130 INVOKANA 300 MG TABLET	SIMPSON, STEPH T	03/31/2017	30	8.25	23065 170900837906207999
1197003	0	55111029336 SUMATRIPTAN SUCC 100 MG TABLET	TARABEIN, RASSA	02/11/2017	9	0.99	23065 170424026856148999
1199621	0	68180051403 LISINOPRIL 10 MG TABLET	SIMPSON, STEPH T	02/07/2017	90	2.43	23065 170384103501034999
1199621	1	68180098003 LISINOPRIL 10 MG TABLET	SIMPSON, STEPH T	06/03/2017	90	0.00	23065 171544334488199999
1201366	0	68462012701 GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	03/12/2017	120	3.30	23065 170714371061218997
1201366	1	65862052405 GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	04/07/2017	120	3.30	23065 170970474315131999
1201366	2	65862052405 GABAPENTIN 800 MG TABLET	TARABEIN, RASSA	05/10/2017	120	3.30	23065 171300507167209999
1201367	0	00378072419 TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	03/12/2017	90	3.30	23065 170713642894078999
1201367	1	00378072419 TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	04/07/2017	90	3.30	23065 171300507167209999
1201367	2	00378072419 TIZANIDINE HCL 4 MG TABLET	TARABEIN, RASSA	05/10/2017	90	3.30	23065 170970474315131999
1201406	0	10702005601 ONDANSETRON HCL 4 MG TABLET	TARABEIN, RASSA	02/20/2017	40	3.28	23065 170515443090155999
1206069	0	68462010530 SUMATRIPTAN SUCC 100 MG TABLET	SIMPSON, STEPH T	03/29/2017	90	3.30	23065 170884072417158999
1208656	0	55111029336 PROAIR HFA 90 MCG INHALER	SIMPSON, STEPH T	04/17/2017	9	8.25	23065 171575163110081999
1214824	0	59310057922 METHYLPREDNISOLONE 4 MG	ALVARADO, ROGER	06/07/2017	21	3.30	23065 171586480824163999
1215004	0	00603459315 LEVOFLOXACIN 500 MG TABLET	SIMPSON, STEPH T	06/07/2017	7	0.00	23065 171586482693172999
1217742	0	24658031205 DOXYCYCLINE HYCLATE 100 MG TAB	SIMPSON, STEPH T	06/29/2017	20	3.30	23065 171805380026188999
1217745	0	65862052405 GABAPENTIN 800 MG TABLET	SIMPSON, STEPH T	06/29/2017	120	3.30	23065 171805400909218999
1217773	0	00603369121 HYDROCODONE-ACETAMINOPH 7.5-325	SIMPSON, STEPH T	06/29/2017	90	3.30	23065 171806051235216999



* 1071000007 *

3639613

13337601 0000000000

PHARMACY NAME:
ADDRESS:
CITY, ST, ZIP:
3100 DAUPHIN ISLAND PKWY
MOBILE AL 36605
PATIENT KEY:
PATIENT NAME:
ADDRESS:
CITY, ST, ZIP:
4903513741
BROCKEL BRUCE DECEAS
4013 MARYDALE DR
MOBILE AL 36605

CVS PHARMACY
PATIENT PRESCRIPTION RECORD
BETWEEN 07/01/2007 AND 10/05/2017
PHARMACY# 4903
TELEPHONE 251-727-8511

SCRIPT COUNT: 346 TOTAL PATIENT PAID AMOUNT: 1765.29

PAGE: 10 of 10
RUN DATE: 11/03/2017 TIME: 09:01:48
Request NBR: 3639613



111000002

3639613

11/03/2017 09:01:48

Walgreens There's a way

Page 1 of 11

INSURANCE PROFILE

01/01/2007 through 11/01/2017

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834

DATE PRINTED: 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days	Entered	Fill	Fill	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
1038633-6507	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY	KVK TECH	10702- 0056-01	C2	5	07/25/2016	10		LGD	TARABEIN, RASSAN	BT4052798 0909	(251)625- 0909	CMRKM PD	0.49
Total 1 Subtotal: 10 \$ 0.49															
1038633-6507	MORPHINE SULF 80MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ENDO	60951- 0655-70	C2	1	07/25/2016	2		LGD	TARABEIN, RASSAN	BT4052798 0909	(251)625- 0909	CMRKM PD	0.09
Total 1 Subtotal: 2 \$ 0.09															
1644436-7609	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093- 0074-01	C4	30	06/30/2016	5		KDT	TARABEIN, RASSAN	BT4052798 0909	(251)625- 0909	CMRKM PD	0.49
1644436-7609	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093- 0074-01	C4	30	05/30/2016	25		CMH	TARABEIN, RASSAN	BT4052798 0909	(251)625- 0909	CMRKM PD	1.94
Total 1 Subtotal: 2 \$ 2.43															
2164232-6085	INVOKANA 300MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	JANSEN	50458- 0141-30	RX	30	05/26/2016	30		DNN	SIMPSON, STEPHEN	BS8273423 4949	(251)633- 4949	CMRKM PD	7.40
2164232-6085	INVOKANA 300MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	JANSEN	50458- 0141-30	RX	30	06/27/2016	30		ECC	SIMPSON, STEPHEN	BS8273423 4949	(251)633- 4949	CMRKM PD	7.40

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

Walgreens There's a way

Page 2 of 11

INSURANCE PROFILE

01/01/2007 through 11/01/2017

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834
DATE PRINTED: 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days Supply	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
2164232-6085	INVOKANA 300MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	JANSEN	50458-0141-30	RX	30	07/28/2016	30		ECC	SIMPSON, STEPHEN	BS8273423 (251)633-4949		CMRKM PD	7.40
2164232-6085	INVOKANA 300MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	JANSEN	50458-0141-30	RX	30	08/27/2016	30		JPD	SIMPSON, STEPHEN	BS8273423 (251)633-4949		CMRKM PD	7.40
Total										4	Subtotal:	120			\$ 29.60
2164233-6085	FENOFIBRATE 145MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	TEVA	00093-2060-98	RX	30	05/26/2016	30		DNN	SIMPSON, STEPHEN	BS8273423 (251)633-4949		CMRKM PD	2.95
2164233-6085	FENOFIBRATE 145MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	TEVA	00093-2060-98	RX	30	06/27/2016	30		ECC	SIMPSON, STEPHEN	BS8273423 (251)633-4949		CMRKM PD	2.95
2164233-6085	FENOFIBRATE 145MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	TEVA	00093-2060-98	RX	30	07/28/2016	30		ECC	SIMPSON, STEPHEN	BS8273423 (251)633-4949		CMRKM PD	2.95
2164233-6085	FENOFIBRATE 145MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	TEVA	00093-2060-98	RX	30	08/27/2016	30		JPD	SIMPSON, STEPHEN	BS8273423 (251)633-4949		CMRKM PD	2.95
Total										4	Subtotal:	120			\$ 11.80
2164455-6085	MORPHINE SULFATE (MM REL. 15MG TAB	TAKE 1 TABLET BY MOUTH DAILY	ROXANE	00054-0235-25	C2	30	05/27/2016	30		EAP	TARABEIN, RASSAN	BT14052798 (251)625-0909		CMRKM PD	2.95
Total										1	Subtotal:	30			\$ 2.95

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

Walgreens There's a way

Page 3 of 11

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834

DATE PRINTED: 11/01/2017

INSURANCE PROFILE

01/01/2007 through 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days Supply	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
2165076-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY	ZYDUS	68382-0905-01	C2	30	05/28/2016	60		JPD	MEGGINSON, AUTRY	AM0463098	(251)433-1895	CMRKM PD	2.95
										Total		1	Subtotal:	60	\$ 2.95
2177536-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093-0074-01	C4	30	06/27/2016	30		JPD	TARABEIN, RASSAN	BT4052798	(251)625-0909	CMRKM PD	2.43
										Total		1	Subtotal:	30	\$ 2.43
2177537-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ZYDUS	68382-0905-01	C2	30	06/27/2016	60		ECC	TARABEIN, RASSAN	BT4052798	(251)625-0909	CMRKM PD	2.95
										Total		1	Subtotal:	60	\$ 2.95
2190782-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME	TEVA	00093-0074-01	C4	30	07/28/2016	30		ECC	TARABEIN, RASSAN	BT4052798	(251)625-0909	CMRKM PD	1.75
										Total		1	Subtotal:	30	\$ 1.75
2190783-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ZYDUS	68382-0905-01	C2	30	07/28/2016	60		ECC	TARABEIN, RASSAN	BT4052798	(251)625-0909	CMRKM PD	2.95
										Total		1	Subtotal:	30	\$ 1.75

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

Walgreens There's a way™

Page 4 of 11

INSURANCE PROFILE

01/01/2007 through 11/01/2017

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834
DATE PRINTED: 11/01/2017BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days Supply	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
2191282-6085	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	KVK TECH	10702-0056-01	C2	20	07/29/2016	40		EAP	TARABEIN, RASSAN	BT4052798 (251)625-0909		CMRKM PD	1.96
Total										1 Subtotal:		60			\$ 2.95
2203714-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093-0074-01	C4	30	08/27/2016	30		JPD	TARABEIN, RASSAN	BT4052798 (251)625-0909		CMRKM PD	1.75
Total										1 Subtotal:		40			\$ 1.96
2203715-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY	ZYDUS	88382-0906-01	C2	30	08/27/2016	60		JPD	TARABEIN, RASSAN	BT4052798 (251)625-0909		CMRKM PD	2.95
Total										1 Subtotal:		60			\$ 2.95
2203880-6085	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	KVK TECH	10702-0056-01	C2	20	08/28/2016	40		JPD	TARABEIN, RASSAN	BT4052798 (251)625-0909		CMRKM PD	1.96
Total										1 Subtotal:		40			\$ 1.96

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

Waldgreen There's a way™

Page 5 of 11

INSURANCE PROFILE

01/01/2007 through 11/01/2017

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834
DATE PRINTED: 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days Supply	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
2217297-6085	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED FOR 30 DAYS	KVK TECH	10702-0056-01	C2	30	09/27/2016	40		DNN	TARABEIN, RASSAN	BT4052798 0909	(251)625-0909	CMRKM PD	2.95
										Total		1	Subtotal:	40	\$ 2.95
2217298-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093-0074-01	C4	30	09/27/2016	30		DNN	TARABEIN, RASSAN	BT4052798 0909	(251)625-0909	CMRKM PD	1.75
										Total		1	Subtotal:	30	\$ 1.75
2217300-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ZYDUS	68382-0905-01	C2	30	09/27/2016	60		DNN	TARABEIN, RASSAN	BT4052798 0909	(251)625-0909	CMRKM PD	2.95
										Total		1	Subtotal:	60	\$ 2.95
2220347-6085	INVOKANA 300MG TABLETS	TAKE 1 TABLET BY MOUTH DAILY	JANSSEN	50458-0141-30	RX	30	10/03/2016	30		RLW	SIMPSON, STEPHEN	BS8273423 4949	(251)633-4949	CMRKM PD	7.40
										Total		1	Subtotal:	30	\$ 7.40
2231341-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093-0074-01	C4	30	10/27/2016	30		RLW	TARABEIN, RASSAN	BT4052798 0909	(251)625-0909	CMRKM PD	0.00

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

Walgreens There's a way

Page 6 of 11

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834

INSURANCE PROFILE

DATE PRINTED: 11/01/2017

01/01/2007 through 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days	Supply	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt				
2231342-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ZYDUS	68382-0905-01	C2	30		10/27/2016	60		RLW	TARABEIN, RASSAN	BT4052798 0909	(251)825-PD	CMRKM	0.00				
											<u>Total</u>						1	Subtotal:	30	\$ 0.00
2231343-6085	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED FOR 30 DAYS	KVK TECH	10702-0056-01	C2	30		10/27/2016	40		RLW	TARABEIN, RASSAN	BT4052798 0909	(251)825-PD	CMRKM	0.00				
											<u>Total</u>						1	Subtotal:	60	\$ 0.00
2244555-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME	TEVA	00093-0074-01	C4	30		01/25/2017	30		DNN	TARABEIN, RASSAN	BT4052798 0909	(251)825-PD	CMRKM	1.75				
											<u>Total</u>						1	Subtotal:	40	\$ 0.00
2244555-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME	TEVA	00093-0074-01	C4	30		11/26/2016	30		DNN	TARABEIN, RASSAN	BT4052798 0909	(251)825-PD	CMRKM	0.00				
											<u>Total</u>						1	Subtotal:	30	\$ 0.00
2244555-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME	TEVA	00093-0074-01	C4	30		12/26/2016	30		JPD	TARABEIN, RASSAN	BT4052798 0909	(251)825-PD	CMRKM	0.00				
											<u>Total</u>						1	Subtotal:	30	\$ 0.00

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

Waldgreen There's a way

Page 7 of 11

INSURANCE PROFILE

01/01/2007 through 11/01/2017

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834

DATE PRINTED: 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days	Supply	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone Plan	Cust Amt
----------	------------	--------------	----------	-----	-------	------	--------	--------------	----------	----------	-----	----------	------	----------------	----------

2244556-6085	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED FOR 60 DAYS	KVK TECH	10702- 0056-01	C2	60	11/26/2016	80			DNN	TARABEN, RASSAN	874052798 (251)625- 0909	CMRKM PD	0.00	
Total										3	Subtotal:	90				\$ 1.75

2244557-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED FOR 60 DAYS	ZYDUS	68382- 0905-01	C2	60	11/26/2016	120			DNN	TARABEN, RASSAN	874052798 (251)625- 0909	CMRKM PD	0.00	
Total										1	Subtotal:	80				\$ 0.00

2247707-6085	INVOKANA 300MG TABLETS	TAKE 1 TABLET BY MOUTH DAILY	JANSSEN	50458- 0141-30	RX	30	12/02/2016	30			EAP	SIMPSON, STEPHEN	BS8273423 (251)633- 4949	CMRKM PD	0.00	
Total										1	Subtotal:	30				\$ 0.00

2249237-6085	DULOXETINE DR 30MG CAPSULES	TAKE 1 CAPSULE BY MOUTH DAILY	TEVA	00093- 7543-56	RX	90	12/06/2016	90			EAP	SIMPSON, STEPHEN	BS8273423 (251)633- 4949	CMRKM PD	0.00	
Total										1	Subtotal:	90				\$ 0.00

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

DOCUMENT 124

Walgreens There's a way™

Page 8 of 11

INSURANCE PROFILE

01/01/2007 through 11/01/2017

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834
DATE PRINTED: 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
2260121-6085	INVOKANA 300MG TABLETS	TAKE 1 TABLET BY MOUTH DAILY	JANSSEN	50458-0141-30	RX	30	12/30/2016	30		TJP	SIMPSON, STEPHEN	BS8273423	(251)633-4949	CMRKM PD	0.00
										Total	1	Subtotal:	30		\$ 0.00
2260122-6085	ATORVASTATIN 40MG TABLETS	TAKE 1 TABLET BY MOUTH DAILY	DR.REDDYS	55111-0123-90	RX	90	12/30/2016	90		TJP	SIMPSON, STEPHEN	BS8273423	(251)633-4949	CMRKM PD	0.00
										Total	1	Subtotal:	90		\$ 0.00
2272017-6085	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED FOR 30 DAYS	KVK TECH	10702-0056-01	C2	30	01/23/2017	40		DNN	SIMPSON, STEPHEN	BS8273423	(251)633-4949	CMRKM PD	3.30
										Total	1	Subtotal:	40		\$ 3.30
2273550-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ZYDUS	68382-0905-01	C2	30	01/25/2017	60		RLW	TARABEIN, RASSAN	BT4052798	(251)625-0909	CMRKM PD	3.30
										Total	1	Subtotal:	60		\$ 3.30
2274627-6085	INVOKANA 300MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	JANSSEN	50458-0141-30	RX	90	01/27/2017	90		EAP	SIMPSON, STEPHEN	BS8273423	(251)633-4949	CMRKM PD	8.25

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

There's a way

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834

DATE PRINTED: 11/01/2017

INSURANCE PROFILE

01/01/2007 through 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605

Gender: M

Allergy Conditions: None on file
Health: None on file

Patient Phone: (251) 721-5962

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days	Entered	Fill	Fill	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
						Supply	Date	Qty	Nbr						

2274631-6085	FENOFIBRATE 145MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY	TEVA	00093- 7756-98	RX	90	01/27/2017	90		EAP SIMPSON, STEPHEN	BS8273423 4949	(251)633- PD	CMRKM		3.30
Total										1		Subtotal:		90	\$ 8.25

2289031-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093- 0074-01	C4	30	02/24/2017	30		SBS TARABEIN, RASSAN	BT4052798 0909	(251)625- PD	CMRKM		0.43
Total										1		Subtotal:		90	\$ 3.30

2289031-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093- 0074-01	C4	30	03/26/2017	30		KML TARABEIN, RASSAN	BT4052798 0909	(251)625- PD	CMRKM		0.48
Total										1		Subtotal:		90	\$ 1.78

2289031-6085	ZOLPIDEM 10MG TABLETS	TAKE 1 TABLET BY MOUTH EVERY DAY AT BEDTIME	TEVA	00093- 0074-01	C4	30	04/24/2017	30		DNN TARABEIN, RASSAN	BT4052798 0909	(251)625- PD	CMRKM		0.87
Total										3		Subtotal:		90	\$ 1.78

2289032-6085	MORPHINE SULF 60MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ZYDUS	68382- 0905-01	C2	30	02/24/2017	60		SBS TARABEIN, RASSAN	BT4052798 0909	(251)625- PD	CMRKM		3.30
Total										1		Subtotal:		60	\$ 3.30

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

Walgreens There's a way™

Page 10 of 11

INSURANCE PROFILE

01/01/2007 through 11/01/2017

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834
DATE PRINTED: 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Gender: M

Allergy Conditions: None on file
Health: None on file

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days Supply	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
2301808-6085	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	KVK TECH	10702- 0056-01	C2	30	03/22/2017	40		TJP	TARABEIN, RASSAN	BT4052798 0909	(251)625- 0909	CMRKM PD	3.30
										Total	1	Subtotal:	40		\$ 3.30
2303730-6085	MORPHINE SULFATE 30MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ZYDUS	68382- 0904-01	C2	30	03/26/2017	60		KML	TARABEIN, RASSAN	BT4052798 0909	(251)625- 0909	CMRKM PD	3.30
										Total	1	Subtotal:	60		\$ 3.30
2316278-6085	OXYCODONE 10MG IMMEDIATE REL TABS	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED FOR 30 DAYS	KVK TECH	10702- 0056-01	C2	30	04/12/2017	40		EAP	TARABEIN, RASSAN	BT4052798 0909	(251)625- 0909	CMRKM PD	3.30
										Total	1	Subtotal:	40		\$ 3.30
2317168-6085	MORPHINE SULFATE 30MG ER TABS (12H)	TAKE 1 TABLET BY MOUTH TWICE DAILY AS NEEDED	ZYDUS	68382- 0904-01	C2	30	04/24/2017	60		JPD	TARABEIN, RASSAN	BT4052798 0909	(251)625- 0909	CMRKM PD	3.30
										Total	1	Subtotal:	60		\$ 3.30
2332969-6085	HYDROCODONE/ ACETAMINOPHEN	TAKE 1 TABLET BY MOUTH EVERY 8	ACTAVIS	00591- 2605-05	C2	30	05/25/2017	90		DNN	SIMPSON, STEPHEN	BS8273423 4949	(251)633- 4949	CMRKM PD	3.30

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

Whisper There's a way

Page 11 of 11

INSURANCE PROFILE

01/01/2007 through 11/01/2017

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET
DANVILLE, IL 61834
DATE PRINTED: 11/01/2017

BRUCE BROCKEL
4013 MARYDALE DR
MOBILE, AL 36605
Patient Phone: (251) 721-5962

Allergy Conditions: None on file
Health: None on file

Gender: M

Rx-Store	Medication	Instructions	Drug Mfr	NDC	Class	Days	Supply	Entered Date	Fill Qty	Fill Nbr	RPH	Pbr Name	DEA#	Pbr Phone	Plan	Cust Amt
----------	------------	--------------	----------	-----	-------	------	--------	--------------	----------	----------	-----	----------	------	-----------	------	----------

7.5-325 T
HOURS AS NEEDED
FOR MODERATE PAIN
FOR UP TO 10 DAYS

Total	1	Subtotal:	90	\$ 3.30
-------	---	-----------	----	---------

Total Scripts:	51	Total Price:	\$ 125.54
Using generics you saved a total of:			\$ 0.00
Using more generics you could have saved a total			\$ 0.00
Your insurance saved you a total of:			\$ 10,094.43
Your cash quantity discount saved you a total			\$ 0.00

Page 11 of 11

*****THIS REPORT CONTAINS PATIENT HEALTH INFORMATION WHICH IS LEGALLY PROTECTED UNDER HIPAA LEGISLATION*****
THIS INFORMATION MUST BE USED AND STORED IN ACCORDANCE WITH HIPAA POLICIES

This letter, together with any attachments, is intended only for the use of the individual or entity to which it is addressed. It may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination or copying of this letter or any attachment is strictly prohibited. If you have received this letter in error, please notify the original sender immediately and dispose of this letter, along with any attachments. Thank you.

CUSTODIAN OF RECORDS
1901 EAST VOORHEES STREET DANVILLE, IL 61834

REFUND: NOV2000 06/01/11 ALL INFORMATION FURNISHED HEREIN IS UNCLASSIFIED PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DOC NAME DRUG MFR CTL PLAN RX IMAGE ID
DOC NAME DOC ADDRESS DEAN#
ORIG DATE QTY REFILLS DAYS SUPPLY RX COMMENTS
ENTER DATE CIND ENT/YER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 0985421 MORPHINE SULFATE IMM REL 15MG TAB ROXANE C2 CRRKMPD 0650756144355368911
TARABEIN, R 27535 US HIGHWAY 98 DAPHNE, AL 36605 (251) 625-0909 BT4052798
SIG: TK 1 T PO BID FOR BREAKTHROUGH PAIN
09/29/2015 60 0 30

RX NUMBER	DRUG NAME	DOC ADDRESS	REFILLS	DAYS SUPPLY	RX COMMENTS	DRUG MFR	CTL	PLAN	RX IMAGE ID	DEA#	PARTIAL CODE	PLAN
DOC NAME	DOC ADDRESS	REFILLS	DAYS SUPPLY	RX COMMENTS	DRUG MFR	CTL	PLAN	RX IMAGE ID	DEA#	PARTIAL CODE	PLAN	
ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL	CUST AMT	TOT AMT	FILL SOLD DATE	CLAIM #	PARTIAL CODE	PLAN		
AUTH NBR	AUTH BY											
09/29/2015	JDM/KAM	60		ORIG	2.65	10.03	09/29/2015	152725121841106999			CMRKNPD	
RX 0985622	MORPHINE SULFATE	30MG ER TABS (12H)		ZYDUS			C2	CMRKNPD	0650757144355369212			
TARABEIN, R 27535 US HIGHWAY 98 DAPHNE, AL 36605								(251) 625-0909	BT4052798			
SIG: TK 1 T PO BID PRN												
09/29/2015	60	30										
09/29/2015	JDM/KAM	60		ORIG	2.65	52.57	09/29/2015	152725123085180999			CMRKNPD	
RX 0990927	MORPHINE SULFATE	1MM REL, 15MG TAB		ROXANE			C2	CMRKNPD	06507951444614837212			
TARABEIN, R 27535 US HIGHWAY 98 DAPHNE, AL 36605								(251) 625-0909	BT4052798			
SIG: TK 1 T PO BID PRF BREAKTHROUGH PAIN												
10/29/2015	60	30										
10/29/2015	LGD/LGD	60		ORIG	0.00	12.68	10/29/2015	153025365842170998			CMRKNPD	
RX 0990929	MORPHINE SULFATE	30MG ER TABS (12H)		ZYDUS			C2	CMRKNPD	06507961444614837515			
TARABEIN, R 27535 US HIGHWAY 98 DAPHNE, AL 36605								(251) 625-0909	BT4052798			
SIG: TK 1 T PO BID PRN												
10/29/2015	60	30										
10/29/2015	LSC/LGD	60		ORIG	0.00	55.22	10/29/2015	153025367566081999			CMRKNPD	

RX NUMBER	DRUG NAME	DRUG MFR
DOC NAME	DOC ADDRESS	
ORIG DATE	QTY	REFILLS
ENTER DATE	CIND	ENT/VER
AUTH NBR	AUTH BY	FILL QTY
		RX COMMENTS
		REFILL
		C

CTL	PLAN	DOC	RY IMAGE ID	DEA#	CLAIM #	PARTIAL CODE	PLAN
FILL	SOLD	DATE					

BROCKETT, BRUCE
4013 MARYDALE DR MOBILE, AL 36605

(251) 727-8511

RX Z08304 / MORPHINE SULFATE 30MG ER TABS (12H) ZYDUS C2 CNRKMPP 0608508144891736410
 TARABEIN, R 27535 US HIGHWAY 98 DAPHNE, AL 36605 (251) 625-0909 BT4052798
 SIG: TR 1 T PO BID PRF 30 DAYS
 11/30/2015 60 0 30

11/30/2015	DNN/ABL	60	ORIG	0.00	55.22	11/30/2015	153345420177088998	CMRKMED
RX 2096405	MORPHINE SULF 60MG ER TABS (12H)		2YDUS			CZ	CMRKMED	
ZARABEIN, R	27535 US HIGHWAY 98 DAPHNE, AL 36605						0608549145148982919	
SIG: TK 1 T PO	BID PRF 30 DAYS						(251) 625-0309	BT4052798
12/16/2015	60	0	30					

[illegible][illegible]

	12/30/2015	BKK/JPD	30	ORIG	0.00	1.93	12/30/2015	153643470887154999	CMMRMPD
RX	2110439	MORPHINE SULFATE IMM REL 15MG TAB		ROXANE				060855314540782613	
TARABIN,	R	RG&ZI NEUROLOGY CLINIC 28150 N MAIN ST DAPHNE, AL 36605						(251)625-0909	B74052798
SIG:	TK 1 T PD RT DR REPARENCE PATN								

01/29/2016	BKK/DNN	60	ORIG	2.95	10.23	01/29/2016	160293121130125899	CMBKMPD
RX 2110440	MORPHINE SUF 60MG ER TABS (12H)		ZYDUS			C2	060855414540782618	
TARAEBIN, R	MD21 NEUROLOGY CLINIC 28150 N MAIN ST DAPHNE, AL 36605						(251)625-0909	BT4052798
SIG: TX 1 T PO	RTD PRN FOR 30 DAYS							

01/29/2016	BKK/DNN	60	ORIG	2.95	104.82	01/29/2016	160293123141093999	CMRRMPD
------------	---------	----	------	------	--------	------------	--------------------	---------

[illegible]

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605

(251) 727-8511

RX 1556557 MORPHINE SULFATE IMM REL 15MG TAB ROXANE C2 CMRRKPD 0760914144869099614
TARBEIN, R RGAZI NEUROLOGY CLINIC 28150 N MAIN ST DAPHNE, AL 36605 (251) 625-0909 BT4052798
SIG: TAKE 1 T PO BID PRN FOR BREAK THU PAIN
11/28/2015 4 0 2

11/28/2015	4	0	2
------------	---	---	---

11/28/2015	CDA/CDA	4	ORIG	0.00	1.31	11/28/2015	153320076680170899	CHRRKMPD
RX 1556558	MORPHINE SULFATE 30MG ER TABS (12H)		ZYDUS			C2	0760915144869100119	
TARABEIN, R	GAZI NEUROLOGY CLINIC 28150 N MAIN ST DAPHNE, AL 36605						(251) 625-0909	BT4052798
SIG: TAK1	1 T PO BID PRN							
11/28/2015	4	0	2					

SIG: TAK1 1 T PO BID PRN
11/28/2015 4 0 2

PAT LAST NAME		FIRST		PAT ADDRESS		PAT PHONE# BIRTH DATE	
RX NUMBER		DRUG NAME		DRUG MFR		CTL PLAN	
DOC NAME		DOC ADDRESS		RX IMAGE ID		DEA#	
ORIG DATE		QTY		REFILLS		DAYS SUPPLY	
ENTER DATE		CIND		ENT/VER		FILL QTY	
AUTH NBR		AUTH BY		REFILL		CUST AMT	
TOT AMT		FILL SOLD DATE		CLAIM #		PARTIAL CODE PLAN	
11/28/2015		CDA/CDA		4		ORIG	
0.00		4.15		11/28/2015		15332008115209999	
CHPRMPD							

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE
RX NUMBER DRUG NAME
DOC NAME DOC ADDRESS
ORIG DATE QTY REFILLS DAYS SUPPLY RX COMMENTS
ENTER DATE CIND ENT/VER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL, BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 0996116 MORPHINE SULFATE IMM REL 15MG TAB ROXANE C2 CMRKMPD 0650713144890652916
TARABEIN, R 27535 US HIGHWAY 98 DAPHNE, AL 36605 (251) 625-0909 BT4052798
SIG: TK 1 T PO BID PRN FOR BREAKTHROUGH PAIN 0 30

11/30/2015 JDM/TJP 60 ORIG 5.00 12.68 11/30/2015 153344827267033999 CMRKMPD
RX 0996122 OXYCODONE 10MG IMMEDIATE REL TABS KVK TECH C2 CMRKMPD 0650714144890653211
TARABEIN, R 27535 US HIGHWAY 98 DAPHNE, AL 36605 (251) 625-0909 BT4052798
SIG: TK 1 T PO QD PRN FOR BREAKTHROUGH PAIN 0 10

11/30/2015 JDM/TJP 10 ORIG 5.72 5.00 11/30/2015 153345242232057999 CMRKMPD

REVENUE, MONTH

001/01/16

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED

CLASS. / 11/11

PAT LAST NAME

FIRST

PAT ADDRESS

PAT PHONE# BIRTH DATE

RX NUMBER	DRUG NAME	DOC NAME	DOC ADDRESS	REFILLS	DAYS SUPPLY	RX COMMENTS	CTL	PLAN	RX IMAGE ID	DEA#	PARTIAL CODE	PLAN
DOC NAME	QTY	ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL	CUST AMT	TOT AMT	FILL SOLD DATE	CLAIM #		
AUTH NBR	AUTH BY											

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 721-5962

FX 2124195 MORPHINE SULFATE 1MM REL 15MG TAB ROXANE C2 CMRKNPD 0608503145667561716

TARABEIN, R RGAZI NEUROLOGY CLINIC 28150 N MAIN ST DAPHNE, AL 36605 (251) 625-0909 BT4052798

SIG: TK 1 T PO BID PRF BREAKTHROUGH PAIN 60 0 30

02/23/2016

PAT LAST NAME										PAT FIRST										PAT ADDRESS										PAT PHONE# BIRTH DATE																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
RX NUMBER										DRUG NAME										DRUG MFR										CTL										PLAN										RX IMAGE ID										DEA#																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
DOC NAME										DOC ADDRESS										ENTER DATE										CIND										ENT/VER										FILL QTY										REFILL										CUST AMT										TOT AMT										FILL SOLD DATE										CLAIM #										PARTIAL CODE										PLAN																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
AUTH NBR										AUTH BY																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														</									

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS DRUG MFR CTL PLAN RX IMAGE ID DEAF
ORIG DATE QTY REFILLS DAYS SUPPLY RX COMMENTS
ENTER DATE CIND ENT/VER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 0928744 OXYCODONE 30MG IMM REL TABLETS KVK C2 CMRKMPD 0650710141563209616
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605 (251) 406-8990 BC4507349
SIG: TK 1 T PO Q 6 H FOR 30 DAYS 22

11/10/2014 LMG/LMG 90 ORIG 0.00 83.40 11/10/2014 143143293481125998 CMRKMPD
RX 0933302 OXYCODONE 30MG IMM REL TABLETS KVK C2 CMRKMPD 0650753141805194512
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605 (251) 406-8990 BC4507349
SIG: TK 1 T PO Q 6 H FOR 30 DAYS 22

12/08/2014 MDW/LMG 90 ORIG 0.00 50.82 12/08/2014 143423362155063999 CMRKMPD
RX 0937908 OXYCODONE 30MG IMMEDIATE REL TABS ACTAVIS C2 CMRKMPD 0650791142047461611
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605 (251) 406-8990 BC4507349
SIG: TK 1 T PO Q 6 H FOR 30 DAYS 22

11/10/2014 90 22
RX 0942508 MORPHINE SULF 100MG ER TABS (12H) ENDO C2 CMRKMPD 0650746142257407915
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605 (251) 406-8990 BC4507349
SIG: TK 1 T PO TID FOR 30 DAYS 30

01/29/2015 90 30
RX 0942509 OXYCODONE 30MG IMMEDIATE REL TABS ACTAVIS C2 CMRKMPD 0650747142257408411
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605 (251) 406-8990 BC4507349
SIG: TK 1 T PO Q 8 H FOR 30 DAYS 30

01/29/2015 90 30
RX 0942510 GABAPENTIN 800MG TABLETS GLENMARK FX CMRKMPD 0650748142257408816
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605 (251) 406-8990 BC4507349
SIG: TK 1 T PO QID 120

01/29/2015 120 30
RX 0942511 ROZEREM 8MG TABLETS ORIG 2.65 87.85 01/29/2015 150296302448096999 CMRKMPD
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605 TAKEDA RX CMRKMPD 0650749142257409516
SIG: TK 1 T PO QHS FOR 30 DAYS 30 (251) 406-8990 BC4507349

PAT LAST NAME	FIRST	PAT ADDRESS	PAT PHONE#	BIRTH DATE
RX NUMBER	DOC NAME	DRUG NAME	CTL	PLAN
DOC NAME	DOC ADDRESS	DRUG MFR	RX IMAGE ID	DEA#
ORIG DATE	QTY	REFILLS	DAYS SUPPLY	REFILL
ENTER DATE	CIND	ENT/VER	FILL QTY	CUST AMT
AUTH NBR	AUTH BY		TOT AMT	FILL SOLD DATE
			CLAIM #	PARTIAL CODE
			PLAN	
01/29/2015	FNU/TJP	30	ORIG	6.60
RX 0942512	TIZANIDINE 4MG TABLETS		DR. REDDY'S	243.10
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605			RX CMRMPD	150296304074205999
SIG: TR 1 T PO Q 8 H PRN . DO NOT EXCEED 3 DOSES IN 24 H			(251)406-8990	BC4507349
01/29/2015	90	0	30	
01/29/2015	TJP/TJP	90	ORIG	2.65
RX 0942513	TESTOSTERONE CYP 200MG/ML 10ML		WATSON	27.19
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605			C3 CMRMPD	150296309518139998
SIG: INJECT =ML INTO MUSCLE EVERY WEEK FOR 30 DAYS			(251)406-8990	BC4507349
01/29/2015	10	1	30	

PAT ADDRESS

PAT PHONE# BIRTH DATE

FIRST

PAT LAST NAME

RX NUMBER DRUG NAME
 DOC NAME DOC ADDRESS
 ORIG DATE QTY REFILLS DAYS SUPPLY
 ENTER DATE CIND ENT/VER FILL QTY REFILL
 AUTH NBR AUTH BY

DRUG MFR

CTL PLAN

RX IMAGE ID

DEA#

BCC PHONE#

PARTIAL CODE

PLAN

PLAN

BROCKEL , BRUCE 4013 WARDLE DR MOBILE, AL 36605

(251) 727-8511

RX 0957500 OXYCODONE 30MG IMMEDIATE REL TABS ACTAVIS
 COUGH, J 3715 DAUPHIN ST MOBILE, AL 36605
 SIG: TK 1 T PO Q 6 H FOR 30 DAYS
 04/23/2015 120 0 30

C2 CMRMPD 0650789142988798113

(251) 406-8990 BC4507349

2.65

110.36

04/24/2015

151143652277117999

CMRMPD

PAT LAST NAME	FIRST	PAT ADDRESS	PAT PHONE#	BIRTH DATE
RX NUMBER	DOC NAME	DRUG NAME	CTL	PLAN
DOC NAME	DOC ADDRESS	DRUG MFR	DOC PHONE#	DEA#
ORIG DATE	QTY	REFILLS	DAYS SUPPLY	RX COMMENTS
ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL
AUTH NBR	AUTH BY	CUST AMT	TOT AMT	FILL SOLD DATE
		CLAIM #	PARTIAL CODE	PLAN

BROCKEL, BRUCE 4013 HARRYDALE DR MOBILE, AL 36605

(251) 727-8511

RX 2015754	OXYCONTIN 30MG CONTROLLED REL TABS	PURDUE	C2	CHKRMPD	0608570143570303516	
TARABEIN, R	27535 US HIGHWAY 98 DAPHNE, AL 36605				(251) 625-0909	BT4052798
SIG: TK 1 T	PO BID PRN FOR 30 DAYS					

06/30/2015 60 0 30

06/30/2015	HMS/EAP	60	ORIG	
RX 2028300	OXYCONTIN 30MG CONTROLLED REL TABS	PURDUE		
TARABEIN, R	27535 US HIGHWAY 98 DAPHNE, AL 36605			
SIG: TK 1 T	PO BID PRN FOR 5 DAYS			

6.60 406.09

06/30/2015 151816269986212999

CHKRMPD

07/28/2015	ECC/DNN	10	ORIG	
RX 2028301	ZOLPIDEM 10MG TABLETS	TEVA		
TARABEIN, R	27535 US HIGHWAY 98 DAPHNE, AL 36605			
SIG: TK 1 T	PO QD HS			

1.10 68.10

07/30/2015 152114736856216999

CHKRMPD

07/28/2015 5 0 5

(251) 625-0909 BT4052798

PAT PHONE# STREET CITIES

07/30/2015	ECC/DNN	5		ORIG		0.44		0.30		07/30/2015		152114741319118999		CNRKMPD
RX 2028302	GABAPENTIN 800MG TABLETS				TEVA					RX	CNRKMPD	0608524143827952211		
TARABEIN, R	27535 US HIGHWAY 98 DAPHNE, AL	36605								(251) 625-0909		BT4052798		
SIG:	TK 1 T PO QID FOR 30 DAYS													
07/28/2015	120	0	30											
07/30/2015	MES/DNN	120		ORIG		2.65		87.85		07/30/2015		152114745858218998		CNRKMPD
RX 2028303	TIZANIDINE 4MG TABLETS				DR.REDDY'S					RX	CNRKMPD	0608525143827952510		
TARABEIN, R	27535 US HIGHWAY 98 DAPHNE, AL	36605								(251) 625-0909		BT4052798		
SIG:	TK 1 T PO TID FOR 30 DAYS													
07/28/2015	90	0	30											
07/30/2015	MES/DNN	90		ORIG		2.65		27.19		07/30/2015		152114748689130998		CNRKMPD
RX 2028304	OXYCODONE 10MG IMMEDIATE REL TABS				KVK TECH					C2	CNRKMPD	0608526143827952816		
TARABEIN, R	27535 US HIGHWAY 98 DAPHNE, AL	36605								(251) 625-0909		BT4052798		
SIG:	TK 1 T PO QD PRF BREAKTHROUGH PAIN													
07/28/2015	5	0	5											
07/30/2015	ECC/DNN	5		ORIG		0.44		2.31		07/30/2015		152114754990196999		CNRKMPD

INVOICE: 1000000000 44/00/10 PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS ORIG DATE QTY REFILLS DAYS SUPPLY RX COMMENTS CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 1470213 SERTRALINE 50MG TABLETS GREENSTONE RX 0760946143258789410
LINTON, J 2200 LAKESHORE DRIVE BIRMINGHAM, AL 36605 (205) 655-0585 BL9278373
SIG: TK 1 T PO QD
05/25/2015 30 2 0 06152015 RTS

REFUND: NOV2010	11/00/10	NO	WALSHBURY LINDSEY DEAN AUBURN	01/00/10	
PAT LAST NAME	FIRST	PAT ADDRESS		PAT PHONE#	BIRTH DATE
RX NUMBER	DRUG NAME	DRUG MFR	CTL	PLAN	RX IMAGE ID
DOC NAME	DOC ADDRESS				DOC PHONE#
ORIG DATE	QTY	REFILLS	DAYS SUPPLY	RX COMMENTS	DEA#
ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL	CUST AMT
AUTH NBR	AUTH BY				TOT AMT
					FILL SOLD DATE
					CLAIM #
					PARTIAL CODE
					PLAN

RX 1470214 HYDROCODONE/ACETAMINOPHEN 7.5-325 T ACTAVIS
LINTON, J 2200 LAKESHORE DRIVE BIRMINGHAM, AL 36605
SIG: TK 1 T PO Q 6 H PRN MODERATE P FOR 7 DAYS
05/25/2015 30 0 7
05/25/2015 TDJ/KDT 30 ORIG 0.61 8.87 05/25/2015 151455795589074999 CMRRMPD

CMRRMPD

RX NUMBER	DRUG NAME	DRUG MFR	CTL	PLAN	RX IMAGE ID
DOC NAME	DOC ADDRESS			DOC PHONE#	DEA#
ORIG DATE	QTY	REFILLS	DAYS SUPPLY		
ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL	
AUTH NBR	AUTH BY		CUST AMT	TOT AMT	FILL SOLD DATE
					CLAIM #
					PARTIAL CODE
					PLAN

BROCKEL, BRUCE 4013 MARYDALE DR MOBILE, AL 36605

{251}727-8511

RX 0965536 HYDROCODONE/ACETAMINOPHEN 7.5-325 T ACTAVIS C2 CMRKMPD 065070614338686314
 SIMPSON, S 831C HILLCREST RD MOBILE, AL 36605
 SIG: TR 1 T PO Q 8 H PRF PAIN UP TO 10 DAYS (251) 633-4949 B58273423
 06/09/2015 90 0 30

06/09/2015	IGD/IGD	90	ORIG	2.65	24.80	06/09/2015	151606093970217998	CHRMKD
RX 0968316	OXCODONE 10MG	IMMEDIATE	REL TABS					
TARABEIN, R	27535 US HIGHWAY 98	DAPHNE, AL	36605				0650794143589631815	
SIG: TR 1 T	PO OD PRN	FOR BREAKTHROUGH PAIN					(251) 625-0909	BT4052798
06/09/2015								

06/30/2015	JDW/KAM	30	ORIG	2.65	11.35	06/30/2015	151815600059218999	CMRKNPD
RX 0968817	ZOLPIDEM 10MG TABLETS		TEVA				0650793143569631613	
TARABEIN, R	27535 OS HIGHWAY 98 DAPHNE, AL	36605					(251) 625-0909	BT4052798
SIG: TK 1 T PO QHS								

06/30/2015	JDM/KAM	30	ORIG		1.93	0.00	06/30/2015	151815601483151999	CRRMPD	
RX 0968918	GABAPENTIN 800MG TABLETS			GLENNARK			RX CRRMPD	0650795143569633117		
TRABENET, R 27535 US HIGHWAY 98 DAPHNE, AL 36605										
STG: TK 1 T PO QID FOR 30 DAYS										
(251)625-0909 BT4052798										

06/30/2015	LSC/KAM	120	ORIG	2.65	87.85	06/30/2015	151815606106046938	CMRKKPD
RX 0968919	TIZANIDINE 4MG TABLETS					RX	CMRKKPD	0650796143369632417
TARABEIN, R 27535 US HIGHWAY 98 DAPHNE, AL 36605						(251)625-0909	BT4052798	
SIG: TK 1 T PO TID FOR 30 DAYS								

06/30/2015	JDM/KAM	90	ORIG	2.65	27.19	06/30/2015	151815607523054999	CMRKMPPD
------------	---------	----	------	------	-------	------------	--------------------	----------

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN

BROCKET , BRUCE 4013 MARKDALE DR MOBILE, AL 36605 (251) 727-8511

RX 1189144 OXYCODONE/ACETAMINOPHEN 10-325MG TB WATSON C2 CMRKMPD 0760917137833890612
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 BC4507349
SIG: TK 1 T PO Q 4-6 H PRN 0 10

09/04/2013 SLF/TLV 60 ORIG 2.65 39.52 09/04/2013 132477105233132999 CMRKMPD
RX 1194569 MORPHINE SULFATE IMM REL 30MG TAB ROXANE C2 CMRKMPD 0760952137939467812
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 BC4507349
SIG: TK 1 T PO QID PRN 0

08/14/2013 120 30 09/16/2013 132600073744121999 CMRKMPD
RX 1194570 MORPHINE SULF 60MG ER TABS (12H) WALLINCKRODT C2 CMRKMPD 0760951137939467317
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 BC4507349
SIG: TK 1 T PO TID PRN 0

08/14/2013 90 30 09/16/2013 132600104246142999 CMRKMPD
RX 1206801 MORPHINE SULF 60MG ER TABS (12H) WALLINCKRODT C2 CMRKMPD 0760956138176475315
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 BC4507349
SIG: TK 1 T PO TID 0

10/14/2013 90 30 10/14/2013 132873799442021999 CMRKMPD
RX 1206801 MORPHINE SULF 60MG ER TABS (12H) WALLINCKRODT C2 CMRKMPD 0760956138176475315
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 BC4507349
SIG: TK 1 T PO TID 0

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS QTY REFILLS DAYS SUPPLY RX COMMENTS CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
DOC NAME DOC ADDRESS
ENTER DATE CIND ENT/VER FILL QTY REFILL
AUTH NBR AUTH BY

BROCKEL, BRUCE 4013 MARYDALE DR MOBILE, AL 36605

(251) 727-8511

RX 1193751 ZOLPIDEM ER 12.5MG TABLETS ANCHEN C4 CMRKMPD 0760932137921205718
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 BC4507349
SIG: TK 1 T PO QHS
XFER TO STORE: 6507 RX#: 0867936 RPH INIT: LNG ENT INIT: JDW 11/05/2013 XFER FROM STORE DEA: BW8574344 RPH INIT: KDT
08/19/2013 30 1 30

09/14/2013 TDJ/RLJ 30 ORIG 2.65 131.20 09/14/2013 132577728185122998 CMRKMPD
RX 1218993 MORPHINE SUBLF 60MG ER TABS (12H) ROXANE C2 CMRKMPD 0760996138415078513
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 BC4507349
SIG: TK 1 T PO QID

11/11/2013 CMA/CMA 120 30 ORIG 2.65 32.59 11/11/2013 133150141049144999 CMRKMPD
RX 1218994 MORPHINE SUBLF 60MG ER TABS (12H) WALLINCKRODT C2 CMRKMPD 0760997138415078714
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 BC4507349
SIG: TK 1 T PO TID

11/11/2013 CMA/CMA 90 30 ORIG 2.65 190.79 11/11/2013 133150143662123998 CMRKMPD
RX 1230857 LUNESTA 3MG TABLETS SEPRACOR C4 CMRKMPD 0760954138660524719
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 FC3361374
SIG: TK ONE T PO ONCE D HS

12/09/2013 RLJ/RLJ 60 60 ORIG 0.00 580.53 12/09/2013 133433665942070999 CMRKMPD
RX 1230859 GABAPENTIN 800MG TABLETS GLENMARK RX CMRKMPD 0760955138660525212
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 FC3361374
SIG: TK 1 T PO QID PRN

12/09/2013 RLJ/RLJ 120 30 ORIG 0.00 141.77 12/09/2013 133433668153037999 CMRKMPD
RX 1230860 MORPHINE SUBLF 60MG ER TABS (12H) MYLAN C2 CMRKMPD 0760956138660525617
COUCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605 (251) 445-4195 FC3361374
SIG: TK 1 T PO TID PRN
12/09/2013 90 0 30 ORIG 0.00 193.44 12/09/2013 133433669990131999 CMRKMPD
12/09/2013 RLJ/RLJ 90 30 ORIG 0.00 193.44 12/09/2013 133433669990131999 CMRKMPD

REPORT: KAV240

03/01/13

AL MAJOREDDO FURBER DRUG DIVISION 0000

ALMA 000000

PAT LAST NAME

FIRST

PAT ADDRESS

PAT PHONE# BIRTH DATE

RX NUMBER	DRUG NAME	DOC NAME	REFILLS	DAYS SUPPLY	RX COMMENTS	CTL	PLAN	RX IMAGE ID	DEA#			
LOC NAME	DOC ADDRESS	ORIG DATE	QTY	ENT/VER	FILL QTY	REFILL	CUST AMT	TOT AMT	FILL SOLD DATE	CLAIM #	PARTIAL CODE	PLAN
AUTH NBR	AUTH BY											

RX 1230861	MORPHINE SULFATE IMM REL 30MG TAB	ROXANE										
CODCH, J	28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605											
SIG: TK 1 T	PO QTD PRN											
12/09/2013	120	0	30									
12/09/2013	RLJ/RLJ	120	30	ORIG			0.00	35.24	12/09/2013	133433672423120999		CMRRMPD

REFERRAL: K00220 UJ/VL/13 ALL MARYDALE DR MOBILE, AL 36605 UJ/VL/13 PAT PHONE# BIRTH DATE

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DRUG MFR CTL PLAN RX IMAGE ID DEB#

DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS DOC PHONE#

ORIG DATE QTY ENTER DATE CIND ENT/VER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN

AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 0867936 ZOLPIDEM ER 12.5MG TABLETS ANCHEN C4 CHRRKMPD 0650752138368166316 (251) 445-4195 BC4507349

COTCH, J 28150 N PLAIN ST UNIT 8 DAPHNE, AL 36605

SIG: TK 1 T PO QHS 30 0 30

08/19/2013

11/05/2013 JDW/LNG 30 ORIG 2.65 131.20 11/05/2013 133095047486030999 CHRRKMPD

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS DRUG MFR CTL PLAN RX IMAGE ID DEAN# PAT PHONE# BIRTH DATE
ORIG DATE QTY REFILLS DAYS SUPPLY RX COMMENTS CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 0445478 MORPHINE SULF 60MG ER TABS (12H) MALLINCKRODT C2 CNRMPD 1085149139862570414
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TK 1 T PO TID

04/24/2014 90 0 30 2.55 171.42 04/27/2014 141175118532104999 CNRMPD
RX 0445479 GABAPENTIN 800MG TABLETS GLENMARK RX CNRMPD 1085150139862570811
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TK 1 T PO QTD

04/24/2014 120 1 30 2.55 124.92 04/27/2014 141175120553168999 CNRMPD
RX 0445480 CARISOPRODOL 350MG TABLETS WATSON C4 CNRMPD 1085151139862666715
COUCH, J 3715 DAUPHIN ST MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TK 1 T PO BID

03/27/2014 60 0 30 2.55 2.83 04/27/2014 141175193469148999 CNRMPD
04/27/2014 PNB/PNB 60 ORIG 2.55 2.83 04/27/2014 141175193469148999 CNRMPD

REFUN: 040720

06/01/14

ALL PHARMACEUTICALS FOR SALE 0000

FORM: 1300

PAT LAST NAME

FIRST

PAT ADDRESS

PAT PHONE# BIRTH DATE

RX NUMBER	DRUG NAME	DOC NAME	DOC ADDRESS	REFILLS	DAYS SUPPLY	RX COMMENTS	CUST AMT	TOT AMT	FILL SOLD DATE	CLAIM #	PARTIAL CODE	PLAN
DOC NAME	QTY	ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL						
AUTH NBR	AUTH BY											

DRUG NFR

CTL PLAN

RX IMAGE ID
DOC PHONE#
DEA#

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605

(251)727-8511

RX 1553245 MORPHINE SULFATE IMM REL 30MG TAB ROXANE

C2 VIVAMPD 060857134789657317

COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605

(251)478-4900 BC4507349

SIG: TK 1 T PO TID

09/17/2012 90 0 30

09/17/2012	MNJ/SUB	90	ORIG	2.60	21.83	09/17/2012	122613859755146999	VIVAMPD
------------	---------	----	------	------	-------	------------	--------------------	---------

PAT LAST NAME

FIRST

PAT ADDRESS

PAT PHONE# BIRTH DATE

RX NUMBER	DRUG NAME	DRUG MFR	CTL	PLAN	RX IMAGE ID
DOC NAME	DOC ADDRESS			DOC PHONE#	DEA#
ORIG DATE	QTY	REFILLS	DAYS SUPPLY	RX COMMENTS	
ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL	
AUTH NBR	AUTH BY			CUST AMT	TOT AMT
				FILL SOLD DATE	CLAIM #
					PARTIAL CODE
					PLAN

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605

(251) 727-8511

ROXANE
EX 1594786 MORPHINE SULFATE 1MM RET 30MG TAB
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605
SIG. PK 1 T PO TID

C2 VIVAMPD 0608534135515784311
(251)478-4900 BC4507349

SIG: TK 1 T PO TTD
12/10/2012 90 0 30

30

12/10/2012	DNN/SLB	90	ORIG
RX 1594787	MORPHINE SULF 60MG ER TABS (12H)		
CONCISE	1 2001 SPRINGFIELD AVE		

2.60	21.83
DT	

12/10/2012	123453891748119999	VIVAMPD
C2	VIVAMPD	0608535135515784911

COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605
SIG: TK 1 T PO TID

C2 VIVAMED 0608535135515784911
(251) 478-4900 BC4507349

12/10/2012	90	0	30
12/10/2012		DNN/SLB	90

•

COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605
SIG: TK 1 TO 2 TS PO Q 4 TO 6 H PRN P

(251) 478-4900 BC4507349

SIG: IN 1	10	Z	IS	FO	Q	4	TO	6	H	ERN	P
12/10/2012			40				0				7
12/10/2012				DNN/SLB				40			OBT

12/10/2013 1334530050000110000

12/10/2012 DNN/SLB 40

11

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS QTY REFILLS DAYS SUPPLY RX COMMENTS CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
DOC NAME DOC ADDRESS
ENTER DATE CIND ENT/VER FILL QTY REFILL
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 1594781 ZOLPIDEM ER 12.5MG TABLETS ANCHEN C4 CMRKMPD 0608533135515783718
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TK ONE T PO HS PRF SLP 1 30

12/10/2012 RNM/SLB 30 ORIG 2.60 136.27 12/10/2012 123453879652146999 VIVAMPD
02/01/2013 DNM/DNM 30 RFL001 2.65 136.22 02/01/2013 130324359338079999 CMRKMPD
RX 1622653 MORPHINE SULFATE IMM REL 30MG TAB ROXANE C2 CMRKMPD 060851613599959211
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TK 1 T PO TID

01/07/2013 90 0 30
02/04/2013 CUL/AMC 90 ORIG 2.65 24.09 02/04/2013 130354221672055999 CMRKMPD
RX 1622654 MORPHINE SULF 60MG ER TABS (12H) MALLINCKRODT C2 CMRKMPD 060851713599959715
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TK 1 T PO TID

01/07/2013 90 0 30
02/04/2013 CUL/AMC 90 ORIG 2.65 76.52 02/04/2013 130354222685100999 CMRKMPD
RX 1637037 OXYCODONE 15MG* IMMEDIATE REL TABS ACTAVIS C2 CMRKMPD 0608515136241793814
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TK 1 T PO TID

03/04/2013 90 0 30
03/04/2013 AMA/EAP 90 ORIG 2.65 37.08 03/04/2013 130634115445084999 CMRKMPD
RX 1637038 MORPHINE SULF 60MG ER TABS (12H) MALLINCKRODT C2 CMRKMPD 0608514136241793410
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TK 1 T PO TID

03/04/2013 90 0 30
03/04/2013 AMA/EAP 90 ORIG 2.65 76.52 03/04/2013 130634115864083999 CMRKMPD

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE
RX NUMBER DRUG NAME
DOC NAME DOC ADDRESS
ORIG DATE QTY REFILLS DAYS SUPPLY RX COMMENTS
ENTER DATE CIND ENT/VER FILL QTY REFILL CUST AMT TOT AMT
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 1120587 OXYCODONE/ACETAMINOPHEN 10-325MG TB WATSON C2 CMRKMPD 0760983136454845319
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TAKE 1 TABLET BY MOUTH 3 TIMES A DAY 10

03/29/2013 CMA/CMA 30 ORIG 2.65 17.01 03/29/2013 130881564740125999 CMRKMPD
RX 1122249 MORPHINE SULF 60MG ER TABS (12H) MALLINCKRODT
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 C2 CMRKMPD 0760957136488137913
SIG: TAKE 1 T PO TID (251) 478-4900 BC4507349

03/04/2013 90 0 30 2.65 76.52 04/01/2013 130920303363126999 CMRKMPD
RX 1122250 OXYCODONE 15MG+ IMMEDIATE REL TABS ACTAVIS C2 CMRKMPD 0760958136488138916
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TAKE 1 T PO TID PRN

03/04/2013 90 0 30 2.65 37.08 04/01/2013 130920306176142999 CMRKMPD
RX 1134051 MORPHINE SULF 60MG ER TABS (12H) MALLINCKRODT C2 CMRKMPD 0760933136724598710
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TR 1 T PO TID

04/29/2013 90 0 30 2.65 76.52 04/29/2013 131193447285050999 CMRKMPD
RX 1134052 MORPHINE SULFATE IMM REL 30MG TAB FOXANE C2 CMRKMPD 0760934136724598913
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605 (251) 478-4900 BC4507349
SIG: TR 1 T PO QID PRN

04/29/2013 120 0 30 2.65 32.59 04/29/2013 131193450144038999 CMRKMPD
SHJ/CRH
04/29/2013

REPORT: RX0920 11/09/19 AL WALGREENS PURCHASE DATA FOR STORE 01002 FROM 12/01/19

PAT LAST NAME	FIRST	PAT ADDRESS	PAT PHONE#	BIRTH DATE
---------------	-------	-------------	------------	------------

RX NUMBER	DRUG NAME	DOC NAME	REFILLS	DAYS SUPPLY	RX COMMENTS	CTL	PLAN	RX IMAGE ID	DEA#	PARTIAL CODE	PLAN
ORIG DATE	QTY	ENT/VER	FILL QTY	REFILL	CUST AMT	TOT AMT	FILL SOLD DATE	CLAIM #			
ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL							
AUTH NBR	AUTH BY										

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 1134050	ZOLPIDEM ER 12.5MG TABLETS	ANCHEN	C4	CMRMPD	0760932136724598418						
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605											
SIG: TK ONE T PO HS PRF SLP											
04/29/2013	30	1	30								

04/29/2013	SHJ/CRH	30	ORIG		2.65	136.22	04/29/2013	131193445450134999		CMRMPD	
05/31/2013	FNA/FNA	30	REF001			136.22	05/31/2013	1315174229955104999		CMRMPD	
RX 1134053	CARISOPRODOL 350MG TABLETS	WATSON	C4	CMRMPD	0760935136724599211						
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605											
SIG: TK 1 T PO BID											
04/29/2013	60	1	30								

04/29/2013	SHJ/SCM	60	ORIG		1.41	4.22	04/29/2013	1311934451766096999		CMRMPD	
05/27/2013	CMA/CMA	60	REF001			4.22	05/27/2013	131470557566114999		CMRMPD	
RX 1147007	MORPHINE SULFATE IMM REL 30MG TAB	ROXANE	C2	CMRMPD	0760941136974569615						
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605											
SIG: TK 1 T PO 3 TO 4 TIMES D											
05/28/2013	120	0	30								

05/28/2013	TLV/TLV	120	ORIG		2.65	32.59	05/28/2013	131482862664122998		CMRMPD	
RX 1147008	GABAPENTIN 800MG TABLETS	CAMBER	RX	CMRMPD	0760940136974569312						
COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605											
SIG: TK 1 T PO QID											
04/29/2013	120	1	30								

REFUR: KAU22U 02/01/12 AL WALGREENS FURGUS DATA FOR STATE UTILITY

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS ORIG DATE QTY REFILLS DAYS SUPPLY RX COMMENTS CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
 AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251)727-8511

RX 0547739 GABAPENTIN 600MG TABLETS RX BADVMPD 0760994127638323415

JANOSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605 (334)260-8986 BJS063639

SIG: TR 1/2 T PO TID AND 1= TS PO HS ENT INIT: WAB 08/20/2010 XFER FROM STORE DEA: RPH INIT: WAB

XFER TO STORE: 0 RX#: 0000000 RPH INIT: XFER COMPETITOR CVS (251)471-2591

CLOSE CMPTS: STEVE

05/11/2010 90 4 30

07/12/2010 CWM/WAB 90 ORIG 6.00 37.17 07/12/2010 101935091654003999 BADVMPD

PAT LAST NAME

FIRST

PAT ADDRESS

PAT PHONE# BIRTH DATE

RX NUMBER	DRUG NAME	DRUG MFR	CTL	PLAN	RX IMAGE ID	DEA#
DOC NAME	DOC ADDRESS			DOC PHONE#		
ORIG DATE	QTY	REFILLS	DAYS SUPPLY	RX COMMENTS		
ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL	CUST AMT	TOT AMT
AUTH NBR	AUTH BY				FILL SOLD DATE	CLAIM #
						PARTIAL CODE
						PLAN

ORIG DATE	QTY	REFILLS	DAYS SUPPLY	RX COMMENTS
-----------	-----	---------	-------------	-------------

AUTH NBR	AUTH BY
----------	---------

AUTH NBR

AUTH B

BROCKETT, BRUCE 4013 MARYDALE DR MOBILE, AL 36605

(251) 727-8511

RX 0743931 METHADONE 10MG TABLETS

ROYANE

C2

BADVMPD

0760945128813503616

JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605

(334) 260-8988 BJ5063639

B75063639

SIG: TK 2 TS PO Q 8 H. MAX OF 8 TS PER DAY

10/23/2010 240

५०

10/26/2010

BDT/ELU

240

ORIG

12.00

19.57

10/26/2010

102996589077006999

BADVMPD

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN

ORIG DATE QTY ENTER DATE CIND ENT/VER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN

AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 0796795 ZOLPIDEM 10MG TABLETS MYLAN C4 ALBCMPD 0591498129400435514 (334) 260-8988 BJ5063639

JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605

SIG: TK 1 T PO QHS 30 0 30

10/04/2010

03/05/2011 CRC/AHR 5 ORIG 2.19 0.00 03/05/2011 110645429041006995 R ALBCMPD

03/05/2011 CRC/AHR 25 RFL001 2.72 0.00 03/08/2011 110645429041006994 C ALBCMPD

RX 0796806 MORPHINE SULFATE ER 30MG TABLETS MALLINCKRODT

COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605

SIG: TK 1 T PO BID 60 0 30

02/28/2011

03/05/2011 CRH/AHR 60 ORIG 7.00 17.31 03/05/2011 110645590759010998 ALBCMPD

RX 0796807 MORPHINE SULFATE IMM REL 15MG TAB ROXANE

COUCH, J 2001 SPRINGHILL AVE. MOBILE, AL 36605

SIG: TK 1 T PO BID TO TID 90 0 45

02/28/2011

REPORT: KAVYZU		06/01/12		AL WADSWORTH FUNDU UNIT FOR 21VNS 0/000		PAT PHONE# BIRTH DATE	
PAT LAST NAME		FIRST		PAT ADDRESS			
RX NUMBER		DRUG NAME		DRUG MFR		CTL PLAN	
DOC NAME		DOC ADDRESS		RX IMAGE ID		DEA#	
ORIG DATE		QTY		REFILLS		DOC PHONE#	
ENTER DATE		CIND		ENT/VER		FILL QTY	
AUTH NBR		AUTH BY		REFILL		CUST AMT	
						TOT AMT	
						FILL SOLD DATE	
						CLAIM #	
						PARTIAL CODE	
						PLAN	
03/05/2011		CRC/AHR		90		ORIG	
						13.39	
						0.00	
						03/05/2011	
						110645598348015999	
						ALBCHPD	

REPORT: 04/03/11 00/01/11 ALL MAINTENANCE FUNDED WITH FUN STONE 00001
PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DRUG MFR CTL PLAN RX IMAGE ID
DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS DOC PHONE# DEA#
ORIG DATE QTY ENTER DATE CTND ENT/VER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251)727-8511

RX 0700062 ZOLPIDEM 10MG TABLETS TEVA C4 ALBOMPD 0991498129400435514
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605 (344)260-8988 B75063639
SIG: TK 1 T PO QHS
XFER TO STORE: 7609 RX#: 0796795 RPH INIT: AHR ENT INIT: STJ 03/05/2011 XFER FROM STORE DEA: BW7173242 RPH INIT: MAL
10/04/2010 30 1 30

02/03/2011 DLS/BUG 30 ORIG 5.74 0.00 02/03/2011 110346385951021999 ALBOMPD

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE
RX NUMBER DRUG NAME DRUG MFR CTL PLAN RX IMAGE ID
DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS DOC PHONE# DEA#
ORIG DATE QTY ENTER DATE CIND ENT/VER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511
RX 1181623 ZOLPIDEM 10MG TABLETS TEVA C4 BADVMPD 0925685126418094519
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605
SIG: TK 1 T PO QHS PRN (334) 260-8988 BJS063639
01/22/2010 30 0 30
03/21/2010 CCH/DWD 30 ORIG 4.84 0.00 03/21/2010 10080590853001999 BADVMPD

REFUR: KX09ZU 08/03/11 AL WALGREENS KUNSEU DATA FOR SURE VELLOJ
PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DOC NAME DRUG MFR CTL PLAN RX IMAGE ID
DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS DOC PHONE# DEA#
ORIG DATE QTY ENTER DATE CIND ENT/VER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511

RX 0395615 ZOLPIDEM 10MG TABLETS TEVA C4 BADVMPD 0925685126418094519
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605 (34) 260-8988 BJ5063639
SIG: TR 1 T PO QHS PRN
XFER TO STORE: 6085 RX#: 1161623 RPH INIT: DWD ENT INIT: CCH 03/21/2010 XFER FROM STORE DE: BW8880622 RPH INIT: JDB
01/22/2010 30 1 30

02/20/2010 DLT/CMM 30 ORIG 4.84 0.00 02/20/2010 100515342568005999 BADVMPD

REPORT: KAVU20 06/03/11 AL WALGREENS FURNISH FOR STATE 03200 FAX: 200001

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE
RX NUMBER DRUG NAME DRUG MFR CTL PLAN RX IMAGE ID
DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS DOC PHONE# DEA#
ORIG DATE QTY ENTER DATE CIND ENT/VER FILL QTY REFILL COST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251)727-8511

RX 0869113 SERTRALINE 100MG TABLETS GREENSTONE RX BADVMPD 0925614126410193918
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605 (334)260-8988 BJS063639
SIG: TR 1 T PO BID (OAM AND NOON) DISCONTINUE PREVIOUS
XFER TO STORE: 0 RX#: 0000000 RPH INIT: ENT INIT: MLG 03/23/2010 XFER FROM STORE DEA: RPH INIT: MLG
CLOSE CMNTS: TO JCM ENT INIT: MLG 03/23/2010 XFER COMPETITOR CVS (251)471-2591
01/20/2010 60 4 30

01/21/2010 MNH/JRW 60 ORIG 3.00 01/21/2010 100214873138010999 BADVMPD
02/18/2010 AME/DBK 60 REF001 5.77 02/18/2010 100435014987009399 BADVMPD
RX 0869734 ZOLPIDEM 10MG TABLETS TEVA C4 BADVMPD 0925685126418094519 BADVMPD
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605 (334)260-8988 BJS063639
SIG: TR 1 T PO QHS PRN
XFER TO STORE: 2203 RX#: 0395615 RPH INIT: CMW ENT INIT: DLT 02/20/2010 XFER FROM STORE DEA: BW9061172 RPH INIT: JRW
01/22/2010 30 2 30

REPORT: RA0720

08/03/11

ALL MAJOR EVENTS FURNISH DATA FOR BILLING 03200

FORM 1000000

PAT LAST NAME

FIRST

PAT ADDRESS

PAT PHONE# BIRTH DATE

RX NUMBER	DOC NAME	DRUG NAME	DOC ADDRESS	REFILLS	DAYS SUPPLY	RX COMMENTS	DRUG MFR	CTL	PLAN	FX IMAGE	ID	DEA#	PARTIAL CODE	PLAN
ORIG DATE	QTY	ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL	CUST AMT	TOT AMT	FILL SOLD DATE	CLAIM #				
AUTH NBR	AUTH BY													

01/22/2010	NNH/JRW	30	ORIG				4.84	0.00	01/22/2010	100224101949009999			BADVMPD	
RX 0884422	OXYCODONE/APAP 10MG/325MG TABLETS		WATSON						C2	BADVMPD	0925672126652294819			
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605									(334) 260-8988		BJS063639			

SIG: TAKE ONE TABLET BY MOUTH EVERY TWELVE TO TWENTY-FOUR HOURS AS DIRECTED

02/18/2010	DDW/DBK	45	ORIG				6.00	31.33	02/18/2010	100495026141005999			BADVMPD	
RX 0884506	SIMVASTATIN 40MG TABLETS		LUPIN						RX	BADVMPD	0925622126652714218			
MEADOWS, R 217 DOTHAN ROAD ABBEVILLE, AL 36605									(334) 585-6421		AM2131667			

SIG: TK ONE T PO ONCE D

02/18/2010	KRC/TKM	30	ORIG				3.00	3.33	02/21/2010	100495491646008999			BADVMPD	
RX 0884507	ALBUTEROL 0.083% INH SOLN 60 X 3ML		NEPHRON						RX		0925623126652714712			
HARRELSON, R 101 PROFESSIONAL LN ENTERPRISE, AL 36605									(334) 347-3404		BH3901027			

SIG: USE ONE VIAL PER NEBULIZER QID VTD

11/05/2009	360	0							RX	BADVMPD	0925624126652715217			
RX 0884508	GABAPENTIN 600MG TABLETS		GLENMARK						(334) 585-6421		AM2131667			
MEADOWS, R 217 DOTHAN ROAD ABBEVILLE, AL 36605														

SIG: TK ONE T PO TID

08/09/2009	90	0	30				6.00	37.17	02/21/2010	100495497714005999			BADVMPD	
02/18/2010	KRC/TKM	90	ORIG						RX	BADVMPD	0925623126660914711			
RX 0885022	PROAIR INHALEIR (200 PUFFS) 8.5GM		IVAX						(334) 585-6421		AM2131667			

MEADOWS, R 217 DOTHAN ROAD ABBEVILLE, AL 36605

SIG: INHALE 2 PUFFS PO QID PRN

02/19/2010	8.500	3	25				4.92		02/19/2010	100505028301007999			BADVMPD	
RX 0885719	METHADONE 10MG TABLETS		ORIG						C2	BADVMPD	0925635126679338312			
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605									(334) 260-8988		BJS063639			

SIG: TK 2 TS PO Q 6 H

02/21/2010	KGA/JRW	240	ORIG				12.00	19.57	02/21/2010	100526150078006997			BADVMPD	
RX 0885720	BUSPIRONE 10MG TABLETS		MYLAN						RX	BADVMPD	0925634126679338016			
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605									(334) 260-8988		BJS063639			

SIG: TK 2 TS PO QAM AND 2 TS AT NOON FOR 10 DAYS AND THEN TK THREE TS PO QAM AND 3 TS AT NOON

02/21/2010	KGA/JRW	0	30				6.00	18.40	02/21/2010	100526190613008999			BADVMPD	
------------	---------	---	----	--	--	--	------	-------	------------	--------------------	--	--	---------	--

02/21/2010

DOCUMENT 124

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
ORIG DATE QTY ENTER DATE CIND ENT/VER FILL QTY REFILL
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251)727-8511

RX 0657966 PROAIR INHALER (200 PUFFS) 8.5GM IVAX RX BADVMPD 092562312660914711
MEADOWS, R 217 DOTHAN ROAD ABBEVILLE, AL 36605 (34)585-6421 AM2131667
SIG: INHALE 2 PUFFS PO QID PRN
XFER TO STORE: 1777 RX#: 0524681 RPH INIT: WAB ENT INIT: WAB 04/27/2010 XFER FROM STORE DEA: BW8574344 RPH INIT: KYE
02/19/2010 8.500 2 25

03/11/2010 CDA/CDA 8.500 ORIG 35.00 4.92 03/11/2010 100700696995002899 BADVMPD

RX NUMBER DRUG NAME RX IMAGE ID
DOC NAME DOC ADDRESS DEAN#
ORIG DATE QTY REFILLS DAYS SUPPLY RX COMMENTS
ENTER DATE CIND ENT/VER FILL QTY CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605

(251) 727-8511

RX 0524681 PROAIR INHALER (200 PUFFS) 8.5GM IVAX RX BADVMPD 0925623126660914711

MEADOWS, R 217 DOTHAN ROAD ABBEVILLE, AL 36605 (334) 585-6421 AM2131667

SIG: INHALE 2 PUFFS PO QID PRN

XFER TO STORE: 7609 RX#: 0695734 RPH INIT: KYE ENT INT: SLC 06/21/2010 XFER FROM STORE DEA: BW9010024 RPH INIT: AML

02/19/2010 8.500 1 25

04/27/2010 WAB/WAB 8.500 ORIG 35.00 4.92 04/27/2010 101173125582004999 BADVMPD

RX 0547766 METHADONE 10MG TABLETS

JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605 ROXANE

SIG: TK 2 TS PO Q 4-6 H C2 BADVMPD 017787127896385418

07/12/2010 350 0 30 6.00 39.12 07/12/2010 101935327056006999 BADVMPD

07/12/2010

NSJ/CW

350

ORIG

6.00

39.12

07/12/2010

101935327056006999

BADVMPD

REPORT: KXU9ZU 11/02/11 AL WALGREENS KUNGEU DRUGS FOR SURE 01003 FROM: LUCYJ
PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER DRUG NAME DRUG MFR CTL PLAN RX IMAGE ID
DOC NAME DOC ADDRESS REFILLS DAYS SUPPLY RX COMMENTS DOC PHONE# DEAN#
ORIG DATE QTY ENTER DATE CIND ENT/VER FILL QTY REFILL CUST AMT TOT AMT FILL SOLD DATE CLAIM # PARTIAL CODE PLAN
AUTH NBR AUTH BY

BROCKEL , BRUCE 4013 MARYDALE DR MOBILE, AL 36605 (251) 727-8511
RX 0692886 METHADONE 10MG TABLETS ROXANE C2 BADVMPD 0760993127638290813
JANUSH, R 350 TAYLOR ROAD MONTGOMERY, AL 36605
SIG: TK 2 TS PO Q 4 TO 6 H (34) 260-8988 BJ5063639
06/12/2010 350 0 30

PAT LAST NAME FIRST PAT ADDRESS PAT PHONE# BIRTH DATE

RX NUMBER	DOC NAME	DRUG NAME	DRUG MFR	CTL	PLAN	RX IMAGE ID	DEA#
ORIG DATE	QTY	REFILLS	DAYS SUPPLY	RX COMMENTS	DOC PHONE#		
ENTER DATE	CIND	ENT/VER	FILL QTY	REFILL	CUST AMT	TOT AMT	FILL SOLD DATE
AUTH NBR	AUTH BY						CLAIM #
							PARTIAL CODE
							PLAN

06/12/2010	JBA/LIF	350	ORIG		6.00	39.12	06/12/2010	101636422020004998	BADVMPD
RX 0692887	GABAPENTIN 600MG TABLETS		GLENNARK				RX BADVMPD	0760994127638323415	
JANUSH, R 350	TAYLOR ROAD MONTGOMERY, AL 36605						(334)260-8988	BJ5063639	
SIG: TK 1/2 T	PO TID AND 1= TS PO HS								
XFER TO STORE: 1777	RX#: 0547739	RPH INIT: KPM	ENT INIT: CMW	07/12/2010			XFER FROM STORE	DEA: BW8574344	RPH INIT: KYE
05/11/2010	90	5	30						
06/12/2010	JBA/LIF	90	ORIG		6.00	37.17	06/12/2010	101636449591002999	BADVMPD
RX 0695734	PROAIR INHALER (200 PUFFS) 8.5GM		IVAX				RX BADVMPD	0925623126660914711	
MEADOWS, R 217	DOTMAN ROAD ABBEVILLE, AL 36605						(334)585-6421	AM2131667	
SIG: INHALE 2	PUFFS PO QID PRN								
02/19/2010	8.500	0	25						
06/21/2010	SLC/KYE	8.500	ORIG		35.00	4.92	06/21/2010	101723063872010999	BADVMPD

EXHIBIT 3

- | | | |
|-----------------------------------|--------|--|
| 2. Leg swelling | M79.89 | |
| 3. Uncontrolled diabetes mellitus | E11.65 | Lipid panel
Fingerstick A1C
CBC and Differential (Hillcrest)
Comprehensive metabolic panel
Urinalysis, Chemstrip
Urine Microscopic
Sedimentation rate, automated
Thyroid Prof(TSH+FRT4) |
| 4. Chronic pain disorder | G89.4 | |

Plan:

Ultrasound left testicle
Schedule CT scan of testicle or possible hernia
Refill medications
Rx Cipro for orchitis

Orders Placed This Encounter**Procedures**

- Lipid panel
- Fingerstick A1C
- CBC and Differential (Hillcrest)
- Comprehensive metabolic panel
- Urinalysis, Chemstrip
- Urine Microscopic
- Sedimentation rate, automated
- Thyroid Prof(TSH+FRT4)

Follow-up and Disposition

Return in about 4 weeks (around 2/11/2016).

Documented by Megan Haber acting as a scribe for Dr. Simpson. Physical findings, diagnosis, and treatment plan were discussed with the patient who verbalized understanding and agreement.

I, Dr. Simpson, have reviewed this note that was performed by my scribe. This document accurately describes all work, procedures and medical decision making by me.

Meds at end of visit:

Patient's Medications**New Prescriptions**

No medications on file

Current Medications

ALBUTEROL (PROVENTIL HFA / VENTOLIN
HFA / PROAIR) 90 MCG/ACTUATION
INHALER

Inhale 1-2 Puffs by mouth every 4 hours as
needed for Wheezing.

TAKE 1 CAP BY MOUTH DAILY.

DILTIAZEM CD (CARDIZEM CD) 120 MG
CAPSULE

DULOXETINE (CYMBALTA) 30 MG CAPSULE

GABAPENTIN (NEURONTIN) 400 MG
CAPSULE

MORPHINE (AVINZA) 60 MG SR CAPSULE

MORPHINE (MS IR) 15 MG TABLET

RAMELTEON (ROZEREM) 8 MG TABLET

TIZANIDINE (ZANAFLEX) 4 MG TABLET

ZOLPIDEM (AMBIEN) 10 MG TABLET

Take 30 mg by mouth daily.

Take 800 mg by mouth 4 times daily.

Take 60 mg by mouth daily.

Take 15 mg by mouth every 4 hours as
needed for Severe pain.

Take 8 mg by mouth at bedtime.

Take 1 Tab by mouth every 8 hours as
needed for Spasm or Pain.

Take 10 mg by mouth nightly as needed for
Sleep.

Modified Medications

Modified Medication

HYDROCHLOROTHIAZIDE (MICROZIDE)
12.5 MG CAPSULE

Take 1 Cap by mouth daily.

METFORMIN (GLUCOPHAGE) 500 MG
TABLET

Take 2 Tabs by mouth 2 times daily.

Discontinued Medications

FAMOTIDINE (PEPCID) 20 MG TABLET

IBUPROFEN (MOTRIN) 600 MG TABLET

OXYCODONE (OXY-IR) 30 MG IMMEDIATE
RELEASE TABLET

OXYCODONE (OXYCONTIN) 80 MG SR 12
HR TABLET

SERTRALINE (ZOLOFT) 50 MG TABLET

Previous Medication

hydrochlorothiazide (MICROZIDE) 12.5 mg
capsule

Take 1 Cap by mouth daily.

metFORMIN (GLUCOPHAGE) 500 mg tablet

Take 2 Tabs by mouth 2 times daily.

Take 20 mg by mouth 2 times daily as
needed.

Take 1 Tab by mouth every 6 hours as
needed (pain).

Take 30 mg by mouth every 6 hours.

Take 80 mg by mouth every 12 hours.

Take 1 Tab by mouth daily.

Stephen T. Simpson, Jr., MD

Electronically signed 1/14/2016 10:39 AM

ST2011059102

Medicare Advantage on 1/14/2016

Brockel, Bruce R

MRN: 0012914294

Description: 46 year old male

Progress Notes Encounter Date: 6/9/2015

Stephen T Simpson Jr., MD
Internal Medicine

Assessment and Plan:

Patient's Medications**New Prescriptions**

No medications on file

Current MedicationsALBUTEROL (PROVENTIL HFA / VENTOLIN
HFA / PROAIR) 90 MCG/ACTUATION
INHALERInhale 1-2 Puffs by mouth every 4 hours as
needed for Wheezing.DILTIAZEM CD (CARDIZEM CD) 120 MG
CAPSULE

TAKE 1 CAP BY MOUTH DAILY.

DULOXETINE (CYMBALTA) 30 MG CAPSULE
GABAPENTIN (NEURONTIN) 400 MG
CAPSULE

Take 30 mg by mouth daily.

Take 800 mg by mouth 4 times daily.

MORPHINE (AVINZA) 60 MG SR CAPSULE
MORPHINE (MS IR) 15 MG TABLET

Take 60 mg by mouth daily

Take 15 mg by mouth every 4 hours as
needed for Severe pain.RAMELTEON (ROZEREM) 8 MG TABLET
TIZANIDINE (ZANAFLEX) 4 MG TABLET

Take 8 mg by mouth at bedtime.

Take 1 Tab by mouth every 8 hours as
needed for Spasm or Pain.

ZOLPIDEM (AMBIEN) 10 MG TABLET

Take 10 mg by mouth nightly as needed for
Sleep.**Modified Medications****Modified Medication**HYDROCHLOROTHIAZIDE (MICROZIDE)
12.5 MG CAPSULE

Take 1 Cap by mouth daily.

METFORMIN (GLUCOPHAGE) 500 MG
TABLET

Take 2 Tabs by mouth 2 times daily.

Previous Medicationhydrochlorothiazide (MICROZIDE) 12.5 mg
capsule

Take 1 Cap by mouth daily.

metFORMIN (GLUCOPHAGE) 500 mg tablet

Take 2 Tabs by mouth 2 times daily.

Discontinued Medications

FAMOTIDINE (PEPCID) 20 MG TABLET

Take 20 mg by mouth 2 times daily as
needed.

IBUPROFEN (MOTRIN) 600 MG TABLET

Take 1 Tab by mouth every 6 hours as
needed (pain).OXYCODONE (OXY-IR) 30 MG IMMEDIATE
RELEASE TABLET

Take 30 mg by mouth every 6 hours.

OXYCODONE (OXYCONTIN) 80 MG SR 12
HR TABLET

Take 80 mg by mouth every 12 hours.

SERTRALINE (ZOLOFT) 50 MG TABLET

Take 1 Tab by mouth daily.

Stephen T. Simpson, Jr., MD

Electronically signed on 1/14/2016 at 10:51 AM
ST 19536

Medicare Advantage on 1/14/2016

Brockel, Bruce R

MRN: 0012914294

Description: 47 year old male

Progress Notes Encounter Date: 1/14/2016

Patient's Medications**New Prescriptions**

No medications on file

Current Medications

ALBUTEROL (PROVENTIL HFA / VENTOLIN
HFA / PROAIR) 90 MCG/ACTUATION
INHALER

Inhale 1-2 Puffs by mouth every 4 hours as
needed for Wheezing.

CANAGLIFLOZIN (INVOKANA) 100 MG TAB

Take 1 Tab by mouth every morning (before
breakfast).

DILTIAZEM CD (CARDIZEM CD) 120 MG
CAPSULE

TAKE 1 CAP BY MOUTH DAILY.

DULOXETINE (CYMBALTA) 30 MG CAPSULE
GABAPENTIN (NEURONTIN) 400 MG
CAPSULE

Take 30 mg by mouth daily.
Take 800 mg by mouth 4 times daily.

HYDROCHLOROTHIAZIDE (MICROZIDE)
12.5 MG CAPSULE

Take 1 Cap by mouth daily.

METFORMIN (GLUCOPHAGE) 500 MG
TABLET

Take 2 Tabs by mouth 2 times daily.

MORPHINE (AVINZA) 60 MG SR CAPSULE

Take 60 mg by mouth daily.

MORPHINE (MS IR) 15 MG TABLET

Take 15 mg by mouth every 4 hours as
needed for Severe pain.

TIZANIDINE (ZANAFLEX) 4 MG TABLET

Take 1 Tab by mouth every 8 hours as
needed for Spasm or Pain.

ZOLPIDEM (AMBIEN) 10 MG TABLET

Take 10 mg by mouth nightly as needed for
Sleep.

Modified Medications

No medications on file

Discontinued Medications

RAMELTEON (ROZEREM) 8 MG TABLET

Take 8 mg by mouth at bedtime.

Stephen T. Simpson, Jr., MD

Electronically signed 3/16/2016 10:14 AM
ST2011059102

Office Visit on 3/16/2016

Brockel, Bruce R

MRN: 0012914294
Description: 47 year old male

Progress Notes Encounter Date: 1/14/2016

Stephen T Simpson Jr., MD

Internal Medicine

Expand All Collapse All

Provider: Stephen T. Simpson, Jr., MD

Reason for exam: Annual Assessment for VIVA

EXHIBIT 4

[Interactive Catalog](#) [Contact](#) [Who Is Zydus](#)[Our Affiliates](#)[Products](#)[Patients](#)[Healthcare Professionals](#)[Trade Partners](#)

Company Overview

Zydus Pharmaceuticals (USA) Inc. is located in Pennington, NJ, and is the U.S. division of Cadila Healthcare. Since our first commercial launch in August of 2005, we have grown steadily and are now one of the top 10 U.S. generic companies in total prescriptions dispensed. We are also proud to note that since 2005 we have been recognized annually by IMS Health as one of the fastest growing pharmaceutical companies in the U.S. Zydus is focused on providing outstanding customer service, along with high-quality, affordable generic products to our customers and their patients.

Zydus is a vertically integrated generic pharmaceutical company. We manufacture over 50% of our product's active pharmaceutical ingredient (API) and in fact take it a few steps further by even manufacturing our own bottles. This allows us to ensure and maintain our excellent supply record to our customers. We have also already completed 2D bar-coding on all of our manufactured products to meet the future pedigree requirements.

We have an exciting pipeline coming in the next few years including several first-to-file and 505B2 opportunities, nasal sprays, dermatological, injectable, oncology products, and metered dose inhalers. With our purchase of Nesher Pharmaceuticals in St. Louis, MO, we now are also providing controlled substances and additional difficult to manufacture extended release products.

To learn more, please Contact Us through this website or call (609) 730-1900.

[FEATURED PRODUCTS](#)[FACILITIES SLIDESHOW](#)[WHAT ARE GENERICS?](#)[VIEW OUR INTERACTIVE CATALOG](#)[Products](#)[Press Releases](#)[Disclaimer & Privacy Policy](#)[Career Opportunities](#)[Contact Us](#)

73 Route 31 N. Pennington, NJ 08534

© 2018 Zydus Pharmaceuticals, Inc. All rights reserved.
Site created by Connections Marketing



Who Is Zydus

Our Affiliates

Products

Patients

Healthcare Professionals

Trade Partners

Interactive Catalog Contact

Our Products: A - Z

LIST PRINT

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A:

Acamprosate Calcium DR
Tablets

Acetazolamide ER Capsules



Acyclovir Tablets

Amantadine HCl Capsules,
USP

Amiodarone HCl Tablets

A:



Amlodipine Besylate Tablets



Anastrozole Tablets



Atenolol Tablets, USP



Azathioprine Tablets, USP


B:



Benzonatate Capsules, USP

Benztropine Mesylate
Injection, USP

Bicalutamide Tablets

Bromocriptine Mesylate
Capsules

Bupropion ER Tablets

B:

Buspirone Hydrochloride
Tablets, USP

C:



Carvedilol Tablets



Clarithromycin ER Tablets


Clarithromycin for Oral
Suspension, USP

Clarithromycin Tablets, USP



Cyproheptadine HCl Tablets

D:

Dextroamphetamine Sulfate
Tablets, USP

Dipyridamole Tablets, USP

Divalproex Sodium Capsules
(Sprinkle)Divalproex Sodium DR
Tablets, USPDivalproex Sodium ER
Tablets

D:




Donepezil HCl OD Tablets



Doxycycline Capsules, USP

Duloxetine DR Capsules,
USP

E:





Olmesartan Medoxomil
Tablets



Omeprazole DR Capsules,
USP



Oseltamivir Phosphate
Capsules, USP



Oseltamivir Phosphate for
Oral Suspension



Oxycodone HCl Tablets, USP




Pericaicitol Capsules



Paroxetine Tablets, USP



Potassium Chloride ER
Capsules, USP



Potassium Chloride ER
Tablets, USP



Potassium Citrate ER Tablets



Pramipexole Dihydrochloride
Tablets



Pravastatin Sodium Tablets,
USP



Promethazine HCl Tablets,
USP



Pyridostigmine Bromide
Tablets, USP



Ramipril Capsules



Ranitidine Injection, USP



Ribavirin Capsules



Ribavirin for Inhalation
Solution, USP



Ribavirin Tablets



Risperidone OD Tablets



Risperidone Tablets, USP



Ropinirole HCl Tablets



Simvastatin Tablets, USP



Sirolimus Tablets



Sodium
Phenylacetate/Sodium
Benzoate Injection



Tamsulosin HCl Capsules,
USP



Telmisertan Tablets, USP



Topiramate Capsules
Sprinkle



Topiramate Tablets



Tramadol HCl Tablets



Tramadol HCl/APAP Tablets




Venlafaxine HCl ER Capsules



Venlafaxine HCl Tablets



Voriconazole Tablets



Warfarin Sodium Tablets,
USP



Zolmitriptan Orally
Disintegrating Tablets

[Products](#)[Press Releases](#)[Disclaimer & Privacy Policy](#)[Career Opportunities](#)[Contact Us](#)

73 Route 31 N, Pennington, NJ 08534

© 2018 Zydus Pharmaceuticals, Inc. All rights reserved.
Site created by Connections Marketing

EXHIBIT 5

BRUCE BROCKEL

4013 MARYDALE DR, MOBILE, AL 36605

MORPHINE SULFATE 30MG

MFG ZYDUS - Generic for MS CONTIN

**TAKE 1 TABLET BY
MOUTH TWICE DAILY
NEEDED**

Rx **2317168-06085**

QTY 60
NO REFILLS

Walgreens

1251 THREE NOTCH RD, MOBILE, AL 36605

(251) 666-0249

EXHIBIT 6

Created: 10/14/2013 8:35AM

Page 1 of 2

OxyContin 80 mg oral tablet,oral only,ext.rel.12 hr**Active****SIG:** Take 1 tablet po bid04/24/2015 **Prescribed**

DISP: (60) Tablet,oral only,ext.rel.12 hr with 0 refills Provider: John P. Couch MD

Est. Completion: --

User: shoman

Created: 04/24/2015 9:18AM

Printed: 04/24/2015

Comment: ms contin not available at pharmacy replaced with this until available per ben crnp

Percocet 10-325 mg oral tablet**Discontinued****SIG:** take 1 tablet by oral route every 6 hours as needed05/25/2011 **Prescribed**

DISP: (120) tablets with 0 refills

Provider: John P. Couch MD

Est. Completion: 06/24/2011

User: jcouch

Created: 05/25/2011 10:27AM

Comment: Plan to wean to tid after this month and treatments

*Maintenance Medication.*10/14/2013 **Discontinued**

Discontinued by Patient

Provider: John P. Couch MD

Medication Intolerance

User: jpalmer

Created: 10/14/2013 8:35AM

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

Roxicodone 30 mg oral tablet

Expired

SIG: take 1 tablet (30 mg) by oral route every 6 hours for 30 days

05/22/2014 **Prescribed**

DISP: (90) tablets with 0 refills
Est. Completion: 06/21/2014
Created: 05/22/2014 8:55AM
Printed: 05/22/2014

Provider: John P. Couch MD
User: jpalmer

SIG: take 1 tablet by oral route every 6 hours for 30 days *DO NOT FILL UNTIL 06/19/14*

06/16/2014 **Adjusted**

DISP: (90) tablets with 0 refills
Est. Completion: 07/16/2014
Created: 06/16/2014 3:33PM
Printed: 06/16/2014

Provider: John P. Couch MD
User: achristy

07/17/2014 **Refilled**

DISP: (90) tablets with 0 refills
Est. Completion: 08/16/2014
Created: 07/17/2014 3:07PM
Printed: 07/17/2014

Provider: John P. Couch MD
User: chileanfletcher

SIG: take 1 tablet by oral route every 6 hours for 30 days

07/17/2014 **Adjusted**

DISP: (90) tablets with 0 refills
Est. Completion: 08/16/2014
Created: 07/17/2014 3:08PM

Provider: John P. Couch MD
User: chileanfletcher

07/17/2014 **Refilled**

DISP: (90) tablets with 0 refills
Est. Completion: 08/16/2014
Created: 07/17/2014 3:08PM
Printed: 07/17/2014

Provider: John P. Couch MD
User: chileanfletcher

08/15/2014 **Refilled**

DISP: (90) tablets with 0 refills
Est. Completion: 09/14/2014
Created: 07/17/2014 3:09PM
Printed: 07/17/2014

Provider: John P. Couch MD
User: chileanfletcher

09/12/2014 **Refilled**

DISP: (90) tablets with 0 refills
Est. Completion: 10/12/2014
Created: 09/12/2014 9:16AM
Printed: 09/12/2014

Provider: John P. Couch MD
User: chileanfletcher

10/10/2014 **Refilled**

DISP: (90) tablets with 0 refills
Est. Completion: 11/09/2014
Created: 09/12/2014 9:18AM
Printed: 09/12/2014

Provider: John P. Couch MD
User: chileanfletcher

11/06/2014 **Refilled**

DISP: (90) tablets with 0 refills
Est. Completion: 12/06/2014
Created: 11/06/2014 10:19AM

Provider: Judge Lee, Jr.
User: judgelee

Printed: 11/06/2014

12/04/2014	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 01/03/2015 Created: 11/06/2014 10:22AM Printed: 11/06/2014	Provider: John P. Couch MD User: judgelee
12/01/2014	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 12/31/2014 Created: 11/06/2014 10:23AM Printed: 11/06/2014	Provider: John P. Couch MD User: judgelee
11/10/2014	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 12/10/2014 Created: 11/10/2014 8:36AM	Provider: John P. Couch MD User: judgelee
11/06/2014	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 12/06/2014 Created: 11/10/2014 8:37AM Printed: 11/10/2014	Provider: John P. Couch MD User: judgelee
12/04/2014	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 01/03/2015 Created: 11/10/2014 8:37AM	Provider: John P. Couch MD User: judgelee
12/29/2014	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 01/28/2015 Created: 11/10/2014 8:38AM Printed: 11/10/2014	Provider: John P. Couch MD User: judgelee
01/29/2015	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 02/28/2015 Created: 01/29/2015 8:32AM Printed: 01/29/2015	Provider: John P. Couch MD User: monicacarroll
03/02/2015	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 04/01/2015 Created: 02/27/2015 8:35AM Printed: 02/27/2015	Provider: John P. Couch MD User: shoman
02/27/2015	Refilled	DISP: (90) tablets with 0 refills Est. Completion: 03/29/2015 Created: 02/27/2015 10:16AM Printed: 02/27/2015	Provider: John P. Couch MD User: chileanfletcher

SIG: take 1 tablet by oral route Q 6 hours for 30 days *DO NOT FILL UNTIL 03/27/15*

03/23/2015	Adjusted	DISP: (120) tablets with 0 refills Est. Completion: 04/22/2015 Created: 03/23/2015 10:31AM Printed: 03/23/2015	Provider: John P. Couch MD User: achristy
------------	-----------------	---	--

SIG: take 1 tablet (30 mg) by oral route every 6 hours for 30 days

03/26/2015	Adjusted	DISP: (120) tablets with 0 refills Est. Completion: 04/25/2015 Created: 03/26/2015 12:57PM Printed: 03/26/2015	Provider: John P. Couch MD User: bclark
------------	-----------------	---	--

04/23/2015 **Refilled**

DISP: (120) tablets with 0 refills
 Est. Completion: 05/23/2015
 Created: 04/23/2015 12:53PM
 Printed: 04/23/2015

Provider: John P. Couch MD
 User: shoman

Rozerem 8 mg oral tablet

Expired

Rozerem 8 mg oral tablet

Expired

Rozerem 8 mg oral tablet

Expired

Rozerem 8 mg oral tablet

Expired

Rozerem 8 mg oral tablet

Expired

SIG: take 1 tablet (8 mg) by oral route once daily at bedtime for 30 days01/29/2015 **Prescribed**

DISP: (30) tablets with 0 refills
 Est. Completion: 02/28/2015
 Created: 01/29/2015 5:00PM
 Printed: 01/29/2015

Provider: Ben Clark CRNP
 User: bclark

03/02/2015 **Refilled**

DISP: (30) tablets with 0 refills
 Est. Completion: 04/01/2015
 Created: 02/27/2015 8:35AM
 Printed: 02/27/2015

Provider: John P. Couch MD
 User: shoman

02/27/2015 **Refilled**

DISP: (30) tablets with 0 refills
 Est. Completion: 03/29/2015
 Created: 02/27/2015 10:16AM
 Printed: 02/27/2015

Provider: John P. Couch MD
 User: chileanfletcher

SIG: take 1 tablet by oral route QHS for 30 days *DO NOT FILL UNTIL 03/27/15*03/23/2015 **Adjusted**

DISP: (30) tablets with 0 refills
 Est. Completion: 04/22/2015
 Created: 03/23/2015 10:31AM
 Printed: 03/23/2015

Provider: John P. Couch MD
 User: achristy

SIG: take 1 tablet by oral route QHS for 30 days03/26/2015 **Adjusted**

DISP: (30) tablets with 1 refills
 Est. Completion: 05/25/2015
 Created: 03/26/2015 12:57PM
 Printed: 03/26/2015

Provider: John P. Couch MD
 User: bclark

EXHIBIT 7

Printed: 03/27/2014

05/22/2014 **Refilled**

DISP: (30) tablets with 1 refills
 Est. Completion: 07/21/2014
 Created: 05/22/2014 7:23AM
 Printed: 05/22/2014

Provider: John P. Couch MD
 User: chileanfletcher

07/17/2014 **Refilled**

DISP: (30) tablets with 1 refills
 Est. Completion: 09/15/2014
 Created: 07/17/2014 3:07PM
 Printed: 07/17/2014

Provider: John P. Couch MD
 User: chileanfletcher

09/12/2014 **Refilled**

DISP: (30) tablets with 1 refills
 Est. Completion: 11/11/2014
 Created: 09/12/2014 9:16AM
 Printed: 09/12/2014

Provider: John P. Couch MD
 User: chileanfletcher

11/06/2014 **Refilled**

DISP: (30) tablets with 2 refills
 Est. Completion: 02/04/2015
 Created: 11/06/2014 10:19AM
 Printed: 11/06/2014

Provider: John P. Couch MD
 User: judgelee

01/29/2015 **Refilled**

DISP: (30) tablets with 1 refills
 Est. Completion: 03/30/2015
 Created: 01/29/2015 8:32AM
 Printed: 01/29/2015

Provider: John P. Couch MD
 User: monicacarroll

01/29/2015 **Discontinued**

Discontinued by Patient
 Medication Intolerance
 Created: 01/29/2015 4:59PM

Provider: John P. Couch MD
 User: bdark

Fentora 800 mcg buccal tablet, effervescent

Expired

Fentora 800 mcg buccal tablet, effervescent

Expired

Fentora 800 mcg buccal tablet, effervescent**Discontinued****SIG:** place 1 tablet (800 mcg) by buccal route 4 times per day for 30 days11/06/2014 **Prescribed**

DISP: (84) Tab with 0 refills
 Est. Completion: 12/06/2014
 Created: 11/06/2014 11:49AM
 Printed: 11/06/2014

Provider: John P. Couch MD
 User: jpalmer

SIG: place 1 tablet (800 mcg) by buccal route 4 times per day for 30 days12/03/2014 **Adjusted**

DISP: (84) Tab with 0 refills
 Est. Completion: 01/02/2015
 Created: 11/06/2014 11:50AM
 Printed: 11/06/2014

Provider: John P. Couch MD
 User: jpalmer

01/29/2015 **Refilled**

DISP: (84) Tab with 0 refills

Provider: John P. Couch MD

Est. Completion: 02/28/2015
 Created: 01/29/2015 8:32AM
 Printed: 01/29/2015

User: monicacarroll

01/29/2015 **Discontinued**

Discontinued by Patient
 Medication Intolerance
 Created: 01/29/2015 4:57PM

Provider: John P. Couch MD
 User: bclark

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Expired

Lunesta 3 mg oral tablet

Discontinued

SIG: take 1 tablet (3 mg) by oral route once daily at bedtime for 30 days

10/14/2013 **Prescribed**

DISP: (60) tablets with 1 refills
 Est. Completion: 12/13/2013
 Created: 10/14/2013 8:35AM

Provider: John P. Couch MD
 User: jpalmer

EXHIBIT 8

Abstral PA denied

Patient Name: Bruce Brockel
Patient ID: 8454
Sex: Male
Birthdate: [REDACTED]

Create Date: July 16, 2014

Dr. Tara Bryant from Viva called stating she needed a cancer diagnosis to be able to approve Abstral. If a cancer diagnosis can be given then Abstral can be approved. Her number is 205-558-7403.

Electronically Signed by: Donna Newburn, MA -Author on July 16, 2014 01:40:18 PM